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Abstract 
Many African counties, like Kenya, have introduced pneumococcal conjugate vaccines 
(PCVs) with financial support from Gavi, the Vaccine Alliance. However, in the near future, 
they are expected to transition and take up the full costs. Kenya introduced the ten-valent 
PCV (PCV10) in 2011 and enters the accelerated transition phase in 2022. This work 
aimed to study the effects of PCV10 vaccination on pneumococcal carriage and disease in 
the pre- and the immediate post-vaccination period, predict the long-term vaccination 
impact on carriage of pneumococcus and subsequent invasive pneumococcal disease, 
evaluate immune factors that may influence that impact and, ultimately, investigate the 
cost-effectiveness of potential policy options in order to guide Kenya’s decision-making. 
A dynamic transmission model was fitted to pre-vaccination carriage data and its 
predictions were validated against post-vaccination carriage data. In order to evaluate 
immune factors that may influence vaccination impact and thus warrant consideration in 
the mathematical model, statistical modelling of the association between pre-existing 
pneumococcal carriage and vaccine responsiveness, and between maternally-derived 
anti-protein and anti-capsular antibodies and the rate pneumococcal acquisition in 
newborns, was undertaken. A cost-effectiveness analysis was done based on the disease 
incidence predictions from the transmission model. 
The dynamic transmission model was shown be useful as it closely predicted the observed 
magnitude and timing of serotype replacement. Maternal anti-capsular antibodies were 
estimated to have a limited role while impaired immune responses were observed among 
vaccine serotype carriers at the point of vaccination. These two immune factors were 
evaluated within the decision making structure and considered to have negligible impact 
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on the performance of the model. In the conclusion, I estimated that sustaining PCV10 
vaccination in Kenya will be cost-effective but will present a significant challenge to 
affordability by the Kenyan Government. 
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Preface  
This PhD thesis is written in a research paper style format. The first chapter is a general 
introduction to the pneumococcus and pneumococcal vaccines and their impact. It also 
outlines the gaps in knowledge and sets the theme for the four manuscripts, each as a 
chapter, that follow. Three of the manuscripts are already published in peer-reviewed 
journals. The last manuscript is in preparation for submission. The last chapter in the 
thesis integrates the results of the four discrete but related investigations to attempt to give 
an answer to the problems posed in the introduction chapter. 
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Chapter 1: General introduction 
1.1 Context 
Many African counties, like Kenya, have introduced pneumococcal conjugate vaccines 
(PCVs) with financial support from Gavi, the Vaccine Alliance. However, in the near future, 
they are expected to transition and take up the full costs. Kenya introduced the ten-valent 
PCV (PCV10) in 2011 and enters the accelerated transition phase in 2022. Therefore, a 
cost-effectiveness study of the potential policy options is useful in guiding Kenya’s decision 
making on the future of its PCV vaccination programme. This work aimed to study the 
effects of PCV10 vaccination on pneumococcal carriage and disease in the pre- and the 
immediate post-vaccination period, predict the long-term vaccination impact on carriage of 
pneumococcus and subsequent invasive pneumococcal disease, evaluate immune factors 
that may influence that impact and, ultimately, investigate the cost-effectiveness of 
potential policy options. 
1.2 The pneumococcus 
Streptococcus pneumoniae (Pneumococcus) is a gram-positive bacterium, which takes the 
shape of a slightly pointed coccus. It usually occurs in pairs but can also exist singly or in 
short chains and it colonises the mucosal surfaces of the nasopharynx and upper 
respiratory tract. It is characterized by a polysaccharide capsule, which when present 
covers the entire cell, the basis upon which the pneumococcus is typed; there are over 90 
known serotypes to date [1,2]. The capsule also plays an important role in the virulence of 
the bacterium. The capsule protects against non-opsonic killing of the bacterium by human 
neutrophils. The susceptibility to killing is directly linked with the degree of encapsulation 
where serotypes that are heavily encapsulated are more resistant to neutrophil-mediated 
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killing [3]. Most pneumococcal capsules are negatively charged [4]. The negative charge 
repels phagocytes through electrostatic repulsion, which enhances colonisation. Also, 
pneumococcal strains with highly negatively charged capsules are less likely to adhere to 
human airway mucus therefore preventing clearance by mucus [4,5]. Upon adherence of 
pneumococci to epithelial cells, the thickness of the capsule is reduced. This results in the 
exposure of adhesion molecules and allows pneumococci to strengthen the attachment to 
host cells enhancing subsequent uptake [6]. The pneumococcus also contains proteins 
that control the host-pathogen interactions. These proteins have varied roles including 
ensuring viability of the pneumococcus [7–10] and determination of virulence, as is the 
case for the group of choline-binding surface proteins [11–13]. About 30-50% of 
pneumococcal strains express pili on their cell surface and this aids in attachment to the 
host epithelial cells [14], however, the pili are not essential for attachment. The 
pneumococcus is mostly found in humans though the host can range from mice, rats, 
guinea pigs, rhesus monkeys to chimpanzees. 
Transmission of pneumococcus from one human host to another is normally through 
infectious droplets that are passed across by coughing or sneezing or very close person-
person contact e.g. oral contact [15–18]. There exists intra-species competition among 
pneumococci in colonising the human nasopharynx and different serotypes of 
pneumococci vary in their competitive abilities. The biological mechanism of competition 
between pneumococcal serotypes is not yet known. Between-serotype competition has 
however been postulated and quantified based mathematical models fitted to 
epidemiological data [19,20] or mouse experimental colonisation models [21]. In 
mathematical models, a competition structure where the rate of acquisition of a second 
serotype in an already colonised individual is lower than the rate of acquisition of that 
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second serotype in a completely susceptible individual is supported better by 
epidemiological data (i.e. better model-fit) than a competition structure where the 
clearance of a resident serotype is enhanced by the acquisition of a second serotype. In a 
mouse model of intranasal carriage of pneumococci, carriage of a resident strain inhibited 
the acquisition of a challenge strain and this inhibitory effect depended on the dose of the 
challenge strain [21]. Challenge with a secondary strain did not significantly influence the 
rate of clearance of the resident strain. This experimental observation is compatible with 
the assumptions of mathematical models about between-serotype competition structures 
that are best supported by epidemiological data. Therefore between-serotype competition 
is believed to essentially work through acquisition rather than clearance [19–21].  
The duration of carriage, which is a function of the clearance rate, varies across serotypes 
and reduces with age [20,22–24]. Two potential explanations for the reduction in duration 
of carriage with age include: (i) the natural immunity acquired after exposure to 
pneumococcal carriage that reduces duration of carriage in subsequent episodes [25,26] 
and: (ii) the maturation of immune responses with age that are independent of natural 
exposure [27]. Given that some serotypes are poor competitors in colonising the 
nasopharynx and are more easily cleared from it, it has been shown, in a mathematical 
modelling study, that the diversity of pneumococcal serotypes is maintained because of 
weak serotype-specific immunity that stabilizes competition, and acquired non-capsular 
immunity that reduces the serotype-specific differences in fitness, like duration of carriage 
[28]. Anti-capsular antibodies drive serotype-specific immunity against homologous 
colonisation [29–31]. Weak serotype-specific immunity allows repeated colonisation of a 
host with a serotype that has previously been encountered naturally. Non-capsular 
immunity is driven by an immune mechanism mediated by interleukin 17 produced by 
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Th17 T cells as demonstrated in mouse models [26,27]. This type of immunity has been 
observed in longitudinal studies in humans [32,33]. 
Pneumococci carried in the nasopharynx can spread to other parts of the body causing 
various forms of non-invasive and invasive pneumococcal diseases. The non-invasive 
pneumococcal diseases include acute otitis media and non-bacteraemic pneumonia. 
Acute otitis media is caused by direct spread of the pneumococcus through the Eustachian 
tubule and is characterized by inflammation of the middle ear and swelling of the eardrum. 
Non-bacteraemic pneumonia is caused by direct spread through the trachea to the lower 
respiratory tract without isolation of pneumococcus in blood and is diagnosed by chest 
radiographs. Invasive pneumococcal disease (IPD) occurs when the pneumococcus 
invades sterile sites such as the blood stream or the cerebrospinal fluid, causing 
bacteraemia/sepsis, or meningitis.  
1.3 Burden of disease caused by the pneumococcus  
The burden of pneumococcal disease is mainly concentrated in children younger than 5 
years and in the elderly [34,35]. In 2000, before the introduction of pneumococcal 
vaccines, the World Health Organization (WHO) estimated that pneumococcal diseases 
led to 1.6 million deaths worldwide. Over half of these deaths (0.83 million) were in 
children under 5 years. Pneumococcus was estimated to cause around 11% (8–12%) of all 
deaths in children aged 1–59 months, not including pneumococcal deaths in HIV-positive 
children [34]. Furthermore, the highest incidence and case-fatality rates were estimated to 
occur in sub-Saharan Africa and Southeast Asia. In 2008, the WHO estimated that there 
were 0.5 million deaths due to pneumococcal diseases in children under 5 years [36]. 
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More recent global estimates of mortality caused by the pneumococcus are being updated 
and will become available later in 2017 [37].  
1.4 Protection from maternally-derived anti-pneumococcal antibodies 
Exposure to pneumococcus in the natural environment of pregnant women can induce 
natural antibodies against the pneumococcal strains encountered [31,38]. These naturally-
acquired antibodies can be passively passed on to the foetus through trans-placental 
diffusion in the late stages of pregnancy [38]. The transfer of antibodies across the 
placenta is not very efficient, especially for polysaccharide antigens [39], which means that 
the antibody concentration in the infant at birth is normally lower than that in the mother. 
These circulating maternally-derived antibodies could potentially protect infants from 
colonisation, which is a necessary precursor for invasive disease [40]. However, several 
studies have documented the limited role of maternally-derived antibodies in protecting 
infants from pneumococcal colonisation [33,38,41].  
Three limitations of the studies of newborn pneumococcal colonisation and maternally-
derived antibodies [33,38,42–44] might mask a potential association. (1) Children born to 
carrier mothers have a higher risk of being infected by the mother; as maternal carriage 
may stimulate a maternal antibody response, they are also more likely to receive higher 
antibody concentrations by passive transfer from the mother. Therefore, failing to account 
for the colonisation status of the mother at birth would confound the estimate of the 
protective role of antibodies. (2) The first swabs were obtained at 1 month of age at the 
earliest and the inter-swab interval was also at least a month [33,38,43–46]. The duration 
of carriage of some pneumococcal serotypes in young infants can be less than a month 
[20,22]. An insensitive ascertainment of carriage in infants can result in an increased 
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number of missed carriage episodes. (3) The relatively small sample size of these studies 
has limited the power to detect modest protective efficacies. We need studies that 
overcome these limitations to determine an un-biased characterization of the impact of 
maternally-derived antibodies on infant pneumococcal carriage and subsequent disease. 
By extension these would provide un-biased information on which to base potential 
vaccination strategies or modelling assumptions. 
1.5 Pneumococcal vaccines  
The first vaccines introduced against pneumococcus were derived from purified capsular 
polysaccharide, and these could be pooled to offer multi-serotype protection. A 
polysaccharide vaccine that is still in current use is the 23-valent pneumococcal 
polysaccharide vaccine (PPV23). It protects against 23 serotypes of pneumococcus (1, 2, 
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 
33F). However, polysaccharide vaccines are poorly immunogenic in young infants [47,48]. 
In a trial with a 14-valent polysaccharide vaccine, children who were less than two years 
old at the time of primary vaccination were given a booster dose six months later. There 
was no significant increase in antibody to any serotype post-booster, and the geometric 
mean antibody levels waned for most types [47]. In a study among children in Finland, 
aged less than 7 years, there was poor immunogenicity to serotypes 6A and 23F – 
serotypes that frequently cause pneumococcal infections in children. In addition, children 
younger than 2 years of age also responded very poorly to serotypes 19F and 18C [48]. 
Currently, polysaccharide vaccines are not recommended in children younger than two 
years of age. The PPV23 has been mainly used in high-risk groups of older children and 
adults such as those with immunodeficiency or those aged above 65 years. 
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The cause of the poor immunogenicity of polysaccharide vaccines in children under 2 
years is not completely understood. The free polysaccharide antigens induce thymus-
independent anti-polysaccharide antibody responses, which are not fully developed in 
infants [49–51]. Reduced thymus-independent responses are attributed to the low 
numbers of marginal-zone B-cells present during birth and these are poorly developed in 
neonates [51] and in young children [52].Thymus-independent antigens do not require T-
cells to induce immunological response and therefore they do not induce immunological 
memory.  
An interesting observation regarding polysaccharide vaccines is that repeated vaccination 
is associated with hyporesponsiveness (i.e. reduced immunological response) [53], which 
can be long lasting in asplenic children [54] and can be overcome, in the elderly, if the two 
doses are administered at least five years apart [55,56]. Furthermore, polysaccharide 
vaccines have not been shown prevent nasopharyngeal carriage in children [57,58] and by 
extension transmission of pneumococcus, therefore, they do not elicit herd-protection in 
the population. However, in adults, immunisation with specific capsular polysaccharides 
greatly reduced the incidence of pneumonia caused by pneumococci in vaccinated 
individuals and non-vaccinated individuals who frequently interacted with vaccinees [59]. 
As polysaccharide vaccines are not protective in infants, vaccine formulations that could 
stimulate immunity even in young children were explored. The idea of conjugating the 
polysaccharide to an immunogenic protein carrier was conceived in the early 1930s where 
the immunological specificity of an antigen prepared by combining the capsular 
polysaccharide of type III pneumococcus with foreign protein was described [60]. This lead 
to the development of the first glycoconjugate vaccine for use in humans, a Haemophilus 
influenzae type b (Hib) conjugate vaccine, that was licensed in the USA in 1987 and 
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introduced into the US infant immunization schedule [61]. Pneumococcal Conjugate 
Vaccines (PCVs) were subsequently formulated by conjugating pneumococcal 
polysaccharides to carrier proteins. The carrier proteins stimulate the immune system 
through T-helper cells [62,63] which activate polysaccharide-specific B cells to proliferate 
and differentiate into plasma cells, thus making the conjugate vaccines immunogenic even 
in infants and young children. However, the process of conjugation is complex which has 
limited the number of serotypes that can be included in a vaccine and led to high 
manufacturing costs. The first PCV included antigens against seven serotypes - 4, 6B, 9V, 
14, 18C, 19F and 23F. Successively, more serotypes have been included in PCVs and 10-
valent (PCV10 serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), and 13-valent 
(PCV13 serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugate 
vaccines have been licensed and are now widely in use. 
Other formulations of pneumococcal vaccines that are in clinical development include 
pneumococcal whole cell vaccines and protein vaccines [64–66]. Because these vaccines 
are not targeted at specific capsular polysaccharides they are expected to protect 
recipients against all serotypes of pneumococcus.   
1.6 Impact of PCVs on carriage of pneumococcus and subsequent disease  
Impact on carriage 
Reduction in nasopharyngeal carriage of vaccine-serotype pneumococci has been 
documented after vaccination with PCVs [67–69]. In a meta-analysis of individually 
randomised studies of the efficacy of PCV7 against carriage [70], the aggregate vaccine 
efficacy against vaccine serotype carriage was estimated as 57% (95% credible interval: 
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50-65%) 6 months after completion on the vaccination schedule. The peak vaccine 
efficacy, measured two months after completion of vaccination schedule, was estimated as 
62%. Moreover, by reducing the likelihood of acquisition of the pneumococcus in the 
nasopharynx, conjugate vaccines reduce pneumococcus transmission and thereby offer 
indirect protection against IPD to the unvaccinated, herd immunity. For example, in the 
Active Bacterial Core Surveillance (ABCs) in USA there was an estimated decline of 
between 64–77% in vaccine serotype IPD from pre-introduction of PCV7 to 4 years post-
introduction among adults [71]. In England and Wales, vaccine serotype disease 
decreased in all age groups; there was a reduction of 98% in individuals younger than 2 
years and of 81% in those aged 65 years or older 4 years following introduction of PCV7 
[72]. However, non-vaccine-serotype pneumococci rapidly colonise this vacated ecological 
niche which gives rise to near-complete serotype replacement carriage where the overall 
carriage prevalence remains unchanged [73–76]. This leads to serotype-replacement 
disease the extent of which depends on the invasiveness of the replacing serotypes, 
therefore, ongoing surveillance post-introduction is always necessary, but this is not in 
place for most developing countries that have introduced PCVs. In contrast to developed 
countries [71], circulation of vaccine serotypes in low-income countries has not been 
eliminated. Data from Kenya [77] and The Gambia [78] suggests that the prevalence of 
vaccine serotypes remains high several years after vaccine introduction. In infants, the 
prevalence of PCV7 serotypes was estimated at 5% in The Gambia in 2012 [78] and the 
prevalence of PCV10 serotypes was estimated at 8% in Kenya [77]   
Impact on disease 
Despite the impact of serotype replacement, PCVs have been shown to be efficacious in 
preventing serious forms of vaccine-type pneumococcal disease [71,74,79–92], 
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radiologically-confirmed pneumonia [85,87,93,94] and acute otitis media (AOM) [95–98]. 
The duration of protection of PCV against disease can be as long as 6 years [99]. The 
efficacy of PCV is higher against vaccine-serotype pneumococcal disease than against 
radiologically-confirmed pneumonia or AOM. This is because the later endpoints are not 
specific for pneumococcal aetiology; vaccine efficacy would be biased downwards when 
there is low specificity of the endpoint. Both radiologically-confirmed pneumonia [100] and 
AOM [101,102] have many aetiologies including but not limited to Streptococcus 
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Therefore, PCV can only 
be expected to prevent the portion of radiological pneumonia and AOM with vaccine-
serotype pneumococcal aetiology.  
There are few individually randomised trials in Africa on the efficacy of PCVs against 
disease. In a randomised placebo-controlled trial in The Gambia among children aged 6 to 
51 weeks, the efficacy of the 9-valent PCV was estimated to be 37% against the first 
episode of radiologically-confirmed pneumonia while the efficacy against vaccine serotype 
IPD and all IPD was 77% and 50%, respectively [93]. In a randomised controlled trial in 
South Africa, where children were vaccinated at ages 6, 10 and 14 weeks, the efficacy of a 
9-valent PCV against the first episode of IPD among HIV negative and HIV positive 
children was 83% and 65% respectively [94].  
Effectiveness studies from population-based surveillance in some African countries have 
also reported a reduction in disease following PCV introduction. South Africa introduced 
PCV7 in 2009 and replaced it with PCV13 in 2011. The rate of IPD among all ages 
dropped by 40% by 2012 [103]. The Gambia introduced PCV7 in 2009 and replaced it with 
PCV13 in May 2011. Using population-based surveillance and nested case-control 
studies, PCV vaccination in The Gambia was associated with a reduction in the incidence 
		 18	
of radiologically-confirmed pneumonia by 23%, 29% and 22% in children aged 2-11 
months, 12-23 months and 2-4 years, respectively, up to the period 2014/15. The 
reduction in the incidence of pneumococcal pneumonia was 58%, 75% and 57%, 
respectively, in the same age groups [104]. Using the period before the introduction of 
PCV13 as the baseline (May 12, 2008–May 11, 2010) and a post vaccination period 
spanning two years (Jan 1, 2013–Dec 31, 2014), the incidence of IPD reduced by 55% 
and 56% in children aged 2-23 months and 2-4 years respectively [105].  
Mozambique introduced PCV10 in March 2013. Over three years after PCV introduction, 
data from three main sentinel hospitals have recorded a steep decline in pneumococcal 
meningitis cases in children below of the age of five years. The proportion of cases of 
pneumococcal meningitis decreased from 33.6% to 1.9% in 2015 among children with 
suspected acute bacterial meningitis [91]. 
Kenya introduced PCV10 at the beginning of 2011. In Kilifi, a coastal area in Kenya with 
enhanced surveillance for IPD and carriage prevalence, the vaccine was introduced with a 
catch-up campaign among children <5 years. Vaccine-type pneumococcal carriage and 
IPD dropped substantially in all age groups. Carriage of vaccine serotypes was reduced by 
two-thirds both in children younger than 5 years and in older individuals [77,106]. In 
children <5 years, the incidence of vaccine-serotype IPD fell by 92% while the overall IPD 
decreased by 68% in the post vaccination period (2012-2016) [107]. Among children aged 
2-59 months in Kilifi, PCV10 introduction was associated with a reduction in clinically-
defined and radiologically-confirmed pneumonia of 27% and 48%, respectively [108]. 
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1.7 Immune correlates of protection against disease and carriage 
PCVs induce an immune response characterized by an increase in the anti-capsular 
antibodies to the antigens contained in the vaccine. High levels of vaccine-induced anti-
capsular antibodies have been associated with reduction in IPD [109,110] and 
pneumococcal carriage [111]. For IPD a common correlate of protection (CoP) across 
vaccine-serotypes of 0.35 mcg/ml was derived for PCV7 [109,112] and used for licensing 
extended formulations of PCV such as PCV10 and PCV13 [113]. However, the use of a 
single CoP has recently been criticized as the threshold varied widely across serotypes in 
PCV13 [114]. The statistical method used to derive the CoP for IPD equated relative risk of 
IPD between vaccine and control groups (i.e. one minus the vaccine efficacy) to the 
relative risk of having antibody concentration below the protective threshold. Then, the 
protective threshold was derived from reverse cumulative distribution curves of the 
antibody concentrations of the vaccinated and the control groups as the concentration at 
which this equation is satisfied [112]. A key simplifying assumption of the approach is that 
the relationship between the risk of disease and antibody concentration is a step function, 
where the risk of disease above the threshold is negligible (all or nothing protection), which 
can be violated in reality. 
Carriage is a precursor to IPD [40] and is an endpoint that is both easy and faster to 
measure relative to IPD. In addition to preventing disease, a vaccine that prevents 
transmission confers herd protection against carriage and disease and therefore has 
additional value. This is worth considering when licensing future pneumococcal vaccines. 
Carriage has therefore become a target for vaccine development [115] and  future vaccine 
development will benefit from a better understanding of the relationship between antibody 
development and reduced carriage. In this context, a clear CoP against carriage would be 
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a useful output in the characterisation of the antibody-carriage relationship. However, there 
is only one study, conducted in the United Kingdom, that has identified a clear correlate of 
protection against carriage and this is for only a single serotype [31]. In this study, 
individuals with antibody concentration above 5mcg/ml were protected against acquisition 
of serotype 14. Nonetheless, the study used data from adult subjects, which might limit the 
application of the threshold in children, and related carriage to naturally-acquired 
antibodies rather than vaccine-induced ones.  
1.8 Hyporesponsiveness 
Even though children mount an immune response after vaccination with PCV, the 
magnitude of this response is dependent on the carriage status at the time of vacation. 
Individuals with prevalent carriage at the time of vaccination have an impaired response 
leading to lower concentration of homologous antibody post-vaccination [116–121]. PCV 
responses in African children are generally thought to be higher than those seen in 
developed country settings [79,122–124]. For example, the serotype-specific geometric 
mean fold-rise after a 3-dose primary series of PCV was lower in USA [79] and Finland 
[124] compared to South Africa [122] and The Gambia [123]. Since carriage rates in early 
infancy are extremely high in countries like The Gambia [125] and Kenya [106,126], it is 
possible that hyporesponsiveness does not occur, or is immunologically irrelevant, in 
tropical Africa. However, no study in Africa has yet examined the question of 
hyporesponsiveness. If the reduced responsiveness among carriers leads to lower 
immunogenicity then vaccination strategies that speedily reduce carriage in the whole 
population, such as catch-up campaigns, might be more effective than cohort introduction. 
Hyporesponsiveness might also impact on the fit of mathematical models of carriage if not 
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included in the mechanistic structure, depending on the magnitude of the resulting 
reduction in vaccine efficacy.  
1.9 Roll out of Pneumococcal vaccines  
PCV7 was the first conjugate vaccine licensed for use in infants in the United States of 
America (US) in the year 2000. By August 2008, PCV7 had been introduced in 26 high-
income countries. However, the conjugate vaccines were not introduced in developing 
countries until the year 2009 when Rwanda announced the introduction of PCV7 in its 
childhood immunization programme. The delay in the roll out of PCV vaccination programs 
in developing countries was mainly caused by the high vaccine price. According to the US 
Centers for Disease Control and Prevention (CDC), the contract price for PCV7 in 2001 
was US $45.99 per dose and US $58.75 per dose in the private sector [127]. When 
PCV13 was introduced in the US in 2010, the CDC contract price was US$91.75 per dose, 
currently (2017) it is US$126.97 per dose [128].  
In order to lower the cost of production and by extension the vaccine price per dose, 
vaccine-manufacturing companies would need to increase the manufacturing capacity to 
take advantage of economies of scale. With limited supply, the price of vaccine would be 
too high for developing countries. However, manufacturers would not have the incentive to 
make huge investments if there is no matching demand for the vaccines, which creates a 
stalemate.  
In the Latin American and Caribbean (LAC) countries, PCV vaccination was introduced 
largely with the support of a bulk procurement mechanism for vaccines and related 
supplies [129]. This mechanism was operated by the Pan American Health Organization 
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(PAHO) revolving fund [130] in which forty-one member countries pool their recourses to 
procure vaccines in bulk at lower prices. PAHO prices for PCV10 and PCV13 have 
declined slightly from US$14.24 and US$16.34, respectively, in 2012 but remain high at 
US$12.85 and US$14.50, respectively, in 2017 [131]. 
In many developing countries in Africa, PCVs were introduced through financial support 
from Gavi, the Vaccine Alliance. Gavi developed an innovative vaccine funding and 
delivery mechanism known as the pneumococcal Advanced Market Commitment 
(pneumococcal AMC). Under the pneumococcal AMC, donors committed funds for vaccine 
procurement and Gavi made an advanced commitment to manufacturers to purchase 
specific volumes of vaccine meeting specific requirements (target product profile); this 
gave vaccine manufacturers the incentive to invest in expanding their manufacturing 
capacity and in vaccine research. In return companies signed a legally-binding 
commitment to provide the vaccines at an agreed price to developing countries in the long 
term, ten years [132].  
Countries with an average Gross National Income (GNI) per capita of less than $1580 over 
the three years before application to Gavi are, in principle, eligible for support from Gavi for 
introduction of PCV vaccination in their childhood immunization programs. As of March 
2017, 59 developing countries had been approved for pneumococcal vaccine support and 
more than 50 of them had introduced PCV [133]. Initially, countries are expected to pay a 
small fraction (6%) of the agreed vaccine price, which is currently $3.05, in a co-financing 
agreement, while Gavi pays the rest. However, as each country’s GNI grows and goes 
above the eligibility threshold it enters the accelerated transition phase where, within five 
years, it is expected to take up the full cost of the vaccine [134].  
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1.10 The future of PCV vaccination in Kenya  
Gavi’s initiative to help developing countries access PCVs has been a success, 
considering the uptake of PCVs and the subsequent impact of vaccination in reducing the 
burden of pneumococcal disease in these countries. The challenge that remains for 
countries that have depended on Gavi support is how to sustain the programmes once 
they transition out of Gavi support. At the moment four African countries (Angola, Congo 
Rep., Ghana and Nigeria) are in the accelerated transition phase [134] and five more 
(Ivory Coast, Lesotho, Sudan, Kenya  and  Zambia) are expected to join within the next 
five years. 
Kenya is expected to enter the accelerated transition phase in 2022 which should lead to 
taking up the full cost of the PCV vaccination programme by 2027 [135]. Policy makers in 
Kenya will need to decide in 2022 whether to enter the accelerated transition phase or 
alter or discontinue the programme. PCV is the most expensive vaccine in the national 
immunization programme. However, for most African countries the decision to introduce 
PCV was not preceded by an evaluation of the balance of predicted costs and benefits of 
PCV introduction because Gavi provided the majority of vaccine costs. For Kenya, with 
good local data on disease burden and impact, the decision to continue or amend the PCV 
programme should be based on a rational process informed by infectious disease 
modelling and cost-effectiveness analyses.  
1.11 Research objectives 
The overall aims of the research presented in this thesis are to:  
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1. Model the effects of PCV10 vaccination on pneumococcal carriage and disease in 
the pre- and the immediate post-vaccination period. 
2. Predict the long-term vaccination impact on carriage of pneumococcus and 
subsequent invasive pneumococcal disease 
3. Evaluate immune factors that may influence that impact 
4. Investigate the cost-effectiveness of upcoming policy options in order to guide 
decision-making. 
1.12 Approach used in tackling the research objectives 
To produce valid estimates of the cost-effectiveness of PCV, observed and modelled 
incidence estimates for IPD and/or those of other non-invasive pneumococcal diseases 
are required. Disease incidence estimates are used to calculate the treatment and other 
related costs and to estimate the disability-adjusted-life-years (DALYs). However, disease 
prediction models are subject to a host of influencing factors that demand consideration. 
The principal problem with limited-valency vaccines is serotype replacement: the rapid 
colonisation of the vacated ecological niche by non-vaccine-type pneumococci, which 
results in serotype replacement disease. The additional impact of PCV vaccination on 
carriage and disease, through herd immunity, also needs to be accounted for. Other 
factors, such as social contact patterns, can also influence transmission of carriage. 
Mathematical transmission models are useful tools in encompassing these dynamics and 
have been used in predicting PCV vaccination impact [74,75,136–139]. I use transmission 
modelling in this thesis for prediction of vaccination impact. 
Mathematical transmission models require data for calibration and validation. I use data 
that is mainly collected within the Kilifi Health and Demographic Surveillance System  
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(KHDSS) [140]. KHDSS is housed within the Kenya Medical Research Institute-Wellcome 
Trust Research Programme (KWTRP) in Kilifi, which is located on the Indian Ocean coast 
of Kenya. KHDSS was established in 2000 with an initial population of about 198,000 and 
covers an area of 891 Km2. There are currently about 290,000 residents in its population 
register. Records of births, pregnancies, migrations and deaths among residents are 
updated by 4-monthly household visits, which enable an accurate track of denominators 
for estimating disease burden among the residents. Within the KHDSS area there is a 
single government referral hospital, Kilifi County Hospital (KCH). Approximately 55% of the 
children admitted at KCH are residents of KHDSS. At KCH, morbidity events are linked in 
real time to the population register through an integrated data management system. Since 
2008 linked surveillance was extended to include KHDSS vaccine clinics for the purpose 
of monitoring vaccination coverage [141].   
Using the KHDSS platform studies have generated detailed data on a wide range 
measures, including nasopharyngeal carriage and invasive pneumococcal disease from 
routine surveillance before and after vaccine introduction, that can be used to support 
mathematical models [20,69,140–142]. There are also complementary results from local 
epidemiological studies that provide information on duration of carriage, competitive 
strength of serotypes and rates of social contacts [20,143]. 
The report of the work in this thesis is presented in a research paper style structured into 
four research chapters with the following titles: 
1. Sustained reduction in vaccine-type invasive pneumococcal disease despite waning 
effects of a catch-up campaign in Kilifi, Kenya: a mathematical model based on pre-
vaccination data. 
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2. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of 
pneumococci: Hyporesponsiveness and immune correlates of protection for 
carriage 
3. Effect of maternally-derived anti-protein and anti-capsular IgG antibodies on the 
rate of acquisition of nasopharyngeal carriage of pneumococcus in newborns. 
4. The merits of sustaining pneumococcal vaccination after transitioning from Gavi 
support – a cost-effectiveness study for Kenya 
In research paper 1, I developed an age-structured dynamic transmission model of 
pneumococcal carriage calibrated with the detailed pre-vaccination data from KHDSS and 
used the post-vaccination data to validate its predictions. In Kilifi, unlike the rest of the 
country, PCV10 was introduced with a catch-up campaign in <5 year olds. Given the 
continued observation of vaccine serotypes in circulation, 5 years after PCV10 introduction 
[77], I also investigated if vaccine-serotype invasive pneumococcal disease may re-
emerge once the effects of the under-5 year old catch-up campaign wear off.  
Mathematical models can broadly be categorised as either agent-based or compartmental. 
In an agent-based model transition between states in the model is determined by the 
behaviour of the individual and not the group as a whole, as is the case with a 
compartmental model. One main advantage of a compartmental model is that it is 
computationally faster. Except for two models that are agent-based [136,138], published 
transmission-dynamic models of pneumococcal transmission to study vaccination impact 
are compartmental [74,75,137–139,144,145].  
Pneumococcal transmission models invariably group hypothetical individuals according 
their pneumococcal carriage status where an individual can be completely susceptible, 
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carry single serotypes, or carry two serotypes simultaneously. In order to reproduce 
serotype replacement, the models almost always group serotypes into two broad 
categories, vaccine-serotypes and non-vaccine serotypes, and encode a mechanism of 
competition between these two serotype groups. Very few models have however 
considered more than two serotype groups [75,136,138].  
The grouping of serotypes into aggregate types tackles the problem with a large number of 
serotypes for which individual characteristics might not be available. However, a key 
criticism of grouping of serotypes is that the aggregate types can have dynamics that are 
different than the individual serotypes included. The grouping of serotypes may also 
artificially promote their co-existence in the model because it artificially reduces serotype-
specific fitness differences.  
From the two pre-vaccination pneumococcal carriage surveys conducted in Kilifi, Kenya, 
the data that our model was fitted to, 46 different serotypes were detected in carriage 
[106]. A transmission model that accounts for the characteristics of each of these 
serotypes individually would be impractical; we do not have information on the duration of 
carriage of each of the serotypes circulating in Kilifi, also, some of them are rarely carried 
and thus occur in very low frequencies, which would lead to convergence problems in 
model fitting especially when the small numbers are further considered by age groups in 
an age-structured model. Some pooling of serotypes was necessary in the model used.  
I pooled serotypes into three classes; vaccine-serotypes, strong non-vaccine serotypes 
and weak non-vaccine serotypes. The separation between weak and strong non-vaccine 
serotypes was based on prior information on the some of the serotypes susceptibility to 
competition. The reason why I did not split the vaccine serotypes into say two classes as 
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we did with the non-vaccine serotypes is because I intended the model to reproduce 
serotype replacement with a small number of competition parameters as possible, by 
limiting the number of compartments. The extent of serotype replacement would be more 
accurately predicted if the heterogeneity within non-vaccine serotypes, rather than those 
within vaccine-serotypes, is incorporated in the model. This is because heterogeneity in 
the non-vaccine serotypes is higher by virtue having a larger number of serotypes.  
In the interests of parsimony, several aspects of pneumococcal immunology and 
epidemiology are simplified in the generation of this model.  Two such simplifying 
assumptions are: (i) the immunogenicity of the vaccine is independent of the carriage 
status of the vaccinees; (ii) children are born completely susceptible to carriage acquisition 
with no protection from maternally acquired antibodies. In order to test the validity of these 
assumptions in Kilifi I undertook statistical modelling of data from prior studies in Kilifi 
examining the safety and immunogenicity of PCV, which also monitored carriage. These 
analyses form research papers 2 and 3 respectively and inform research paper 4. 
For research paper 4, I used the model from research paper 1 but extended the fitting 
process to also include age stratified post-vaccination (2011-2016) pneumococcal 
carriage. I then use the model to predict the impact of continuing or discontinuing the 
PCV10 programme in 2022. On the basis of those predictions I assessed the cost-
effectiveness of continuing with the PCV10 vaccination programme for 11 years from year 
2022 relative to stopping the vaccination programme at that time.  
In a final chapter I will integrate the results of the four discrete investigations to attempt to 
give an answer to the problems posed in the present chapter. 
		 29	
References 
 
[1] Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin 
Microbiol 1995;33:2759–62. 
[2] Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, et al. 
Biochemical, genetic, and serological characterization of two capsule subtypes 
among Streptococcus pneumoniae serotype 20 strains: Discovery of a new 
pneumococcal serotype. J Biol Chem 2012;287:27885–94. 
doi:10.1074/jbc.M112.380451. 
[3] Weinberger DM, Trzcinski K, Lu YJ, Bogaert D, Brandes A, Galagan J, et al. 
Pneumococcal capsular polysaccharide structure predicts serotype prevalence. 
PLoS Pathog 2009;5:e1000476. doi:10.1371/journal.ppat.1000476. 
[4] Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. 
Pneumococcal capsules and their types: Past, present, and future. Clin Microbiol 
Rev 2015;28:871–99. doi:10.1128/CMR.00024-15. 
[5] Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. Capsule 
enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect 
Immun 2007;75:83–90. doi:10.1128/IAI.01475-06. 
[6] Hammerschmidt S, Wolff S, Hocke A, Rosseau S, Müller E, Rohde M. Illustration of 
Pneumococcal Polysaccharide Capsule during Adherence and Invasion of Epithelial 
Cells Illustration of Pneumococcal Polysaccharide Capsule during Adherence and 
Invasion of Epithelial Cells. Infect Immun 2005;73:4653–67. 
doi:10.1128/IAI.73.8.4653. 
[7] Nel JG, Theron AJ, Durandt C, Tintinger GR, Pool R, Mitchell TJ, et al. Pneumolysin 
activates neutrophil extracellular trap formation. Clin Exp Immunol 2016;184:358–67. 
doi:10.1111/cei.12766. 
[8] Mirza S, Benjamin WH, Coan PA, Hwang SA, Winslett AK, Yother J, et al. The 
effects of differences in pspA alleles and capsular types on the resistance of 
Streptococcus pneumoniae to killing by apolactoferrin. Microb Pathog 2016;99:209–
19. doi:10.1016/j.micpath.2016.08.029. 
[9] Plumptre CD, Hughes CE, Harvey RM, Eijkelkamp BA, McDevitt CA, Paton JC. 
Overlapping functionality of the pht proteins in zinc homeostasis of Streptococcus 
pneumoniae. Infect Immun 2014;82:4315–24. doi:10.1128/IAI.02155-14. 
[10] André GO, Politano WR, Mirza S, Converso TR, Ferraz LFC, Leite LCC, et al. 
Combined effects of lactoferrin and lysozyme on Streptococcus pneumoniae killing. 
Microb Pathog 2015;89:7–17. doi:10.1016/j.micpath.2015.08.008. 
[11] Voss S, Hallström T, Saleh M, Burchhardt G, Pribyl T, Singh B, et al. The choline-
binding Protein PspC of Streptococcus pneumoniae interacts with the C-terminal 
heparin-binding domain of vitronectin. J Biol Chem 2013;288:15614–27. 
doi:10.1074/jbc.M112.443507. 
[12] Harada T, Ogawa Y, Eguchi M, Shi F, Sato M, Uchida K, et al. Phosphorylcholine 
and SpaA, a choline-binding protein, are involved in the adherence of Erysipelothrix 
rhusiopathiae to porcine endothelial cells, but this adherence is not mediated by the 
PAF receptor. Vet Microbiol 2014;172:216–22. doi:10.1016/j.vetmic.2014.04.012. 
[13] Verhoeven D, Xu Q, Pichichero ME. Vaccination with a Streptococcus pneumoniae 
trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects 
against lethal pneumonia in an infant murine model. Vaccine 2014;32:3205–10. 
doi:10.1016/j.vaccine.2014.04.004. 
		 30	
[14] Harfouche C, Filippini S, Gianfaldoni C, Ruggiero P, Moschioni M, Maccari S, et al. 
RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone 
RrgB, is protective In Vivo and elicits opsonic antibodies. Infect Immun 
2012;80:451–60. doi:10.1128/IAI.05780-11. 
[15] Xie X, Li Y, Zhang T, Fang HHP. Bacterial survival in evaporating deposited droplets 
on a teflon-coated surface. Appl Microbiol Biotechnol 2006;73:703–12. 
doi:10.1007/s00253-006-0492-5. 
[16] Walther B a, Ewald PW. Pathogen survival in the external environment and the 
evolution of virulence. Biol Rev Camb Philos Soc 2004;79:849–69. 
doi:10.1017/S1464793104006475. 
[17] Hamburger M, Green MJ. The problem of the dangerous carrier of hemolytic 
streptococci; observations upon the role of the hands, of blowing the nose, of 
sneezing, and of coughing in the dispersal of these microorganisms. J Infect Dis 
1946;79:33–44. 
[18] Walsh RL, Camilli A. Streptococcus pneumoniae Is Desiccation Tolerant and 
Infectious upon Rehydration. MBio 2011;2:e00092-11. doi:10.1128/mBio.00092-11. 
[19] Auranen K, Mehtälä J, Tanskanen A, S Kaltoft M. Between-strain competition in 
acquisition and clearance of pneumococcal carriage--epidemiologic evidence from a 
longitudinal study of day-care children. Am J Epidemiol 2010;171:169–76. 
doi:10.1093/aje/kwp351. 
[20] Lipsitch M, Abdullahi O, Dʼamour A, Xie W, Weinberger DM, Tchetgen ET, et al. 
Estimating Rates of Carriage Acquisition and Clearance and Competitive Ability for 
Pneumococcal Serotypes in Kenya With a Markov Transition Model. Epidemiology 
2012;23:1–10. doi:10.1097/EDE.0b013e31824f2f32. 
[21] Lipsitch M, Dykes JK, Johnson SE, Ades EW, King J, Briles DE, et al. Competition 
among Streptococcus pneumoniae for intranasal colonization in a mouse model. 
Vaccine 2000;18:2895–901. 
[22] Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, et al. Rates of 
acquisition and clearance of pneumococcal serotypes in the nasopharynges of 
children in Kilifi District, Kenya. J Infect Dis 2012;206:1020–9. 
doi:10.1093/infdis/jis447. 
[23] Melegaro A, Choi Y, Pebody R, Gay N. Pneumococcal carriage in United Kingdom 
families: estimating serotype-specific transmission parameters from longitudinal 
data. Am J Epidemiol 2007;166:228–35. doi:10.1093/aje/kwm076. 
[24] Hoti F, Erästö P, Leino T, Auranen K. Outbreaks of Streptococcus pneumoniae 
carriage in day care cohorts in Finland - implications for elimination of transmission. 
BMC Infect Dis 2009;9:102. doi:10.1186/1471-2334-9-102. 
[25] Zhang Q, Leong SC, McNamara PS, Mubarak A, Malley R, Finn A. Characterisation 
of regulatory t cells in nasal associated lymphoid tissue in children: Relationships 
with pneumococcal colonization. PLoS Pathog 2011;7. 
doi:10.1371/journal.ppat.1002175. 
[26] Lu Y-J, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, et al. Interleukin-17A 
mediates acquired immunity to pneumococcal colonization. PLoS Pathog 
2008;4:e1000159. doi:10.1371/journal.ppat.1000159. 
[27] Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R. Impaired Innate and 
Adaptive Immunity to Streptococcus pneumoniae and Its Effect on Colonization in an 
Infant Mouse Model  . Infect Immun 2009;77:1613–22. doi:10.1128/IAI.00871-08. 
[28] Cobey S, Lipsitch M. Niche and neutral effects of acquired immunity permit 
coexistence of pneumococcal serotypes. Science 2012;335:1376–80. 
doi:10.1126/science.1215947. 
		 31	
[29] Roche AM, Richard AL, Rahkola JT, Janoff EN, Weiser JN. Antibody blocks 
acquisition of bacterial colonization through agglutination. Mucosal Immunol 
2015;8:176–85. doi:10.1038/mi.2014.55. 
[30] Zangari T, Wang Y, Weiser JN. Streptococcus pneumoniae Transmission Is Blocked 
by Type-Specific Immunity in an Infant Mouse Model. MBio 2017;8:e00188-17. 
doi:10.1128/mBio.00188-17. 
[31] Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody 
responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a 
longitudinal household study. J Infect Dis 2005;192:387–93. doi:10.1086/431524. 
[32] Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, Mäkelä PH. Epidemiological 
evidence for serotype-independent acquired immunity to pneumococcal carriage. J 
Infect Dis 2009;200:99–106. doi:10.1086/599364. 
[33] Lebon A, Verkaik NJ, Labout J a M, de Vogel CP, Hooijkaas H, Verbrugh H a., et al. 
Natural antibodies against several pneumococcal virulence proteins in children 
during the pre-pneumococcal-vaccine era: The generation R study. Infect Immun 
2011;79:1680–7. doi:10.1128/IAI.01379-10. 
[34] Brien KLO, Wolfson LJ, Watt JP, Henkle E, Deloria-knoll M, Mccall N, et al. Burden 
of disease caused by Streptococcus pneumoniae in children younger than 5 years : 
global estimates. Lancet 2009;374:893–902. doi:10.1016/S0140-6736(09)61204-6. 
[35] Fedson DS, Scott J a, Scott G. The burden of pneumococcal disease among adults 
in developed and developing countries: what is and is not known. Vaccine 1999;17 
Suppl 1:S11-8. doi:10.1016/S0264-410X(99)00122-X. 
[36] Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. 
WHO 2013. 
http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo
_hib/en/ (accessed September 18, 2017). 
[37] The Evidence Base for Pneumococcal Conjugate Vaccines: Data for decision-
making around PCV use in childhood. 2017. 
[38] Holmlund E, Quiambao B, Ollgren J, Nohynek H, Käyhty H. Development of natural 
antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and 
pneumolysin in Filipino pregnant women and their infants in relation to 
pneumococcal carriage. Vaccine 2006;24:57–65. doi:10.1016/j.vaccine.2005.07.055. 
[39] Palmeira P, Quinello C, Ana L, Zago A, Carneiro-sampaio M. IgG Placental Transfer 
in Healthy and Pathological Pregnancies Cl ´. Clin Dev Immunol 2012;2012. 
doi:10.1155/2012/985646. 
[40] Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien KL, et al. The 
fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 
2012;11:841–55. doi:10.1586/erv.12.53. 
[41] Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, Phuanukoonnon S, et al. 
Maternal antibodies to pneumolysin but not to pneumococcal surface protein a delay 
early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine 
Immunol 2009;16:1633–8. doi:10.1128/CVI.00247-09. 
[42] Lopes CRC, Berezin EN, Ching TH, Canuto JDS, Costa VO Da, Klering EM. 
Ineffectiveness for infants of immunization of mothers with pneumococcal capsular 
polysaccharide vaccine during pregnancy. Braz J Infect Dis 2009;13:104–6. 
doi:S1413-86702009000200006 [pii] ET  - 2010/02/09. 
[43] Munoz FM, Englund J a, Cheesman CC, Maccato ML, Pinell PM, Nahm MH, et al. 
Maternal immunization with pneumococcal polysaccharide vaccine in the third 
trimester of gestation. Vaccine 2001;20:826–37. doi:http://dx.doi.org/10.1016/S0264-
410X(01)00397-8. 
		 32	
[44] Rosen A, Håkansson A, Aniansson G, Hansson C, Andersson B, Nylén O, et al. 
Antibodies to pneumococcal polysaccharides in human milk: lack of relationship to 
colonization and acute otitis media. Pediatr Infect Dis J 1996;15:498–507. 
[45] Lopes CC, Berezin EN, Scheffer D, Huziwara R, Sliva MI, Brandao  a., et al. 
Pneumococcal Nasopharyngeal Carriage in Infants of Mothers Immunized with 23V 
Non-conjugate Pneumococcal Polysaccharide Vaccine. J Trop Pediatr 2012;58:348–
52. doi:10.1093/tropej/fmr107. 
[46] Turner P, Turner C, Green N, Ashton L, Lwe E, Jankhot  a, et al. Serum antibody 
responses to pneumococcal colonization in the first 2 years of life: results from an 
SE Asian longitudinal cohort study. Clin Microbiol Infect 2013;19:E551-8. 
doi:10.1111/1469-0691.12431. 
[47] Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to 
pneumococcal vaccination in children younger than five years of age. J Infect Dis 
1983;148:131–7. 
[48] Leinonen M, Säkkinen A, Kalliokoski R, Luotonen J, Timonen M, Mäkelä PH. 
Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in 
pre-school age children. Pediatr Infect Dis 1986;5:39–44. 
[49] Bondada S, Wu HJ, Robertson DA, Chelvarajan RL. Accessory cell defect in 
unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine 
2000;19:557–65. doi:10.1016/S0264-410X(00)00161-4. 
[50] Mitchell R, Kelly DF, Pollard AJ, Trück J. Polysaccharide-specific B cell responses to 
vaccination in humans. Hum Vaccines Immunother 2014;10:1661–8. 
doi:10.4161/hv.28350. 
[51] Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to 
encapsulated bacteria and conjugate vaccines. Clin Dev Immunol 2008;2008. 
doi:10.1155/2008/628963. 
[52] Martin F, Kearney JF. MARGINAL-ZONE B CELLS. Nat Rev Immunol 2002;2:323–
35. doi:10.1038/nri799. 
[53] Bjarnarson SP, Benonisson H, Del Giudice G, Jonsdottir I. Pneumococcal 
polysaccharide abrogates conjugate-induced germinal center reaction and depletes 
antibody secreting cell pool, causing hyporesponsiveness. PLoS One 
2013;8:e72588. doi:10.1371/journal.pone.0072588. 
[54] Papadatou I, Orthopoulos G, Theodoridou M, Spoulou V. Long-lasting 
hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) in asplenic patients with β-thalassemia major. Vaccine 2015;33:3779–83. 
doi:10.1016/j.vaccine.2015.06.100. 
[55] Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. 
Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among 
adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. 
Vaccine 2011;29:2287–95. doi:10.1016/j.vaccine.2011.01.029. 
[56] Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: Long-
term persistence of circulating antibody and immunogenicity and safety after 
revaccination in adults. Vaccine 2012;30:4435–44. 
doi:10.1016/j.vaccine.2012.04.052. 
[57] Herva E, Luotonen J, Timonen M, Sibakov M, Karma P, Mäkelä PH. The effect of 
polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal 
carriage of Streptococcus pneumoniae. Scand J Infect Dis 1980;12:97–100. 
[58] Russell FM, Carapetis JR, Satzke C, Tikoduadua L, Waqatakirewa L, Chandra R, et 
al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent 
pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide 
		 33	
vaccine booster. Clin Vaccine Immunol 2010;17:1970–6. doi:10.1128/CVI.00117-10. 
[59] Macleod BYCM, Hodges RG, Heidelberger M, Bernhard AWG. Prevention of 
Pneumococcal Pneumonia by Immunization with specific capsular polysaccharides. 
J Exp Med 1945;82:445–65. 
[60] Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-
proteins. J Exp Med 1931;54:437–47. 
[61] Stanley A P, Robert S D, G. Scott G, Caroline B H, Martha L, Edgar K M, et al. 
Haemophilus Vaccine influenzae Type b Conjugate. Pediatrics 1988;81:908–11. 
[62] Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, 
and clinical trials. Hum Vaccin Immunother 2013;9:2505–23. doi:10.4161/hv.26109. 
[63] Mccool TL, Harding C V., Greenspan NS, Schreiber JR. B- and T-cell immune 
responses to pneumococcal conjugate vaccines: Divergence between carrier- and 
polysaccharide-specific immunogenicity. Infect Immun 1999;67:4862–9. 
[64] Gonçalves VM, Dias WO, Campos IB, Liberman C, Sbrogio-Almeida ME, Silva EP, 
et al. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP 
production, and stability. Vaccine 2014;32:1113–20. 
doi:10.1016/j.vaccine.2013.10.091. 
[65] Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 
2011;23:407–13. doi:10.1016/j.coi.2011.04.002. 
[66] Feldman C, Anderson R. Review: Current and new generation pneumococcal 
vaccines. J Infect 2014;69:309–25. doi:10.1016/j.jinf.2014.06.006. 
[67] Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction 
of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 
9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J 
Infect Dis 2002;185:927–36. 
[68] Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of 
pneumococcal nasopharyngeal carriage in early infancy after immunization with 
tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria 
toxoid. Pediatr Infect Dis 1997;16:1060–4. 
[69] Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, et al. 
Immunogenicity, Impact on Carriage and Reactogenicity of 10-Valent Pneumococcal 
Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine in Kenyan 
Children Aged 1-4 Years: A Randomized Controlled Trial. PLoS One 
2014;9:e85459. doi:10.1371/journal.pone.0085459. 
[70] Le Polain O, Flasche S, Prieto-Merino D, Goldblatt D, Edmunds WJ. The Efficacy 
and Duration of Protection of Pneumococcal Conjugate Vaccines Against 
Nasopharyngeal Carriage. Pediatr Infect Dis J 2015;34:858–64. 
doi:10.1097/INF.0000000000000717. 
[71] Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal 
conjugate vaccines on nasopharyngeal carriage and invasive disease among 
unvaccinated people: Review of evidence on indirect effects. Vaccine 2013;32:133–
45. doi:10.1016/j.vaccine.2013.05.005. 
[72] Miller E, Andrews NJ, Waight P a, Slack MP, George RC. Herd immunity and 
serotype replacement 4 years after seven-valent pneumococcal conjugate 
vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 
2011;11:760–8. doi:10.1016/S1473-3099(11)70090-1. 
[73] Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Wei W, et al. Five 
winters of pneumococcal serotype replacement in UK carriage following PCV 
introduction. Vaccine 2015;33:2015–21. 
[74] Choi YH, Jit M, Gay N, Andrews N, Waight P a, Melegaro A, et al. 7-Valent 
		 34	
pneumococcal conjugate vaccination in England and Wales: is it still beneficial 
despite high levels of serotype replacement? PLoS One 2011;6:e26190. 
doi:10.1371/journal.pone.0026190. 
[75] Bottomley C, Roca A, Hill PC, Greenwood B, Isham V. A mathematical model of 
serotype replacement in pneumococcal carriage following vaccination. J R Soc 
Interface 2013;10. 
[76] Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus 
influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 
1999;5:336–45. 
[77] Hammitt LL, Akech DO, Morpeth SC, Karani A, Nyongesa S, Ooko M, et al. 
Population impact of 10-valent pneumococcal conjugate vaccine (PCV) on 
nasopharyngeal carriage of Streptococcus pneumoniae in Kilifi, Kenya. 10th Int. 
Symp. Pneumococci Pneumococcal Dis., Glasgow, Scotland.: 2016. 
[78] Roca A, Bojang A, Bottomley C, Gladstone RA, Adetifa JU, Egere U, et al. Effect on 
nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the 
Expanded Programme of Immunization in The Gambia. Vaccine 2015;33:7144–51. 
doi:10.1016/j.vaccine.2015.11.012. 
[79] O’Brien K, Moulton L, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy, 
safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in 
children. Northern California Kaiser Permanente Vaccine Study Center Group. 
Pediatr Infect Dis J 2000;19:187–95. 
[80] O’Brien K, Moulton L, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and 
safety of seven-valent conjugate pneumococcal vaccine in American Indian children: 
group randomised trial. Lancet 2003;362:355–61. 
[81] Segal N, Greenberg D, Dagan R, Ben-Shimol S. Disparities in PCV impact between 
different ethnic populations cohabiting in the same region: A systematic review of the 
literature. Vaccine 2016;34:4371–7. doi:10.1016/j.vaccine.2016.07.004. 
[82] Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the 
seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012;31:501–8. 
doi:10.1097/INF.0b013e31824de9f6. 
[83] Madhi SA, Nunes MC. The potential impact of pneumococcal conjugate vaccine in 
Africa: Considerations and early lessons learned from the South African experience. 
Hum Vaccin Immunother 2016;12:314–25. doi:10.1080/21645515.2015.1084450. 
[84] De Oliveira LH, Camacho LAB, Coutinho ESF, Martinez-Silveira MS, Carvalho AF, 
Ruiz-Matus C, et al. Impact and effectiveness of 10 and 13-valent pneumococcal 
conjugate vaccines on hospitalization and mortality in children aged less than 5 
years in Latin American countries: A systematic review. PLoS One 2016;11:1–25. 
doi:10.1371/journal.pone.0166736. 
[85] Lucero MG, Nohynek H, Williams G, Tallo V, Simões E a F, Lupisan S, et al. 
Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically 
confirmed pneumonia among children less than 2 years of age in the Philippines: a 
randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009;28:455–
62. doi:10.1097/INF.0b013e31819637af. 
[86] Myint TTH, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The 
impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal 
disease: A literature review. Adv Ther 2013;30:127–51. doi:10.1007/s12325-013-
0007-6. 
[87] Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RAN, Nohynek H, et al. 
Pneumococcal conjugate vaccines for preventing vaccine-type invasive 
pneumococcal disease and X-ray defined pneumonia in children less than two years 
		 35	
of age ( Review ). Cochrane Database Sytematic Rev 2009 2010;CD004977. 
[88] Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. 
Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska 
Native Pneumococcal Conjugate Vaccine Coverage. JAMA 2007;297:1784–92. 
[89] Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al. Impact 
of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal 
disease in Finnish children - A population-based study. PLoS One 2015;10:1–11. 
doi:10.1371/journal.pone.0120290. 
[90] Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, et al. Effects of 
Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal 
Carriage in The Gambia: A Cluster-Randomized Trial. PLoS Med 2011;8:e1001107. 
doi:10.1371/journal.pmed.1001107. 
[91] Nhantumbo AA, Weldegebriel G, Katsande R, De Gouveia L, Comé CE, Cuco AZ, et 
al. Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in 
Mozambique, 2013 - 2015. PLoS One 2017;12:2013–5. 
doi:10.1371/journal.pone.0177746. 
[92] von Mollendorf C, Tempia S, von Gottberg A, Meiring S, Quan V, Feldman C, et al. 
Estimated severe pneumococcal disease cases and deaths before and after 
pneumococcal conjugate vaccine introduction in children younger than 5 years of 
age in South Africa. PLoS One 2017;12:e0179905. 
doi:10.1371/journal.pone.0179905. 
[93] Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of 
nine-valent pneumococcal conjugate vaccine against pneumonia and invasive 
pneumococcal disease in The Gambia: randomised, double-blind, placebo-
controlled trial. Lancet 2005;365:1139–46. doi:10.1016/S0140-6736(05)71876-6. 
[94] Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 
9-valent pneumococcal conjugate vaccine in children with and those without HIV 
infection. N Engl J Med 2003;349:1341–8. doi:10.1056/NEJMoa035060. 
[95] Shea KM, Weycker D, Stevenson  a E, Strutton DR, Pelton SI. Modeling the decline 
in pneumococcal acute otitis media following the introduction of pneumococcal 
conjugate vaccines in the US. Vaccine 2011;29:8042–8. 
doi:10.1016/j.vaccine.2011.08.057. 
[96] Lau WCY, Murray M, El-turki A, Saxena S, Ladhani S, Long P, et al. Impact of 
pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. 
Vaccine 2015;33:5072–9. doi:10.1016/j.vaccine.2015.08.022. 
[97] Littorin N, Ahl J, Uddén F, Resman F, Riesbeck K. Reduction of Streptococcus 
pneumoniae in upper respiratory tract cultures and a decreased incidence of related 
acute otitis media following introduction of childhood pneumococcal conjugate 
vaccines in a Swedish county. BMC Infect Dis 2016;16:407. doi:10.1186/s12879-
016-1750-5. 
[98] Ben-shimol S, Givon-lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of 
Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal 
and Nonpneumococcal Otitis Media. Clin Infect Dis 2016;63:611–8. 
doi:10.1093/cid/ciw347. 
[99] Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, et al. Long-term 
immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in 
human immunodeficient virus infected and non-infected children in the absence of a 
booster dose of vaccine. Vaccine 2007;25:2451–7. 
doi:10.1016/j.vaccine.2006.09.019. 
[100] Madhi SA, Klugman KP. World Health Organisation definition of “radiologically-
		 36	
confirmed pneumonia” may under-estimate the true public health value of conjugate 
pneumococcal vaccines. Vaccine 2007;25:2413–9. 
doi:10.1016/j.vaccine.2006.09.010. 
[101] Rosenblut A, Napolitano C, Pereira A, Moreno C, Kolhe D, Lepetic A, et al. Etiology 
of acute otitis media and serotype distribution of Streptococcus pneumoniae and 
Haemophilus influenzae in Chilean children <5 years of age. Medicine (Baltimore) 
2017;96:e5974. doi:10.1097/MD.0000000000005974. 
[102] Buzatto GP, Tamashiro E, Proenca-Modena JL, Saturno TH, Prates MC, Gagliardi 
TB, et al. The pathogens profile in children with otitis media with effusion and 
adenoid hypertrophy. PLoS One 2017;12:1–12. doi:10.1371/journal.pone.0171049. 
[103] von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et 
al. Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. N Engl 
J Med 2014;371:141111140010002. doi:10.1056/NEJMoa1401914. 
[104] Mackenzie GA, Hill PC, Sahito SM, Jeffries DJ, Hossain I, Bottomley C, et al. Impact 
of the introduction of pneumococcal conjugate vaccination on pneumonia in The 
Gambia : population-based surveillance and case-control studies. Lancet Infect Dis 
2017:1–9. doi:10.1016/S1473-3099(17)30321-3. 
[105] Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of 
the introduction of pneumococcal conjugate vaccination on invasive pneumococcal 
disease in The Gambia: A population-based surveillance study. Lancet Infect Dis 
2016:703–11. doi:10.1016/S1473-3099(16)00054-2. 
[106] Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. 
Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal 
carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in 
Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Heal 
2014:8–10. doi:10.1016/S2214-109X(14)70224-4. 
[107] Hammitt LL, Anthony E, Morpeth SC, Mutuku A, Ojal J, Mturi N, et al. Population 
effect of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal 
disease and nasopharyngeal carriage in Kilifi, Kenya. Manuscr Prep 2017. 
[108] Silaba M, Ooko M, Bottomley C, Sande J, Benamore R, Park K, et al. The impact of 
10-valent Pneumococcal Conjugate Vaccine on the incidence of radiologically-
confirmed pneumonia and on clinically-defined pneumonia among children in Kilifi, 
Kenya. Manuscr Prep n.d. 
[109] Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, et al. 
Estimating the protective concentration of anti-pneumococcal capsular 
polysaccharide antibodies. Vaccine 2007;25:3816–26. 
doi:10.1016/j.vaccine.2007.01.119. 
[110] Millar E V, O’Brien KL, Bronsdon M a, Madore D, Hackell JG, Reid R, et al. 
Anticapsular serum antibody concentration and protection against pneumococcal 
colonization among children vaccinated with 7-valent pneumococcal conjugate 
vaccine. Clin Infect Dis 2007;44:1173–9. doi:10.1086/513199. 
[111] Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, et al. 
Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular 
serum antibody concentrations after pneumococcal conjugate vaccine 
administration. Vaccine 2016;34:4313–20. doi:10.1016/j.vaccine.2016.06.075. 
[112] Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, et al. Serological 
criteria for evaluation and licensure of new pneumococcal conjugate vaccine 
formulations for use in infants. Vaccine 2003;21:3265–72. doi:10.1016/S0264-
410X(03)00230-5. 
[113] Principi N, Esposito S. Serological criteria and carriage measurement for evaluation 
		 37	
of new pneumococcal vaccines. Hum Vaccines Immunother 2015;11:1494–500. 
doi:10.1080/21645515.2015.1033600. 
[114] Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. 
Serotype-specific effectiveness and correlates of protection for the 13-valent 
pneumococcal conjugate vaccine: A postlicensure indirect cohort study. Lancet 
Infect Dis 2014;14:839–46. doi:10.1016/S1473-3099(14)70822-9. 
[115] Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O’Brien KL, Scott JAG, et al. 
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses 
While Sustaining Herd Immunity in High-Income Countries. PLoS Med 2015;12:1–5. 
doi:10.1371/journal.pmed.1001839. 
[116] Borrow R, Stanford E, Waight P, Helbert M, Balmer P, Warrington R, et al. Serotype-
specific immune unresponsiveness to pneumococcal conjugate vaccine following 
invasive pneumococcal disease. Infect Immun 2008;76:5305–9. 
doi:10.1128/IAI.00796-08. 
[117] Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after 
vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 
2011;10:307–22. doi:10.1586/erv.11.8. 
[118] Väkeväinen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, et al. 
Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants 
carrying pneumococcus at the time of vaccination. J Pediatr 2010;157:778–83.e1. 
doi:10.1016/j.jpeds.2010.04.071. 
[119] Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist C-A. Nasopharyngeal 
carriage of Streptococcus pneumoniae shortly before vaccination with a 
pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in 
early infancy. J Infect Dis 2010;201:1570–9. doi:10.1086/652006. 
[120] Tamura K, Matsubara K, Ishiwada N, Nishi J, Ohnishi H, Suga S, et al. 
Hyporesponsiveness to the infecting serotype after vaccination of children with 
seven-valent pneumococcal conjugate vaccine following invasive pneumococcal 
disease. Vaccine 2014;32:1444–50. doi:10.1016/j.vaccine.2014.01.031. 
[121] Sigurdardottir ST, Center KJ, Davidsdottir K, Arason VA, Hjalmarsson B, Elisdottir R, 
et al. Decreased immune response to pneumococcal conjugate vaccine after 23-
valent pneumococcal polysaccharide vaccine in children. Vaccine 2014;32:417–24. 
doi:10.1016/j.vaccine.2013.11.029. 
[122] Mbelle N, Huebner RE, Wasas  a D, Kimura  a, Chang I, Klugman KP. 
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent 
pneumococcal conjugate vaccine. J Infect Dis 1999;180:1171–6. 
doi:10.1086/315009. 
[123] Obaro SK, Adegbola R a, Chang I, Banya W a, Jaffar S, Mcadam KW, et al. Safety 
and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 
administered simultaneously but in a separate syringe with diphtheria, tetanus and 
pertussis vaccines in Gambian infants. Pediatr Infect Dis J 2000;19:463–9. 
[124] Nurkka  a, Ahman H, Korkeila M, Jäntti V, Käyhty H, Eskola J. Serum and salivary 
anti-capsular antibodies in infants and children immunized with the heptavalent 
pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20:25–33. 
doi:10.1097/00006454-200101000-00006. 
[125] Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, et al. 
Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a 
longitudinal study. Clin Infect Dis 2008;46:807–14. doi:10.1086/528688. 
[126] Tigoi CC, Gatakaa H, Karani A, Mugo D, Kungu S, Wanjiru E, et al. Rates of 
acquisition of pneumococcal colonization and transmission probabilities, by 
		 38	
serotype, among newborn infants in Kilifi District, Kenya. Clin Infect Dis 
2012;55:180–8. doi:10.1093/cid/cis371. 
[127] VFC | 2001-04-06 CDC Vaccine Price List 2001. 
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-
list/2001/2001-04-06.html (accessed August 21, 2017). 
[128] VFC | 03-12-2010 CDC Vaccine Price List 2010. 
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-
list/2010/2010-03-12.html (accessed August 21, 2017). 
[129] de Oliveira LH, Trumbo SP, Matus CR, Sanwogou NJ, Toscano CM. Pneumococcal 
conjugate vaccine introduction in Latin America and the Caribbean: progress and 
lessons learned. Expert Rev Vaccines 2016:1–10. 
doi:10.1586/14760584.2016.1166961. 
[130] About the Pan American Health Organization (PAHO). PAHO 2016. 
http://www.paho.org/hq/index.php?option=com_content&view=article&id=91&Itemid
=220&lang=en (accessed August 23, 2017). 
[131] Revolving Fund Prices. PAHO 2017. 
http://www.paho.org/hq/index.php?option=com_content&view=article&id=9561%3A2
014-revolving-fund-prices&catid=839%3Arevolving-fund&Itemid=40714&lang=en 
(accessed August 23, 2017). 
[132] How the pneumococcal AMC works - Gavi, the Vaccine Alliance n.d. 
http://www.gavi.org/funding/pneumococcal-amc/how-the-pneumococcal-amc-works/ 
(accessed March 24, 2017). 
[133] Countries approved for support - Gavi, the Vaccine Alliance 2014. 
http://www.gavi.org/results/countries-approved-for-support/ (accessed January 20, 
2015). 
[134] Transition process - Gavi, the Vaccine Alliance n.d. 
http://www.gavi.org/support/sustainability/transition-process/ (accessed July 10, 
2017). 
[135] Kenya : Gavi support documents - Proposals, reports, plans, decision letters n.d. 
http://www.gavi.org/country/kenya/documents/ (accessed March 24, 2017). 
[136] Nurhonen M, Cheng AC, Auranen K. Pneumococcal transmission and disease in 
silico: a microsimulation model of the indirect effects of vaccination. PLoS One 
2013;8:e56079. doi:10.1371/journal.pone.0056079. 
[137] Van Effelterre T, Moore MR, Fierens F, Whitney CG, White L, Pelton SI, et al. A 
dynamic model of pneumococcal infection in the United States: implications for 
prevention through vaccination. Vaccine 2010;28:3650–60. 
doi:10.1016/j.vaccine.2010.03.030. 
[138] Choi YH, Jit M, Flasche S, Gay N, Miller E. Mathematical modelling long-term effects 
of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in 
England and Wales. PLoS One 2012;7:e39927. doi:10.1371/journal.pone.0039927. 
[139] Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-
dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-
valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine 
2009;27:4694–703. doi:10.1016/j.vaccine.2009.05.062. 
[140] Scott JAG, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The Kilifi 
Health and Demographic Surveillance System (KHDSS). Int J Epidemiol 
2012;41:650–7. doi:10.1093/ije/dys062. 
[141] Adetifa IMO, Bwanaali T, Wafula J, Mutuku A, Karia B, Makumi A, et al. Cohort 
Profile: The Kilifi Vaccine Monitoring Study. Int J Epidemiol 2016:dyw202. 
doi:10.1093/ije/dyw202. 
		 39	
[142] Etyang AO, Munge K, Bunyasi EW, Matata L, Ndila C, Kapesa S, et al. Burden of 
disease in adults admitted to hospital in a rural region of coastal Kenya: An analysis 
of data from linked clinical and demographic surveillance systems. Lancet Glob Heal 
2014;2:216–24. doi:10.1016/S2214-109X(14)70023-3. 
[143] Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying 
age-related rates of social contact using diaries in a rural coastal population of 
Kenya. PLoS One 2014;9:e104786. doi:10.1371/journal.pone.0104786. 
[144] Flasche S, Ojal J, Le O, Waroux P De, Otiende M, Brien KLO, et al. Assessing the 
efficiency of catch-up campaigns for the introduction of pneumococcal conjugate 
vaccine : a modelling study based on data from PCV10 introduction in Kilifi , Kenya. 
BMC Med 2017;15:1–10. doi:10.1186/s12916-017-0882-9. 
[145] Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models 
of pneumococcal carriage and the impact of the Heptavalent Pneumococcal 
Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010;10:90. 
doi:10.1186/1471-2334-10-90. 
[146] Colijn C, Cohen T, Hanage WP, Fraser C, Coexistence N, Link C. No coexistence 
for free : Neutral null models for multistrain pathogens. Epidemics 2009;1:2–13. 
doi:10.1016/j.epidem.2008.07.001. 
 
  
		 40	
Chapter 2: Research paper 1 
Title: Sustained reduction in vaccine-type invasive pneumococcal disease despite waning 
effects of a catch-up campaign in Kilifi, Kenya: a mathematical model based on pre-
vaccination data. 
Author(s): John Ojal, Stefan Flasche, Laura L. Hammitt, Donald Akech, Moses C. Kiti, 
Tatu Kamau, Ifedayo Adetifa, Markku Nurhonen, J. Anthony G. Scott, Kari Auranen 
Journal/Publisher: Vaccine, 2017 Aug 16; 35(35 Pt B): 4561-4568 
Type of publication: Original contribution  
Stage of publication: In press 
Academic peer-reviewed: Yes  
Copyright: Open access  
Candidate’s role:  
I conceived the study. I developed the mathematical transmission model and implemented 
it in the R software to generate all the results presented in the manuscript. I wrote the first 
draft of the manuscript, reviewed and responded to all comments from co-authors as well 
as those from journal reviewers to generate the published manuscript. 
Candidate’s signature:  
 
Supervisor or senior author’s signature to confirm Candidates role: 
  
		 41	
Sustained reduction in vaccine-type invasive pneumococcal disease despite waning 
effects of a catch-up campaign in Kilifi, Kenya: a mathematical model based on pre-
vaccination data. 
 
John Ojal1,3, Stefan Flasche3, Laura L. Hammitt1,2, Donald Akech1, Moses C. Kiti1, Tatu 
Kamau4, Ifedayo Adetifa1,3, Markku Nurhonen5, J. Anthony G. Scott1,3, Kari Auranen5,6 
 
1. KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya 
2. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA		
3. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and 
Tropical Medicine, London, United Kingdom 
4. Kenya Ministry of Health, Nairobi, Kenya 
5. Department of Public Health Solutions, National Institute for Health and Welfare (THL), Finland 
6. Department of Mathematics and Statistics, University of Turku, Finland 
 
Key words:  pneumococcal conjugate vaccine; nasopharyngeal carriage; Kenya; 
mathematical model 
 
Corresponding author:  
John Ojal  
PO Box 230- 80108 
Kilifi, Kenya. 
Tel +254 728 095 710 
E-mail: jojal@kemri-wellcome.org / john.ojal@lshtm.ac.uk  
		 42	
Abstract 
Background: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine 
together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-
vaccination surveillance study based in Kilifi, there was a substantial decline in invasive 
pneumococcal disease (IPD). However, given the continued circulation of the vaccine 
serotypes it is possible that vaccine-serotype disease may re-emerge once the effects of 
the catch-up campaign wear off.  
Methods: We developed a compartmental, age-structured dynamic model of 
pneumococcal carriage and invasive disease for three serotype groups: the 10-valent 
vaccine serotypes	and two groups of non-vaccine serotypes based on their susceptibility to 
mutual competition. The model was calibrated to age- and serotype-specific data on 
carriage and IPD in the pre-vaccination era and used to predict carriage prevalence and 
IPD up to ten years post-vaccination in Kilifi. The model was validated against the 
observed carriage prevalence after vaccine introduction. 
Results:  The model predicts a sustained reduction in vaccine-type pneumococcal carriage 
prevalence from 33% to 8% in infants and from 30% to 8% in 1-5 year olds over the 10-
year period following vaccine introduction. The incidence of IPD is predicted to decline 
across all age groups resulting in an overall reduction of 56% in the population, 
corresponding to 10.4 cases per 100000 per year. The vaccine-type IPD incidence is 
estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to increase 
by 52%. The model’s predictions of carriage prevalence agree well with the observed data 
in the first five years post-vaccination. 
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Conclusion: We predict a sustained and substantial decline in IPD through PCV 
vaccination and that the current regimen is insufficient to fully eliminate vaccine-serotype 
circulation in the model. We show that the observed impact is likely to be sustained despite 
waning effects of the catch-up campaign. 
Background 
Reduction in nasopharyngeal carriage of vaccine-type pneumococci has been 
documented after vaccination with pneumococcal conjugate vaccines (PCVs) [1–3]. 
Moreover, by reducing pneumococcal acquisition, PCVs reduce pneumococcal 
transmission in the community offering indirect protection to the unvaccinated [4]. 
However, non-vaccine-type pneumococci rapidly colonise this vacated ecological niche, 
which can result in serotype replacement carriage	[5] and replacement disease reducing 
the overall impact of PCVs [6]. With support from Gavi, The Vaccine Alliance, African 
countries have been introducing PCVs since 2009. Kenya introduced a 10-valent PCV 
(PCV10) targeting serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in 2011. In Kilifi, a 
coastal area with enhanced surveillance for invasive pneumococcal disease (IPD) and 
carriage prevalence, the introduction was supplemented by a catch-up campaign in 
children <5 years old. At the same time annual carriage prevalence surveys have been 
conducted in the Kilifi Health and Demographic Surveillance System (KHDSS) population 
since 2009 [5]. 
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Within a few months post-vaccination vaccine-type pneumococcal carriage and disease 
had	dropped substantially in all age groups. However, vaccine serotypes (VTs) continue to 
circulate in the community [7,5]. This raises the concern that, after the population effects of 
the catch-up campaign have worn off, vaccine-type pneumococcal disease will re-emerge.  
We developed a dynamic compartmental model parameterized with detailed data from the 
KHDSS population [8] to describe the pre-vaccination pneumococcal epidemiology and 
predict the long-term impact of PCV10 in Kilifi. We use post-vaccination data on carriage 
and disease over the past five years for validation of the model predictions. 
Methods  
Data  
Kilifi County Hospital (KCH) is the main referral hospital in KHDSS. At KCH, morbidity 
events linked with the population register have been used to define the incidence of 
hospital presentation with infectious diseases, including IPD [8,9]. Datasets on 
pneumococcal carriage, IPD and contact patterns in KHDSS are described in detail 
elsewhere [5,10,11]. Here we briefly describe them as used in the current analysis. 
Nasopharyngeal pneumococcal carriage surveys 
Two cross-sectional surveys of pneumococcal carriage were done pre-vaccination. 
Nasopharyngeal swabs were collected and pneumococcal serotype-specific carriage 
ascertained [5] to obtain the pre-vaccination age-specific prevalence and serotype 
distribution of carriage. The two datasets were combined since there were no significant 
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differences between them in the carriage prevalence or serotype distribution (Appendix 
chapter 1).  
The non-vaccine serotypes (NVTs) were classified as weak or strong based on their 
susceptibility to competition and carriage incidence, as estimated in a prior field study 
within KHDSS [12]. Strong NVTs (23B, 11A, 15A, 6A, 16F, 35B, 10A, 13, 23A 19A, 21; 
ordered by increasing susceptibility to competition) were less susceptible to competition. 
Two NVTs (34, 15B/C) were classified as strong for their higher carriage incidences 
compared to many of the ones chosen on the basis of susceptibility. The remaining NVTs 
were classified as weak (Appendix chapter 2).  
Prospective diary survey 
Selected residents from KHDSS filled in a diary on the ages of all persons they physically 
contacted on one randomly assigned weekday [10]. For children, the diary was completed 
by their guardians. This information defined a social mixing matrix of contact frequencies 
between age groups.  
Carriage model structure 	
We developed a compartmental, age-structured dynamic model with 14 pneumococcal 
carriage states (Figure 1). The model has a Susceptible-Infected-Susceptible (SIS) 
structure for three serotype groups: the PCV10 serotypes, strong NVT and weak NVT.  
At any point in time, an unvaccinated individual can be susceptible (non-carrying) in state !; carry a VT, !	; carry a weak NVT, !!; carry a strong NVT, !!; carry simultaneously a 
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weak and strong NVT, !!"; carry simultaneously a VT and weak NVT, !!; or carry 
simultaneously a VT and a strong NVT, !!. Once vaccinated, the individual moves to one 
of the corresponding states (!(!), !(!),!!(!), !!(!), !!"(!), !!(!), !!(!)). The equations of inter-
state transitions are presented in Appendix chapter 3.  
Parameterisation  
Population structure 
The model population	is stratified into six age groups (<1, 1-5, 6-14, 15-20, 21-49 and ≥ 
50 years) corresponding to those in the diary survey and reflecting the age structure in 
KHDSS as of 1st January 2010. Individuals in the model are born completely susceptible to 
carriage according to prevailing birth rates and die according to age-specific mortality rates 
from KHDSS (Table 1). 
Acquisition of carriage 
A susceptible unvaccinated individual in age group i becomes colonised with VTs, strong 
NVTs or weak NVTs at age-group-specific time-dependent rates (forces of infection) 
denoted by !!"(!),	!!"#(!) and !!"#(!), respectively. The forces of infection were expressed 
as functions of the social mixing matrix and age-group specific factors (!!) that scale the 
rate of social contacts into infectious contacts (Appendix chapter 3). Due to competition 
between serotypes in colonising the nasopharynx, the acquisition rate of a secondary 
serotype is lower than the acquisition rate of that serotype in a completely susceptible 
individual. Three competition parameters, !!!, !!! and !!!, represent the fraction by which 
acquisition rates of secondary serotypes are reduced in <6 year olds infected with VTs, 
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weak NVTs and strong NVTs, respectively. Two competition parameters, !!" = !! = !! 
and !!, were used for individuals aged ≥ 6 years infected with VTs/weak NVTs and strong 
NVTs, respectively.  
Clearance of carriage 
The immune clearance rates of carriage (Appendix chapter 4) depend on the serotype 
group and age (<1, 1-5 and >5 years) and were obtained from a prior study in Kenyan 
children [12]. 
Disease 
For each serotype group and age group, case-to-carrier ratios were calculated as ratios of 
the observed IPD incidence at KCH [11] to the respective model-predicted pre-vaccination 
carriage incidence. The case-to-carrier ratios were assumed to remain unchanged post-
vaccination and were multiplied with the predicted carriage incidence to predict post-
vaccination IPD incidence. 
Vaccination  
In Kenya, children receive PCV10 at age 6, 10 and 14 weeks. In the model, !=80% of all 
newborns are considered vaccinated at age 18 weeks, one month after the third dose of 
the 3-dose series (Table 1). A catch-up programme is simulated by vaccinating 65% of 
children younger than 5 years at the onset of the vaccination programme. Upon 
vaccination, an individual moves to the corresponding state in the vaccine-protected 
compartment based on his/her prevailing carriage status.  
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The vaccine efficacy against carriage is modelled as a 50% reduction (! = 0.50) in the 
acquisition rate of VTs in a vaccinated individual relative to an unvaccinated individual 
(Table 1). The vaccine efficacy against carriage progression to disease (VEprog) was 
calculated as a function of ! and the vaccine efficacy against IPD (VEIPD = 85%) as:  
!"!"#$ = 1− !!!"!"#!!! = 70%.  
We assumed that a proportion ! = 0.12 of the vaccinated population loses their protection 
every year. This corresponds to an average duration of protection for an individual of just 
over 8 years (Table 1). 
Implementation and model calibration  
In the first stage, the stationary solution of the transmission model was fitted to the age-
stratified pre-vaccination carriage prevalence and serotype distribution (Appendix chapter 
1). Using a multinomial likelihood function and uninformative priors in a Bayesian 
framework, the five competition parameters (!!", !!!, !!, !!! and !!!) and six 
scaling/infectivity parameters (!!, !!, !!, !!, !!, !!) were estimated (Appendix chapter 5). In 
each iteration, bootstrapping the social contact data and reconstructing the mixing matrix 
incorporated uncertainty in the social contact rates. A stationary population with equal birth 
and mortality rates was assumed.  
In the second stage, the posterior samples of model parameters obtained in the first stage 
were applied in a prediction model. Projections were made assuming a constant 
population. To measure how fast the effect of the catch-up campaign wanes, we 
calculated the additional cases of IPD the campaign prevents in the first 10 years and 
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estimated the time required to achieve 90% of that effect. Simulations were performed in R 
[13].  
Sensitivity analysis  
The sensitivity of the predicted IPD incidence averted, i.e., the difference in the overall 
incidence of IPD before and at 10 years post-vaccination, was assessed with respect to 
uncertainties in the assumed levels of: (i) vaccine efficacy against carriage acquisition; (ii) 
vaccine efficacy against IPD; (iii) the waning rate of vaccine-induced protection against 
carriage; (iv) vaccine coverage.  
We performed additional simulations under a growing population using birth and death 
rates corresponding to the local demographics [8]. The probabilities of contact per person 
per day were recalculated for each time step according to the current population (Appendix 
chapter 6). 
Model validation 
We visually assessed proximity of the base-case predictions of the age-group specific 
carriage of VTs and NVTs to the corresponding observed values over a five-year period 
post-vaccination (2011-2015). 
Results 
Model fit to pre-vaccination epidemiology 
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There was a good agreement between the observed age-group and serotype-group 
specific pre-vaccination carriage prevalence and their posterior estimates (Figure 2). 
Within each age group, the 95% credible intervals agreed with the data. Nonetheless, the 
differences in the posterior mean estimates of the proportions of carriers of VTs and NVTs 
among pneumococcal carriers were in most instances larger than observed in individuals 
≥6 years old, compared to the differences in individuals <6 years old.	
Competition parameters  
The probability of infection per contact was higher among 1-5 and 6-14 year olds as 
compared to other age groups (Table 1). An individual <6 years carrying a vaccine-
serotype had a 61% (95% credible interval, CrI, 29%-85%) protection against acquiring 
NVTs, relative to an uninfected individual of the same age group. In older age groups, the 
corresponding level of protection was 23% (95% CrI 1%-70%).  
Model projections on pneumococcal carriage  
Under the base-case model, the overall prevalence of pneumococcal carriage was 
estimated to remain essentially at its pre-vaccination level, with only a slight reduction from 
44% to 41% within 10 years post-vaccination. The prevalence of VTs in the overall 
population was estimated to reduce from 16% to 4%, with a simultaneous increase in the 
prevalence of NVTs from 28% to 36%.  
The prevalence of VTs was predicted to reduce in all age groups. In the older, mostly 
unvaccinated population, the reduction was estimated to be about two thirds of the pre-
vaccination level (Table 2), suggesting a benefit of herd immunity. Changes in the 
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prevalence of VTs and NVTs occur within the first 4 to 5 years post-vaccination and little 
change was predicted thereafter (Figure 3).  
Model projections on IPD 
The incidence of IPD from VTs was projected to decline in all age groups. The changes in 
IPD and carriage were linked and over 50% reduction in IPD occurs within the first 4 to 5 
years after PCV introduction. The overall reduction in the incidence of IPD ten years post-
vaccination is predicted to be 56% (Table 3). The overall reduction in the incidence of IPD 
from year 5 to 10 was 7% (95% predictive interval: -0.4% to 14%). As a result of waning 
direct effects of the catch-up campaign and increasing herd-effects of routine immunisation 
with time, we estimated that the incremental benefit of a catch-up over routine vaccination 
alone would be negligible from year 7 after introduction of PCV10. 
Sensitivity analyses 
Among the variables included in the sensitivity analysis, the duration of protection had the 
largest effect on the predicted IPD incidence averted in year 10, followed by the vaccine 
efficacy against carriage. The vaccine efficacy against IPD had the least influence (Figure 
S1).  
Assuming a growing population, the overall prevalence of carriage was projected to 
decline to a somewhat lower level of 35% (95% prediction interval 30%-40%) ten years 
post-vaccination (Appendix chapter 7).  
Model validation 
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The point predictions and corresponding 95% prediction intervals (PI) of carriage 
prevalence cover most of the observed values, showing good predictive ability (Figure S2). 
Among <1 and 1-5 year olds the model predicted much lower carriage prevalence of NVTs 
in year 2015 (49% vs. 70% observed and 38% vs. 52% observed, respectively).  
Discussion 
We used a model calibrated with local data to predict the incidence of pneumococcal 
carriage and IPD in Kilifi, Kenya, over a 10-year period post-vaccination to assess whether 
additional measures have to be considered to prevent a resurgence of vaccine-type 
pneumococci once the impact of the catch-up campaign wanes. We validated the model 
against immediate post-vaccination epidemiological data, a unique exercise in 
pneumococcal carriage models, and found that such resurgence is unlikely if the routine 
immunisation programme continues.   
Most PCV introductions in African countries have occurred since year 2011. Therefore, 
only a few years of observation are available to assess impact. A meta-analysis of four 
randomized trials in African children aged 9–24 months showed that carriage of VTs 
decreased with vaccination but the overall carriage remained the same [14]. In the United 
Kingdom, the overall prevalence of pneumococcal carriage was stable four years post-
vaccination [15]. In our model predictions, the overall carriage prevalence remains 
essentially unchanged due to serotype replacement in carriage. Replacement carriage 
was most prominent in <6 year olds because the pre-vaccination proportion of VTs among 
pneumococcal carriers was highest in young children (Appendix chapter 1). We predict 
that elimination of VTs in this community is unlikely. In high-income countries that have 
almost eliminated circulation of VTs, a reduced-dose schedule has been considered to 
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improve the cost-effectiveness of the program [16]. The World Health Organization (WHO) 
also recently convened a working group to review the policy recommendations for the 
optimal use of PCVs in low- and middle-income countries, which includes discussion of 
reduced dose schedules [17]. Theoretically, where herd protection has been established, it 
may be possible to sustain it using, for example, a single dose in infancy and a booster 
dose in the second year of life. In the Kenyan setting, however, where vaccine-type 
pneumococci continue to circulate several years post introduction of PCV with a catch-up 
campaign, it would be difficult to argue that disease prevention among infants is currently 
guaranteed by herd protection.  
In the model presented, the incidence of IPD is predicted to decline across all age groups. 
The non-vaccine-type IPD incidence is expected to increase by 52%, which translates to 
an increase in the annual incidence of 1.9 per 100000, suggesting little replacement 
disease relative to the reduction in the annual overall vaccine-type IPD incidence of 12.3 
per 100000. This is explained by the lower average case-to-carrier ratios (i.e., lower 
invasiveness) of the replacing non-vaccine serotypes (Appendix chapter 8).  
South Africa and The Gambia introduced PCV7 in 2009 and replaced it with PCV13 in 
2011 [18,19]. The reduction in vaccine-type and overall IPD reported in these countries are 
similar to the predictions our model produces for Kilifi, Kenya, over the first few years post-
vaccination. This, however, does not validate the model because of differences across the 
settings. The vaccination coverage in Kenya is likely to differ from coverage in The 
Gambia and South Africa, and Kenya introduced PCV10. We thus validated our model 
predictions against observed carriage prevalence and IPD incidence in Kilifi. The model 
predictions were generally consistent with the observed data (Figure S2). The model, 
however, underestimated prevalence of carriage of NVTs in <6 year olds in 2014-15. 
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Relaxing the assumption of a constant population size only made minimal difference to the 
goodness of fit (Figure S3).  
Pneumococcal serotypes are heterogeneous in transmissibility and mutual competition 
[12,20]. By splitting the NVTs into two groups and allowing unequal mutual competition 
between these groups, our model accounts for some of this heterogeneity. We did not split 
VTs because we aimed to reproduce serotype replacement with as small a number of 
parameters as possible, by limiting the number of compartments. Splitting NVTs was 
preferred because the group has a larger number of serotypes and hence more 
heterogeneity. The model projected differing magnitudes of change in the prevalence of 
the strong and weak NVTs. Given the different case-to-carrier ratios of the two groups of 
NVTs (Appendix chapter 8), the projected non-vaccine-type IPD incidence is different from 
what would have been predicted using a single group of NVTs. Nonetheless, grouping 
serotypes can create some ‘super types’ that might have different characteristics, e.g. 
higher acquisition rate of the VTs group compared to the individual serotypes in the group. 
This might lead to conservative vaccine effectiveness estimates. Grouping of serotypes 
may also result in the estimated acquisition rate of NVTs being lower than that of individual 
serotypes in the group. This would lead to an underestimation of the indirect impact of 
vaccination on NVTs - lower than the observed predicted prevalence of NVTs.  
To limit the number of estimated parameters, age dependency in competition was 
considered using two age classes (<6 and ≥6 years). Some discrepancies between the 
fitted and observed age-specific serotype distributions were present. The proportion of 
carriers of VTs was overestimated among carriers aged ≥15 years (Figure 2); the 
susceptibility to competition of VTs against NVTs is likely biased downwards in adults, thus 
underestimating the reduction in prevalence of VTs. With our current specification, the 
		 55	
estimates of competition parameters in age group ≥6 years largely depend on data from 
the age groups 6-14 years. A model including more groups of VTs and NVTs or individual 
serotypes [21–23] would allow for even more heterogeneity. However, the estimation of 
competition parameters from available carriage data would become increasingly difficult in 
a highly compartmentalized model. 
We estimated case-to-carrier ratios using hospital-based data on IPD incidence in KHDSS 
[8]. The access to care for IPD is unknown in KHDSS, but meningitis incidence is 
underestimated by over 30% by hospital-based surveillance [24]. Since IPD and meningitis 
are severe syndromes, the underestimation of IPD incidence could be similar implying 
case-to-carrier ratios are likely underestimated. Nonetheless, since the ratios estimated 
pre-vaccination are applied post-vaccination, the predicted reduction in IPD is not affected.  
We excluded partial protection from first and second doses. Our estimates of the vaccine 
impact may thus be conservative if the vaccines’ efficacy is substantial after fewer than 
three doses. We treated vaccine efficacy against carriage and its waning as equal for 
routine and catch-up vaccination. A Kenyan trial estimated vaccine efficacy against 
carriage of 40% among children aged 1-4 years [3], lower than the 50% for infant 
vaccination [25–27]. The duration of protection of catch-up vaccination is not documented 
yet. One dose of PCV administered outside of infancy may have a more enduring effect 
than 3 routine infant doses. If so, our similar treatment of the duration of immunity means 
there is no inflection on the carriage prevalence of VTs as the cohort of highly immune <5 
year olds who received a catch-up dose is replaced by a new birth cohort of less immune 
children over time. 
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We assumed children are born completely susceptible to acquisition of pneumococcus 
ignoring the influence of maternal antibodies. Newborns in a Kenyan study had a very high 
rate of first acquisition [20]. Early acquisition has also been reported in other African 
settings [28–30]. In Netherlands and Papua New Guinea a protective effect of maternal 
IgG antibodies against colonisation in infancy was not observed [31,32]. Based on high 
early acquisition rates and insufficient evidence of protection from maternal antibodies in 
some studies, this assumption is plausible.  
A significant reduction in IPD caused by vaccine-related serotypes 6A and 19A IPD has 
been observed in some PCV10-using settings [33]. However, surveillance in Kilifi recorded 
no change in carriage of serotype 6A and increased carriage of serotype 19A after vaccine 
introduction [7]. We have not observed a change in IPD caused by these serotypes. We 
therefore did not account for 6A and 19A as vaccine serotypes. 
In conclusion, we predict a substantial and sustainable decline in the carriage prevalence 
of VTs among vaccinated and unvaccinated individuals and consequently a reduction of 
about 56% in overall IPD incidence ten years post-vaccination. While we show that the 
current schedule is sufficient to limit vaccine-type pneumococcal carriage to current levels, 
it is unlikely to achieve elimination of VTs. Strategies that heavily rely on protection from 
the herd, including a reduced dose schedule, will need additional efforts to stop circulation 
of VTs before their implementation.  
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Table 1: Parameters of the dynamic transmission model and the sources of information. 
The parameters are classified as those estimated (calibrated) in the context of the model 
and those derived from external sources. 
 
Parameter / input Estimate/Value (Interval*) Source 
Calibrated   
Competition parameters !!! = 0.44 (0.13, 0.82) 
 !!! = 0.59 (0.19, 0.96)  !!! = 0.39 (0.15, 0.71) !! = 0.11 (0.004, 0.49) !!" = !! = !! = 0.77 (0.30, 0.99) 
 
Estimated 
Probability of infection per 100 contacts  !! =0.13 (0.07, 0.25) !! =0.40 (0.30, 0.55) !! =0.32 (0.24, 0.43) !! =0.07 (0.04, 0.13) !! =0.16 (0.11, 0.23) !! =0.06 (0.04, 0.09) 
Estimated 
Case-to-carrier ratios** Appendix chapter 7 [11] 
   
From external sources   
Clearance rates Appendix chapter 3 [12] 
Birth rate 32.0 per 1000/year [8] 
Age-specific mortality  Appendix chapter 5  [8] 
Contact rates   [10] 
Vaccine efficacy against carriage 
acquisition (!) 50% (40-60) [3,25–27] 
Vaccine efficacy against IPD 85% (80-90) [34] 
Waning rate of protection against 
carriage (!) 0.12 per year (0.09 – 0.20) [35] 
Routine vaccination coverage (!)  80% (70-90) [9,11] 
Catch-up coverage 65% (60-70) [9,11] 
* The intervals indicated for the estimated parameters are 95% credible intervals. The intervals indicated for the rest of the parameters are the ranges within 
which they were sampled in the model to account for their uncertainty and assess the model’s sensitivity. 
**IPD incidence from Kilifi district hospital in KHDSS is divided by the carriage incidence from the model to obtain case-to-carrier ratios (Appendix chapter 
7) 
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Table 2: The prevalence of nasopharyngeal carriage of pneumococci pre- and 10 years post-vaccination. The table presents the posterior 
predictive mean values with the 95% posterior predictive intervals.  
 Pre-vaccination   10 years post-vaccination 
Age group 
(years) 
Carriage  
prevalence 
VT* Strong 
 NVT** 
Weak  
NVT 
  Carriage  
prevalence 
VT Strong  
NVT 
Weak  
NVT 
           
<1 80.8 (67.8-90.1) 32.6 (25.1-40.5) 37.5 (30.6-45.8) 9.9 (7.1-13.2)   75.7 (61.4-87.2) 8.3 (1.6-18.2) 50.9 (40.9-62.6) 15.2 (10.5-22.2) 
1-5 72.5 (65.2-78.5) 29.5 (23.9-35.2) 29.7 (24.6-35.2) 13.1 (9.6-17.0)   67.2 (58.9-74.6) 8.0 (1.5-16.9) 39.2 (32.2-48.5) 19.3 (14.1-25.5) 
6-14 54.0 (43.1-64.8) 17.0 (13.9-21.2) 26.8 (18.9-35.0) 9.9 (7.4-13.5)   49.7 (38.6-61.0) 4.4 (0.9-9.6) 32.0 (23.6-41.2) 12.8 (9.5-17.1) 
15-20 27.9 (17.0-41.7) 9.1 (5.7-13.9) 13.4 (7.6-20.7) 5.3 (3.1-8.6)   25.3 (15.6-38.0) 2.5 (0.5-6.0) 15.8 (9.5-24.3) 6.8 (4.1-10.8) 
21-49 25.5 (17.0-35.5) 8.6 (5.8-12.1) 12.0 (7.6-17.5) 4.8 (3.0-7.2)   23.2 (15.2-33.0) 2.5 (0.5-5.6) 14.2 (9.2-20.9) 6.2 (3.9-9.3) 
50+ 21.0 (14.0-30.0) 7.1 (4.7-10.1) 9.8 (6.2-14.6) 4.0 (2.6-6.0)   19.1 (12.7-27.3) 2.0 (0.4-4.5) 11.7 (7.6-17.2) 5.2 (3.3-7.9) 
           
Overall 44.4 (40.2-48.9) 15.9 (13.3-18.7) 20.4 (16.8-24.2) 8.0 (6.1-10.2)   40.8 (36.0-46.0) 4.3 (0.8-9.1) 25.4 (21.2-30.0) 10.9 (8.4-13.8) 
* Vaccine serotypes 
** Non-vaccine serotypes 
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Table 3: The incidence of invasive pneumococcal disease (IPD) pre- and 10 years post-vaccination. The table presents the posterior predictive 
mean values with the 95% predictive intervals. 
 
 Pre-vaccination IPD incidence (/100,000/year)  10 years post-vaccination IPD incidence (/100,000/year)   
Age group (years) VT Strong NVT Weak NVT  VT Strong NVT Weak NVT IRR* 
         
<1 67.0 21.0 7.1  6.7 (1.1, 15.1) 37.0 (29.5, 50.4) 11.6 (9.4, 15.6) 0.59 (0.51, 0.72) 
1-5 39.3 5.1 0.7  6.4 (1.2, 14.7) 7.8 (6.5, 10.0) 1.1 (0.9, 1.4) 0.34 (0.24, 0.50) 
6-14 7.3  1.0 0.0  1.4 (0.3, 3.3) 1.2 (1.1, 1.5) 0.0 (0.0, 0.0) 0.33 (0.20, 0.54) 
15-20 1.0 0.0 0.0  0.3 (0.1, 0.5) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.26 (0.05, 0.54) 
21-49 4.2 0.9 0.0  1.2 (0.2, 2.3) 1.1 (1.0, 1.3) 0.0 (0.0, 0.0) 0.45 (0.28, 0.66) 
≥50 9.2 2.8 4.1   2.5 (0.5, 5.1) 3.4 (3.1, 3.9) 5.3 (4.7, 6.3) 0.71 (0.60, 0.82) 
         
All ages 14.8 2.7  0.9  2.5 (0.5, 5.6) 4.2 (3.5, 5.3) 1.3 (1.1, 1.6) 0.44 (0.34, 0.56) 
(*) The incidence rate ratio (IRR) is between the overall IPD incidence before vaccination and the IPD incidence 10 years post vaccination. 
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Figure 1. Model structure flow diagram. The epidemiological states include individuals 
that are susceptible (non-carrying), !; carry a vaccine serotype, !; carry a weak non-
vaccine serotype, !!; carry a strong non-vaccine serotype, !!; carry simultaneously a 
weak and a strong non-vaccine serotype, !!"; carry simultaneously a vaccine serotype 
and a weak non-vaccine serotype, !!; or carry simultaneously a vaccine serotype and a 
strong non-vaccine serotype, !! (see text). Once vaccinated, the individual moves to one 
of the corresponding states, !(!),  !(!),!!(!),!!(!),!!(!)!"# !!(!) . The acquisition rates from 
the single to multiple serotype carriage states are reduced by competition parameters 
denoted by ! with two subscripts; the first denoting the serotype group (!, ! !"# !, for VT, 
strong NVT and weak NVT respectively) of the resident serotypes and the second 
denoting the age-group. The competition parameters have two sets of values, one for age 
group <6 and another for age group ≥6 years (see text). The age-group specific VT, weak 
NVT and strong NVT clearance rates are denoted by r!", r!"# and r!"#, respectively. In 
addition to the transitions between the 14 epidemiological states as shown in the Figure, 
individuals die from any states at age-specific death rates and new individuals are born 
into the completely susceptible state.  
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Figure 2. Model fit. Observed prevalence (red points) of pneumococcal carriage across 
age groups (top-left panel) and the proportion of carriers of VT (top-right panel), strong 
NVT (bottom-left panel) and weak NVT (bottom-right panel) among pneumococcal carriers 
prior to vaccine introduction. The black points show the corresponding estimated values of 
the prevalence/proportion, based on data given in Appendix chapter 1. The capped bars 
represent the 95% credible intervals. The dotted lines in the top-left panel (and the points 
they pass through) are the observed (red) and the predicted (black) proportions of double 
carriers among <1 and 1-5 year olds. For these two age groups, the top-right, bottom-left 
and bottom-right panels present the proportions of single carriers of the respective types 
(VT, strong NVT, weak NVT) among all carriers in the age group. 
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Figure 3: Model projections on carriage prevalence over 10 years by age group. 
Projected cumulative prevalence of pneumococcal carriage of VT (red), strong NVT (blue) 
and weak NVT (lime green) by age group over time since vaccine introduction. For each 
age group, the dotted lines show the 95% predictive intervals for the overall prevalence of 
pneumococcal carriage.	
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Supplementary Figure S1: Sensitivity analysis for inputs. The impact of uncertainties 
in four selected model inputs (y-axis) on the predicted number of averted IPD cases per 
year per 100,000 in year 10 after vaccine introduction (x-axis). The vertical line at the 
middle of the plot marks the mean number of IPD cases (10.2) averted in year 10 per 
100,000 when all the shown inputs are at their respective means. The horizontal bars 
correspond to predicted ranges of the number of averted IPD cases when each input 
variable is sampled from a normal distribution, with respective 95% ranges as given in the 
brackets. The number of averted cases is based on a linear model approximation of the 
simulation output. 
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Supplementary Figure S2: Observed and predicted carriage prevalence over time, under constant population. Observed 
(circular dots with 95% credible intervals shown by spikes) and predicted (lines with 95% predictive intervals shown by shaded 
areas) carriage prevalence of VT (red), strong NVT (blue) and weak NVT (lime green) over time since vaccine introduction. The age 
groups are labelled at the panel titles. 
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Supplementary Figure S3: Observed and predicted carriage prevalence over time, under growing population. Observed 
(circular dots with 95% credible intervals shown by spikes) and predicted (lines with 95% predictive intervals shown by shaded 
areas) carriage prevalence of VT (red), strong NVT (blue) and weak NVT (lime green) over time since vaccine introduction. The age 
groups are labelled at the panel titles. 
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Appendix  
Chapter 1. Prevalence of pneumococcal carriage in Kilifi, Kenya.  
Serotypes were grouped as vaccine-types (VT, those included in PCV10), 
strong non-vaccines serotypes (23B, 11A, 15A, 6A, 16F, 35B, 10A, 13, 23A, 
19A, 21, 34, 15B/C; see appendix chapter 2), and weak non-vaccine-types 
(the rest). The data came from two surveys of pneumococcal carriage in Kilifi, 
Kenya (2009-2010) [5]. The reported prevalences in table A.1 below are age-
standardised, with the KHDSS reference population as at 1 Jan 2010 
(midpoint of the two survey years), since the surveys were based on 10 age 
strata collapsed to six in the current analysis. Based on the total number of 
individuals in each age group, the numbers of carriers of VTs, strong NVTs 
and weak NVTs as presented in this table were calculated to match the 
estimated standardised carriage prevalence of the respective serotype 
groups. 
 
Table A.1: Prevalence of pneumococcal carriage and the serotype 
distribution by age group.  
 
Age group 
 (years) 
      Number of  
carriers N (%) 
VT  
N (%) 
Strong NVT  
N (%) 
Weak 
NVT  
N (%) 
Total  
N (%) 
      
<1 51 (83.6) 25 (41.0) 22 (36.1) 4 (6.6) 61 (100.0) 
1-5 200 (72.5) 88 (31.9) 79 (28.6) 33 (12.0) 276 (100.0) 
6-14 86 (52.8) 26 (16.0) 48 (29.4) 12 (7.4) 163 (100.0) 
15-20 29 (26.9) 8 (7.4) 13 (12.0) 8 (7.4) 108 (100.0) 
21-49 49 (25.3) 11 (5.7) 27 (13.9) 11 (5.7) 194 (100.0) 
≥50 43 (20.5) 10 (4.8) 22 (10.5) 11 (5.2) 210 (100.0) 
 
.   	
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Chapter 2. Division of serotypes into VTs, strong NVTs and weak NVTs 
Vaccine serotypes (VTs) are serotype in the PCV-10 vaccine (1, 4, 5, 6B, 7F, 9V, 14, 18C, 
19F and 23F). The non-vaccine serotypes (NVTs) were classified as weak or strong based 
on their susceptibility to competition (a measure of competitive strength of a serotype 
defined as the rate at which individuals carrying that serotype switch to carry another 
serotype, relative to the rate at which that other serotype colonizes an uncolonised person) 
and carriage incidence, as estimated in a prior field study within KHDSS1. In our model 
strong NVTs were categorised as those less susceptible to competition by having a lower 
susceptibility; NVTs with susceptibility estimate of 1 and below were considered strong. 
These serotypes were: 23B, 11A, 15A, 6A, 16F, 35B, 10A, 13, 23A 19A and 21, ordered 
by increasing susceptibility to competition. Two NVTs (34, 15B/C) were also classified as 
strong for their higher carriage incidences than many of the ones chosen on the basis of 
susceptibility. The remaining NVTs were classified as weak (Table A.2). 
 
Table A.2: Categorisation of serotypes 
Serotype Serotype  
group 
Susceptibility Incidence 
(per 1000 days) 
Duration of carriage 
(days) 
19F VTs 0.481 3.07 88.5 
23B strong NVTs 0.523 0.93 60.3 
6B VTs 0.524 1.77 115.6 
11A strong NVTs 0.544 1.08 72.3 
15A strong NVTs 0.560 0.65 55.0 
6A strong NVTs 0.580 2.51 123.8 
23F VTs 0.586 1.46 67.8 
16F strong NVTs 0.703 0.44 52.5 
9V VTs 0.752 0.88 44.6 
35B strong NVTs 0.813 1.15 88.1 
10A strong NVTs 0.874 0.97 65.2 
23A strong NVTs 0.910 0.34 54.2 
14 VTs 0.911 1.36 69.5 
19A strong NVTs 0.956 0.87 58.9 
13 strong NVTs 0.969 0.79 70.4 
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18C VTs 0.970 0.49 49.7 
21 strong NVTs 1.059 0.31 93.0 
34 strong NVTs 1.166 0.71 76.3 
19B weak NVTs 1.176 0.54 63.5 
1 VTs 1.183 0.25 31.0 
35A weak NVTs 1.191 0.29 61.9 
15B strong NVTs 1.353 1.25 51.8 
other weak NVTs 1.366 1.86 41.3 
7C weak NVTs 1.400 0.62 40.1 
15C strong NVTs 1.503 1.08 56.3 
3 weak NVTs 1.519 0.74 40.8 
20 weak NVTs 1.533 0.59 28.3 
33B weak NVTs 2.074 0.38 29.6 
 
1 Lipsitch M, Abdullahi O, Dʼamour A, Xie W, Weinberger DM, Tchetgen ET, et al. Estimating Rates of Carriage Acquisition and 
Clearance and Competitive Ability for Pneumococcal Serotypes in Kenya With a Markov Transition Mode. Epidemiology 2012;23:1–10. 
 
Chapter 3. Dynamic model structure in equations 
All parameters and states in the equations below have been defined in the main article 
(see also Figure 1). The quantities !, !! and ! !  denote the birth rate, age-specific death 
rate and population size at time !, respectively. The term !!(!) denotes the rate of 
movement to the next age group from the !!! age group (see Appendix chapter 6). The 
term ! ∗ ! !  in the first equation applies only to the first age group (< 1 year olds). In the 
first age group, all terms with +!!!! !  denoting movement into the age group, by aging, 
from a lower age category should be excluded from all equations. In the last age group, 
≥50 years, all terms with −!! !  denoting movement from the age group by aging should 
be excluded from all equations. 
 !!! !!" = !!" ∗ !! ! + !!"# ∗ !!" ! + !!"# ∗ !!" ! − !! ! ∗ !!" ! + !!"# ! + !!"# ! − ! ∗ !! !+ ! ∗ !! ! ! + ! ∗ ! ! − !! ∗ !! ! − !! ! ∗ !! ! + !!!! ! ∗ !!!! !  
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!!! !!" = !!"# ∗ !!" ! + !!"# ∗ !!" ! − !!" ∗ !! ! + !!" ! ∗ !! ! − !! !∗ !! ∗ !!"# ! + !! ∗ !!"# ! − ! ∗ !! ! + ! ∗ !! ! ! − !! ∗ !! ! − !! ! ∗ !! !+ !!!! ! ∗ !!!! !  !!!" !!" = !!"# ∗ !!"# ! + !!" ∗ !!" ! − !!"# ∗ !!" ! + !!"# ! ∗ !! ! − !!" !∗ !! ∗ !!! ! + !! ∗ !!"# ! − ! ∗ !!" ! + ! ∗ !!"! ! − !! ∗ !!" ! − !! ! ∗ !!" !+ !!!! ! ∗ !!"!! !
 !!!" !!" = !!"# ∗ !!"# ! + !!" ∗ !!" ! − !!"# ∗ !!" ! + !!"# ! ∗ !! ! − !!" !∗ !! ∗ !!" ! + !! ∗ !!"# ! − ! ∗ !!" ! + ! ∗ !!"! ! − !! ∗ !!" ! − !! ! ∗ !!" !+ !!!! ! ∗ !!"!! !
 !!!"# !!" = !! ∗ !!"# ! ∗ !!" ! + !! ∗ !!"# ! ∗ !!" ! − !!"# + !!"# ∗ !!"# ! − ! ∗ !!"# ! + !∗ !!"#! ! − !! ∗ !!"# ! − !! ! ∗ !!"# ! + !!!! ! ∗ !!"#!! !
 !!!" !!" = !! ∗ !!"! ! ∗ !! ! + !! ∗ !!" ! ∗ !!" ! − !!"# + !!" ∗ !!" ! − ! ∗ !!" ! + ! ∗ !!"! ! − !!∗ !!" ! − !! ! ∗ !!" ! + !!!! ! ∗ !!"!! !  !!!" !!" = !! ∗ !!"# ! ∗ !! ! + !! ∗ !!" ! ∗ !!" ! − !!"# + !!" ∗ !!" ! − ! ∗ !!" ! + ! ∗ !!"! !− !! ∗ !!" ! − !! ! ∗ !!" ! + !!!! ! ∗ !!"!! !  
 !!! ! !!" = !!" ∗ !! ! ! + !!"# ∗ !!"! ! + !!"# ∗ !!"! ! − !! ! !∗ 1 − ! ∗ !!" ! + !!"# ! + !!"# ! + ! ∗ !! ! − ! ∗ !! ! ! − !! ∗ !! ! ! − !! !∗ !! ! ! + !!!! ! ∗ !!!!! !  !!! ! !!" = !!"# ∗ !!"! ! + !!"# ∗ !!"! ! − !!" ∗ !! ! ! + 1 − ! ∗ !!" ! ∗ !! ! ! − !! ! !∗ !! ∗ !!"# ! + !! ∗ !!"# ! + ! ∗ !! ! ! − ! ∗ !! ! ! − !! ∗ !! ! ! − !! !∗ !! ! ! + !!!! ! ∗ !!!!! !
 
		 74	
!!!"! !!" = !!"# ∗ !!"#! ! + !!" ∗ !!"! ! − !!"# ∗ !!"! ! + !!"# ! ∗ !! ! ! − !!"! !∗ 1 − ! ∗ !! ∗ !!" ! + !! ∗ !!"# ! + ! ∗ !!" ! − ! ∗ !!"! ! − !! ∗ !!"! ! − !! !∗ !!"! ! + !!!! ! ∗ !!"!!! !
 !!!"! !!" = !!"# ∗ !!"#! ! + !!" ∗ !!"! ! − !!"# ∗ !!"! ! + !!"# ! ∗ !! ! ! − !!"! !∗ 1 − ! ∗ !! ∗ !!" ! + !! ∗ !!"# ! + ! ∗ !!" ! − ! ∗ !!"! ! − !! ∗ !!"! ! − !! !∗ !!"! ! + !!!! ! ∗ !!"!!! !  !!!"#! !!" = !! ∗ !!"# ! ∗ !!"! ! + !! ∗ !!"# ! ∗ !!"! ! − !!"# + !!"# ∗ !!"#! ! + ! ∗ !!"# ! − !∗ !!"#! ! − !! ∗ !!"#! ! − !! ! ∗ !!"#! ! + !!!! ! ∗ !!"#!!! !
 !!!"! !!" = !! ∗ !!"# ! ∗ !! ! ! + 1 − ! ∗ !! ∗ !!" ! ∗ !!"! ! − !!"# + !!" ∗ !!"! ! + ! ∗ !!" !− ! ∗ !!"! ! − !! ∗ !!"! ! − !! ! ∗ !!"! ! + !!!! ! ∗ !!"!!! !  !!!"! !!" = !! ∗ !!"# ! ∗ !! ! ! + 1 − ! ∗ !! ∗ !!" ! ∗ !!"! ! − !!"! + !!" ∗ !!"! ! + ! ∗ !!" !− ! ∗ !!"! ! − !! ∗ !!"! ! − !! ! ∗ !!"! ! + !!!! ! ∗ !!"!!! !  
 
The forces of infection by VTs, weak NVTs, and strong NVTs are defined by equations 1, 2 
and 3 below:  !!" ! = !!" ∗ !! ! + !!" ! + !!" ! + !! ! ! + !!"! ! + !!"! !                   (1)!  !!"# ! = !!" ∗ !!" ! + !!"# ! + !!" ! + !!"! ! + !!"#! ! + !!"! !        (2)!  !!"# ! = !!" ∗ !!" ! + !!"# ! + !!" ! + !!"! ! + !!"#! ! + !!"! !           (3)!  
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where the !!" is the per capita transmission rate between an individual (carrier) in age 
class j and a (susceptible) individual in age class i. These rates are expressed as a 
function of the social mixing matrix !!" as !!" = !!∗!!"!! , where the age group specific 
proportionality factor !! scales the rate of social contacts into infectious contacts and 
represents the susceptibility to acquisition of carriage, given a contact1. The elements of 
the matrix !!" are the mean numbers of social contacts an individual in age class ! makes 
with individuals in age class ! per unit time and !! is the population size of the !!! age 
group. The unknown scaling factors !! were allowed differ across age groups, based on 
the initial observation that the pre-vaccination prevalence of carriage in the three first age 
groups was significantly different but the prevalence in each of the age groups above the 
age of 15 years were similar despite the varying average rates of social contacts. 
 
Chapter 4. Clearance rates  
To obtain the average age-group specific clearance rate for each serotype group, a 
weighted mean of the clearance rates of individual serotypes in the group was computed. 
The incidences of the individual serotypes were used as weights. For infants, the 
clearance rates were computed for the strong NVTs and weak NVTs. For 1-5 and ≥6 year 
olds, a single clearance rate was computed for the weak and strong NVTs by taking the 
weighted average of the clearance rates of all NVTs. 
 
1 Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-
spread infectious agents. Am J Epidemiol 2006;164:936–44. doi:10.1093/aje/kwj317. 
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Table A.3: Clearance rates (per month) by age group and serotype group.     
 
 Serotype group 
Age group (years) VT Strong NVT Weak NVT 
<1 0.271 0.285 0.601 
1-5 0.546 0.662 0.662 
≥6 0.934 0.928 0.928 
 
 
 
 
Chapter 5. Estimation of the model parameters 
 
The model was calibrated to the age-specific prevalence and serotype distributions in the 
pre-vaccination era (Appendix chapter 1), assuming a steady-state distribution of carriage 
in the population. Since the calibration data recorded only one serotype for each carrying 
individual, there were only four carriage states (!! ,!! ,!!"  and  !!") on which to define the 
likelihood. The model output has three additional states !!"# ,!!" ,!!" . Therefore, for the 
age groups 6-14, 15-20, 21-49 and ≥50 years, the model output for the seven carriage 
states was collapsed into four states as follows: !!! = !! + 0.5 ∗ !!" + !!"  !!"! = !!" + 0.5 ∗ !!" + !!"#  !!"! = !!" + 0.5 ∗ !!" + !!"#  
This choice carries the assumption that in a doubly-colonised individual either of the two 
colonising serotypes was detected with 50% probability. 
For the two youngest age groups, <1 and 1-5 years, data on the proportion of doubly-
colonised individuals among pneumococcal carriers were available from a study in Kenya. 
Consequently, in the numerical estimation algorithm (see below), the proportion ! “of 
doubly-colonised individuals in <6 year olds was randomly generated from a normal 
distribution with mean 24% and standard deviation of 3.5%. For any realisation of the 
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proportion, the expected number of doubly-colonised individuals in the first two age groups 
is then !!"# =  ρ ∗ (V+  !! +  !!). The observed data for the two youngest age groups 
was adjusted to include five classes of carriage by 
!! = !! ,!! 1− ! ,!!" 1− ! ,!!" 1− ! ,!!"# !  
 
Accordingly, the model output for the carriage states was collapsed into 5 states by adding 
together the doubly-colonised states !! = !!" + !!" + !!"#  so that collapsed model 
output was !! ,!! ,!!" ,!!" ,!!  for <6 year olds. 
 
Denote the vectors containing the number of individuals in each !!! carriage status in the !!! age group in the empirical calibration data by !!". Denote the vectors containing the 
model output of the proportions of the carriage status in the !!!age group by !! ! . Vector ! contains all model parameters that are estimated from the data. 
Denote the set of model parameters by ! = !!, !!, !!, !!, !!, !!, !!!, !!!, !!!, !!" , !! , where !!(! = 1,2,3,4,5,6) are the proportionality factors that scale the rate of social contacts into 
infectious contacts and !!!, !!!, !!!, !!" , !! are the competition parameters. The likelihood 
function of the model parameters is based on a multinomial distribution. In particular, the 
counts !! .  in the !!! age group follow a multinomial distribution, so that their log-likelihood 
based on the observations is  	!!"!"# !!"(!)!!!!!!!!! , 
where !! = 5 for the two youngest age groups and 4 otherwise. For any given set, !, the 
model equations (Appendix chapter 3) were solved to find the stationary numbers of 
individuals in each of the pre-vaccination compartments, from these numbers the age 
group specific carriage distribution in the four (or five for the first two age groups) 
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compartments was derived as the model output. The routine BBsolve in R1 was used to 
solve the system of equations for a stationary solution.  
The Metropolis-Hastings algorithm was used to draw samples from the posterior 
distributions of the parameters. A non-informative (uniform distribution in the range 0-1) 
prior was used for each parameter and the posterior distributions of the parameters were 
summarised to obtain point estimates (posterior mean) and probability (credibility) intervals 
for parameters included in !. 100,000 MCMC iterations were used. After a burn-in of 
40,000 the remaining samples, which were stationary, were thinned to 2000; the posterior 
means and 95% credible intervals of the parameters were calculated from these samples. 
1 Varadhan R, Gilbert PD. BB : An R Package for Solving a Large System of Nonlinear Equations and for Optimizing a High-Dimensional Nonlinear 
Objective Function. October 2009;32:1–26. 
Chapter 6. Population model 
Population under constant mortality across age groups 
Denote the age-specific mortality, i.e., the per capita rate of death by ! ! . The steady-
state age distribution is ! ! = !"# ! ! ! !"!!! , where the normalising constant ! =!"# − ! ! !"!! !"!! . 
In case of constant mortality across age groups ! ! = ! and the steady state age 
distribution is exponential, i.e., ! ! = ! ∗ exp (−! ∗ !). Denote the age group boundaries ! = !!,… , !! = (0,1,6,15,21,50,∞)  (years) and the observed numbers of individuals in 
each of the age groups in the KHDSS in the year before vaccine introduction as !! =(!!,… ,!!). To estimate a constant rate !, the steady-state age distribution was fitted to 
the observed data based on a multinomial likelihood for !: 
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!"# (−!!!)− !"# (−!!!!!) !! .!!!!  
The maximum likelihood estimate for ! was found to be 0.046 per year (or 1.25E-04 per 
day). Based on this estimate, the fitted proportion of individuals in each of the age groups 
is shown in Table A.4. 
 
Table A.4: Observed and model age distribution in the KDHSS before vaccine introduction. 
A constant birth and death rate was assumed. 
Age Group   
(years) 
Number of 
 individuals 
Observed  
Proportion 
Model  
Proportion  
<1 9,424 0.037 0.045 
1-5 45,727 0.180 0.195 
6-14 68,648 0.271 0.256 
15-20 32,815 0.129 0.121 
21-49 72,705 0.287 0.281 
≥50 24,288 0.096 0.102 
 
Under the assumptions of a constant death rate, in age group ! with upper bound !! = !!,… ,!! = (1,6,15,21,50) years, the per capita rate of aging is calculated as: 
!!(!) = ! ∗ exp (−! ∗ !!) for all !. 
Individuals in the age group ≥50 do not move from that age group due to aging. 
Population under age-specific mortality rates 
Predictions of pneumococcal prevalence and invasive disease were done under an 
alternative assumption of a growing population, based the crude birth rate (8.78E-05 per 
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day) and age-specific death rates (Table A.5) in the KHDSS population. This section 
summarises how the per capita rate of aging was derived under this model. 
 
Denote the age-specific per capita mortality rate as !(!) and the number of individuals of 
age ! at calendar time !  by (!, !) . The time evolution of !(!, !) is defined through the 
following equation: !"(!, !)!" = −! !, ! ! !                                                                  (1) 
With boundary conditions (i)  ! 0, ! = !(!)! and (ii) ! !, 0 = ! 0 !(!), where ! is the 
per capita rate of birth, !(!) is the total population at time ! and !(!) is the probability 
density of age at time 0 estimated from the KHDSS data as an exponential distribution so 
that ! ! = ! ∗ exp (−! ∗ !). 
The rate of individuals of age !! (in the !!! age group) moving to the next age group at time ! is given by the solution to equation (1) and its boundary conditions. For the solution, we 
write ! !! = !"# − ! ! !"!!!  for survival up to age !!, ! ! − !! ! for the number of 
individuals (per time unit) born at time ! − !! (if ! > !!), and ! 0 ! !! − !  for the number 
of individuals (per time unit) of age !! − ! (if ! ≤ !!). The former deals with individuals born 
after the start of the simulation while the latter deals with individuals who belonged to the 
initial population at time ! = 0. The following numbers of individuals of age !! moving to 
the next age group at time ! are obtained: ! ! − !! !" !! , ! > !! , 
! 0 ! !! − ! ! !!! !! − ! , ! ≤ !! 
The division of the second expression by ! !! − !  corresponds to the survival probability 
being conditioned on the individual(s) being alive at age !! − !. 
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The total numbers of individuals moved to the next age group were further divided 
according to the proportions of the 14 epidemiological states in the transmission model at 
time ! to move an appropriate number of individuals to the next age group at each of the 
states. 
In the discretized model, the per capita rate of aging is calculated as: 
!! ! = ! !!!! !" !!!!(!)  !" ! > !!! 0 ! !! − ! ! !!! !!!! !!(!)  !" ! ≤ !!, 
where !!(!) is the number of individuals in age group ! at time !. 
 
Table A.5: Age specific death rates (per capita per day) in the KHDSS population. These 
are the rates used for ! !  in the above equations. 
Age group <1 1-5 6-14 15-20 21-49 ≥50 
Death rate 7.18E-05 6.55E-06 2.73E-06 3.51E-06 1.21E-05 7.31E-05 		
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Chapter 7. Sensitivity analysis 
Simulation under a growing population with a catch-up dose in <5 year olds 
Table A.6:  Prediction of carriage prevalence before and 10-years post vaccination by age group. The table presents the predicted 
mean levels and 95% predictive intervals. A growing population and vaccine introduction with a catch-up dose were assumed. 
 
 Pre-vaccination  10 years post-vaccination 
Age group Carriage  
prevalence 
VT Strong NVT Weak NVT  Carriage  
prevalence 
VT Strong NVT Weak NVT 
          
<1 80.8 (67.8-90.1) 32.6 (25.1-40.5) 37.5 (30.6-45.8) 9.9 (7.1-13.2)  82.9 (71.1-91.5) 10.5 (2.2-21.0) 53.6 (44.1-65.1) 17.6 (12.1-25.6) 
1-5 72.5 (65.2-78.5) 29.5 (23.9-35.2) 29.7 (24.6-35.2) 13.1 (9.6-17.0)  74.6 (67.5-80.5) 9.7 (2.1-19.2) 42.1 (34.6-51.6) 21.8 (16.1-28.7) 
6-14 54.0 (43.1-64.8) 17 (13.9-21.2) 26.8 (18.9-35.0) 9.9 (7.4-13.5)  45.9 (34.0-57.7) 4.4 (0.9-9.1) 28.8 (20.3-38.3) 12.2 (9.1-16.4) 
15-20 27.9 (17.0-41.7) 9.1 (5.7-13.9) 13.4 (7.6-20.7) 5.3 (3.1-8.6)  18.4 (10.9-29.1) 2.0 (0.4-4.8) 11.2 (6.5-18.2) 5.1 (3.0-8.3) 
21-49 25.5 (17.0-35.5) 8.6 (5.8-12.1) 12.0 (7.6-17.5) 4.8 (3.0-7.2)  16.9 (10.6-25.9) 2.0 (0.4-4.4) 10.0 (6.3-15.9) 4.7 (2.8-7.2) 
≥50 21.0 (14.0-30.0) 7.1 (4.7-10.1) 9.8 (6.2-14.6) 4.0 (2.6-6.0)  17.4 (11.5-25.3) 2.0 (0.4-4.2) 10.4 (6.8-15.6) 4.8 (3.1-7.3) 
          
Overall 44.4 (40.2-48.9) 15.9 (13.3-18.7) 20.4 (16.8-24.2) 44.4 (40.2-48.9)  34.9 (29.9-40.2) 4.0 (0.8-8.0) 21.1 (17.2-25.6) 9.6 (7.3-12.2) 
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Table A.7:  Predictions of invasive pneumococcal disease (IPD) incidence before and 10-years post vaccination by age group. The 
table presents the predicted mean levels and 95% predictive intervals (PI). A growing population and vaccine introduction with a 
catch-up dose were assumed. 
 
 
  
 
 
 
 
Pre-vaccination IPD incidence                             10 years post-vaccination IPD 
incidence (95% PI) 
 
Age 
groups 
VT Strong 
NVT 
Weak NVT VT Strong NVT Weak NVT IRR 
        
<1 67.0 21.0 7.1 8.6 (1.8, 18.3) 41.1 (32.2, 55.0) 14 (10.7, 19.0) 0.7 (0.6, 0.8) 
1-5 39.3 5.1 0.7 8.1 (1.6, 17.4) 8.8 (7.2, 11.2) 1.3 (1.0, 1.7) 0.4 (0.3, 0.6) 
6-14 7.3  1.0 0.0 1.5 (0.3, 3.1) 1.1 (0.9, 1.3) 0.0 (0.0, 0.0) 0.3 (0.2, 0.5) 
15-20 1.0 0.0 0.0 0.2 (0.0, 0.4) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.2 (0.0, 0.4) 
21-49 4.2 0.9 0.0 0.9 (0.2, 1.7) 0.8 (0.7, 0.9) 0.0 (0.0, 0.0) 0.3 (0.2, 0.5) 
≥50 9.2 2.8 4.1  2.5 (0.5, 4.7) 3.0 (2.7, 3.5) 4.9 (4.2, 6.0) 0.7 (0.5, 0.8) 
        
Overall  14.8 2.7  0.9 2.4 (0.5, 4.9) 3.3 (2.8, 4.2) 1.1 (0.9, 1.4) 0.4 (0.3, 0.5) 
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Chapter 8. Pre-vaccination IPD Incidence 
Table A.8: Pre-vaccination incidence of invasive pneumococcal disease (IPD) and case-to-carrier ratios by serotype group and age 
group. The IPD cases are from the KHDSS hospital surveillance data. 
 
 Cases IPD incidence* 
(per 100,000 per year) 
 Case-to-carrier ratio** 
(per 10,000) 
Age group 
(years) 
VT Strong  
NVT 
Weak  
NVT 
VT Strong  
NVT 
Weak  
NVT 
 VT Strong  
NVT 
Weak  
NVT 
<1 19 6 2 67.0 21.0 7.1  4.28 (3.03-6.16) 1.02 (0.73 -1.40) 0.90 (0.65-1.31) 
1-5 54 7 1 39.3 5.1 0.7  1.44 (1.11-1.91) 0.15 (0.12-0.20) 0.06 (0.04-0.09) 
6-14 15 2 0 7.3 1.0 0.0  0.32 (0.24-0.40) 0.02 (0.02-0.04) 0.00 (0.00-0.00) 
15-20 1 0 0 1.0 0.0 0.0  0.09 (0.06-0.15) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 
21-49 9 2 0 4.2 0.9 0.0  0.40 (0.27-0.61) 0.06 (0.04-0.10) 0.00 (0.00-0.00) 
≥50 7 2 3 9.2 2.8 4.1  1.07 (0.73-1.65) 0.23 (0.15-0.38) 0.87 (0.57-1.37) 
(*) Average across 3 years (2008,2009,2010) to represent pre-vaccination IPD incidence.  
(**) These are estimated based on modelled carriage incidence and the observed IPD incidence. Figures in the brackets represent the 95% credible intervals 
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Abstract 
Background: Prior studies have demonstrated hyporesponsiveness to 
pneumococcal conjugate vaccines (PCVs) when administered in the presence 
of homologous carriage. This may be substantially more important in Africa 
where carriage prevalence is high. Deriving a correlate of protection (CoP) for 
carriage is important in guiding the future use of extended PCVs as population 
control of pneumococcal disease by vaccination is now focused principally on 
its indirect effect. We therefore explored the complex relationship between 
existing carriage and vaccine responsiveness, and between serum IgG levels 
and risk of acquisition. 
Methods: We undertook secondary analyses of data from two previously 
published clinical trials of the safety and immunogenicity of PCV in Kenya. We 
compared responses to vaccination between serotype-specific carriers and 
non-carriers at vaccination.  We assessed the risk of carriage acquisition in 
relation to PCV-induced serum IgG levels using either a step- or continuous-
risk function.    
Results: For newborns, the immune response among carriers was 51-82% 
lower than that among non-carriers, depending on serotype. Among toddlers, 
for serotypes 6B, 14 and 19F the post-vaccination response among carriers 
was lower by between 29 -70%.  The estimated CoP against acquisition 
ranged from 0.26 to 1.93 mg/mL across serotypes, however, these thresholds 
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could not be distinguished statistically from a model with constant probability 
of carriage independent of assay value. 
Conclusion: We have confirmed hyporesponsiveness in an equatorial African 
setting in both infants and toddlers. Population responses to vaccination are 
likely to improve with time as carriage prevalence of vaccine serotypes is 
reduced. We have not found clear correlates of protection against carriage 
acquisition among toddlers in this population. Assessing the potential of new 
vaccines through the use of CoP against carriage is still difficult as there are 
no clear-cut serotype specific correlates.  
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Introduction 
 
The first pneumococcal conjugate vaccine (PCV), which contained seven 
serotypes, reduced the incidence of pneumococcal disease and the 
prevalence of nasopharyngeal carriage in both vaccinated and unvaccinated 
children as well as adults when introduced into routine infant immunisation 
programme in the USA in 2000 [1]. The indirect protective effect of PCV is 
caused by a vaccine-induced reduction in the risk of acquiring colonisation by 
vaccine serotypes (VTs), which leads to a reduction in onward transmission 
from young children. 
 
Recently, data have emerged that highlight the complexity of interactions 
between pneumococci, the human immune system and the nasopharynx. 
Infants carrying serotypes 6B, 19F or 23F at the time of PCV immunisation 
have reduced primary IgG responses to those serotypes [2,3] and this effect 
persists through to post-booster responses [4]. Rodenburg and colleagues 
showed that, at 24 months of age, children’s responses to PCV against these 
three serotypes were reduced if they had carried them at any point in the 2 
years prior to vaccination [5].  
 
PCV responses in African children are generally thought to be higher than 
those seen in developed country settings [6–9]. For instance, the serotype-
specific geometric mean foldrise between the time of the first dose and one 
month after the third dose of PCV were lower in USA [7] and Finland [9] 
compared to South Africa [6] and The Gambia [8]. Nonetheless, in parts of 
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Africa like The Gambia [10] and Kenya [11,12], carriage rates from very early 
in life are extremely high. Given high responses to PCV it is possible that 
hyporesponsiveness does not occur, or is immunologically irrelevant, in 
equatorial Africa. 
The immunological mechanism that mediates vaccine-induced protection 
against colonisation at the mucosal level, or against disease, is not known. 
While circulating IgG may have a role in preventing colonisation, as 
demonstrated in a mouse model in which antibody blocked colonisation 
through agglutination [13], local B cells producing IgG and/or IgA in the 
nasopharynx may also be relevant and a role for T cells has also been 
suggested [14,15].  Nonetheless, to facilitate the licencing of new formulations 
of PCV, a single aggregate serological correlate of protection against invasive 
pneumococcal disease (IPD), has been derived based on circulating IgG 
[16,17]. However, a recent analysis that suggested correlates of protection 
(CoP) for IPD vary widely by serotype [18] has questioned the biological 
relevance of a single aggregate CoP common to all serotypes. It is likely that, 
as with IPD, the CoP against carriage also vary by serotype.   
Numerous assumptions were made during the development of the common 
serological CoP and there is equipoise in the scientific community about the 
relevance of the CoP to carriage and mucosal disease [19]. For some 
serotypes, greater concentrations of serum IgG were likely to be required to 
protect at mucosal surfaces (e.g. in the nasopharynx) than in blood [20].  
Subsequent analysis of vaccine-induced antibody and the prevention of 
carriage reinforced the notion that if circulating IgG is indeed a relevant 
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correlate for carriage, remarkably high concentrations are required to reduce 
carriage acquisition [21]. Deriving CoP for carriage would guide the future use 
of extended PCVs, as population control of pneumococcal disease by 
vaccination is now focused principally on its indirect effect mediated through 
carriage [22]. 
We therefore set out to explore both the relationship between existing 
carriage and vaccine responsiveness and between serum IgG levels and risk 
of acquisition by undertaking new analyses of two existing field studies of 
PCV in Kenya, with the following questions: (i) Does hyporesponsiveness 
occur in high carriage settings like Kenya? (ii) If so, can we detect this for 
serotypes other than the most common (e.g. 6B, 19F and 23F)? (iii) Is it 
possible to derive a serological correlate of protection against carriage 
acquisition using vaccine-induced IgG responses detected within randomized 
controlled trials of PCV in Kenya? 
Methods  
Data 
 
Data from two previously published clinical trials of the safety and 
immunogenicity of PCV conducted in Kenya [14, 15] were further analysed in 
the current study. The first study (“Newborn study”) recruited 300 newborns 
that were randomized to receive 7-valent PCV (PCV7) in one of two vaccine 
schedules; at 0-10-14 weeks or at 6-10-14 weeks. The subjects received a 
PCV7 or 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) booster 
dose of at 36 weeks. Serological measurements were made at 0, 6, 10, 14, 
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18, 36 and 37 weeks and nasopharyngeal carriage ascertained at 18 and 36 
weeks. The objectives of this study were to examine the effect of a newborn 
vaccination schedule with PCV7 on the development of antibody and carriage 
prevalence. In the current analysis we used the carriage data at the time of 
the booster (week 36) and the serological measurements at week 36 and 
week 37. 
 
The second study (“Toddler study”) recruited 600 children aged 1-4 years to 
examine the effect of 0, 1 or 2 doses of a 10-valent PCV (PCV10), on 
capsular antibody concentrations and nasopharyngeal carriage. Children were 
given PCV10 in three different schedules: Group A received PCV10 at day 0 
and day 60; Group B received PCV10 at day 0 and day 180. Diphtheria-
tetanus-pertussis (DTaP) was given as a control vaccine to group A at day 
180 and to Group B at day 60. A third group, which is not considered in this 
analysis, received Hepatitis A virus (HAV) at day 0 and day 180 and DTaP at 
day 60. Antibody measurements were made at days 0, 30, 90 and 210 and 
nasopharyngeal carriage assessed at days 0, 30, 60, 90 and 180.  Details of 
the study have been published elsewhere [23]. In the current analysis we 
used carriage data from vaccinees in Groups A and B at day 0, 60 and 180 
(vaccination time points), and serological measurements 30 days post 
vaccination i.e. at 30, 90 and 210 days, respectively. 
Analysis 
 
For the newborn study, we calculated the fold-rise in serotype-specific 
geometric mean concentrations (GMC) between weeks 36 and 37, separately, 
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for carriers and non-carriers for each of the seven serotypes in PCV7. The 
differences between the two groups (homologous carriers vs. non-carriers) 
were quantified as ratios of the GMC fold-rises. These ratios were derived 
from log-linear regression models of the booster response taking account the 
vaccine schedule group (6-10-14 vs. 0-10-14), type of booster given (PCV7 
vs. PPV23) and the baseline log-concentration of IgG, at 36 weeks. Baseline 
IgG concentrations is adjusted for since individuals with lower concentrations 
have more room for greater fold-rise than individuals who already have high 
concentration at baseline. 
 
For the toddler study, we pooled paired carriage data and 30-day serological 
responses for each of the time points of PCV10 vaccination (0, 60 and 180 
days). We calculated serotype-specific fold-rises in IgG concentration 30 days 
later (at 30, 90 and 210 days). There were no blood samples at time 60 and 
180 by design therefore we used the IgG at time 30 to adjust for responses to 
vaccines given at 60 and 180 days. We would expect antibody concentrations 
to decay from day 30 to day 60 (and from day 30 to day 180) at the same rate 
for subjects in both Group A and Group B; therefore, the ranks in IgG baseline 
between time 30 days and the time of vaccination are likely to be highly 
correlated, provided that natural boosting is also distributed equally in both 
groups. To assess the impact of carriage at the time of vaccination, GMC fold-
rise ratios between homologous carriers vs. non-carriers were estimated from 
log-linear serotype-specific regression models of the individual level fold-rise 
on the carriage status, taking account of the vaccine group (Group A and B), 
age group (12-23, 24-35, 36-47 and 48-59 months), season (month of sample 
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collection) and pre-vaccine (day 0 or 30) log IgG. We used Generalized 
Estimating Equations (GEE) to account for the correlations between the 
repeated measures within an individual. Data for serotypes 6B, 9V, 14, 19F 
and 23F were selected for the analysis since they were the most frequently 
carried of the 10 vaccine-type serotypes. As a supplementary analysis, we 
also calculated the post-vaccination GMC by pre-vaccination carriage status 
for both the newborn and toddler studies. 
 
In order to derive the serotype-specific antibody threshold for vaccine efficacy 
against acquisition, we restricted our analysis to data from the toddler study 
and, in particular, to toddlers who were non-carriers at day zero.  We 
compared carriage status at day-30 against vaccine-induced IgG 
concentration measured at day 30. We fitted to these two variables a model 
that incorporates a threshold parameter that is estimated through a profile 
likelihood [24], the a:b model. The model is a step-shaped function where the 
step corresponds to the antibody threshold. Thus, in addition to the threshold 
parameter, the model also contains two parameters for constant but different 
acquisition probabilities below and above the threshold. A test for the 
presence of a threshold was achieved by comparing the a:b model to a model 
with constant probability of acquisition independent of assay value, using a 
likelihood ratio test. Confidence intervals around the threshold estimates were 
constructed through bootstrapping.  
 
The a:b model does not allow for adjustment of covariates, therefore, we also 
modelled the risk of serotype-specific acquisition as a continuous function of 
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log-IgG concentration in a Cox proportional hazards model that accounted for 
age group, carriage of a heterologous serotype at the point of vaccination, log 
IgG on the day of vaccination and season. Non-linear relationship between 
the acquisition incidence and log-IgG concentration was allowed through 
restricted cubic splines. Having no colonization by any serotype at day 0 
predisposes one to considerably higher risk of colonization by an index 
serotype relative to someone colonised by a different serotype to the index at 
day 0, due to serotype competition [25,26]. This was the rationale for including 
carriage of a heterologous serotype at the point of vaccination in the model. 
Results 
 
In the newborn study, 235 pairs of 36- and 37-week samples were analysed. 
In these subjects the prevalence of carriage of PCV7 serotypes at 36 weeks 
ranged from 0.9% for serotype 23F to 12.8% for serotype 19F. Compared to 
non-carriers, the GMC fold-rise between week 36 and week 37 among 
carriers was substantially lower by a factor of 51-82% (Table 1). The point 
estimates of the GMC at post-booster (37 weeks) were higher among non-
carriers at the point of vaccination, except of serotype 18C (Supplementary 
table S1). 
 
In the toddler study, between 460-480 samples were analysed depending on 
serotype. The carriage prevalence at the time of vaccination ranged from 
2.1% for serotype 9V to 8.0% for serotype 19F (Table 2). For serotypes 6B, 
14 and 19F the GMC fold-rise post vaccination among carriers was lower by 
between 29 -70%. For serotype 9V and 23F the GMC fold-rise were 53% and 
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1% higher among carriers (Table 2). Except for serotype 9V the point 
estimates of the GMC post-vaccination were higher among non-carriers at the 
time of vaccination (Supplementary table S2). 
 
We computed the serological threshold for vaccine efficacy against acquisition 
among serotype-specific non-carriers at the first vaccination time-point (day 0) 
by using their titres and carriage status 30 days later in the toddler study. The 
estimated thresholds ranged from 0.26 to 1.93 mg/mL across serotypes, 
however, a test for the presence of a threshold at these points suggested no 
significant difference from a model with constant probability of acquisition 
independent of assay value (Table 3).   
 
We analysed carriage acquisition as a continuous function of log IgG. There 
was no convincing monotonically decreasing rate of carriage with increasing 
log IgG for each of the five serotypes (Figure 1). In a situation where a higher 
level IgG had strong negative impact on carriage, the prevalence ratios below 
the average (mean/median) log IgG would be above 1 and the prevalence 
ratios above the average log IgG would be below 1, in the plots. 
Discussion 
 
While inferior quantitative antibody responses to the colonising serotypes 
have been reported amongst children vaccinated with PCV in Philippines [2], 
Israel [3] and South Africa [27], none have studied this phenomenon in high 
carriage settings such as Equatorial Africa. Using data from two clinical trials 
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in Kenya, we have confirmed hyporesponsiveness in equatorial Africa in both 
infants and toddlers, and for the first time described it in serotype 14.  
 
The reduced immune responses to PCV administered to an individual with 
prevailing carriage may reduce the vaccine’s efficacy. The clinical implication 
of this is an increased susceptibility to acquisition of homologous 
pneumococcal serotypes, particularly when the reduction in immune response 
results in lower than sufficient protection against carriage. Several strategies 
can be useful in high carriage settings to counter the effect of 
hyporesponsiveness. The use of a catch-up campaign at the time of PCV 
introduction can speed-up the reduction in vaccine-type carriage thus 
improving the immune responses in cohorts vaccinated in the subsequent 
period of reduced carriage. Using a booster dose in the second year of life 
can also be used to overcome hyporesponsiveness [3]. However, the cost-
effectiveness of such strategies needs to be evaluated to provide further 
evidence for or against their use. 
 
We assessed the association between IgG concentration and the incidence of 
carriage in two ways; using a step function, the a:b model, which explicitly 
models a threshold  and using a model with carriage incidence as a 
continuous function of IgG concentration, which does not explicitly model a 
threshold. The second approach allowed us to study the relation while 
accounting for potential confounding factors. The result from each of the 
approaches is mutually important and complementary in interpreting results 
from the alternative approach.   
		 98	
 
The CoP for carriage were generally higher than the recently derived 
serotype-specific CoP for IPD with the exception of serotype 14 (0.26 mg/ml 
for carriage acquisition vs. 0.46 mg/ml for IPD) [28]. It is expected that the 
CoP for carriage should be substantially higher than that for IPD; therefore, 
the result for serotype 14 is surprising. The evidence for the CoP for carriage 
being lower is, however, limited given the wide 95% confidence intervals of 
the CoP estimate of this serotype (Table 3) and the function of IgG that does 
not show drastic change around the estimated CoP (Figure 1).  
 
For serotype 9V, all the carriers were above the estimated CoP against 
acquisition. This scenario reflects one of the potential problems with the a:b 
model, that in the estimation process the incidence below a candidate 
threshold is not restricted to be higher than that above it. This requirement is, 
however, imposed post-estimation in the test for the existence of a threshold 
at the estimated value [24], such that the test statistic always yields a non-
significant result in such cases. Whether circulating IgG is the correct 
correlate of protection also needs to be considered. The exact mechanism by 
which pneumococci are prevented from colonising the nasopharynx is still 
unclear. 
 
The licensing of future PCVs will likely take into account the potential impact 
on carriage [29]. Therefore, defining the CoP for carriage would provide a way 
of assessing the non-inferiority of new vaccines as has been the case for CoP 
for IPD [16,17]. However, until a better understanding of existing CoP for IPD 
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exists this may be complex. For example, there is limited information to 
sufficiently explain why IPD correlates for some serotypes are high and others 
low. Consequently, predicting whether the CoP for a novel serotype will be 
higher or lower, and by what factor, than available CoP for other serotypes is 
difficult. New PCVs might incorporate serotypes that are carried relatively 
infrequently further complicating the use of CoP for carriage. Only one 
previous study that was conducted in the United Kingdom has reported on 
PCV CoP for carriage where a clear threshold against carriage for a single 
serotype, serotype 14, was identified [20]. A second study in the Navajo 
Nation and White Mountain Apache tribal lands, in USA, did not find 
identifiable IgG threshold level that was associated with prevention of carriage 
acquisition for all the eight serotypes studied [30].  
 
A limitation of the newborn study is that the period between booster dose and 
the assessment of its effect was one week. It generally takes about 4 weeks 
for a full immune response following vaccination. Therefore, what we show is 
that the impact of pre-existing carriage on immune response is notable as 
early as one week. It is possible that after 4 weeks the final concentrations 
between carriers and non-carriers are similar. If that is the case then the effect 
of pre-existing carriage is in delaying immune response. From the toddler 
study, in which there was sufficient time-lapse between vaccination and 
assessment of response, the final concentrations were still different between 
carriers and non-carriers. It is unlikely that the case is different for newborns, 
because the mechanism causing hypo-responsiveness should be similar 
between the two age groups. 
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In conclusion, we have confirmed hyporesponsiveness in an equatorial 
African setting in both infants and toddlers.  Pneumococcal conjugate 
vaccines have been introduced in many African countries where carriage is 
generally high. Hyporesponsiveness might reduce the vaccine’s effectiveness 
in the early years of introduction when the prevalence of vaccine serotypes is 
still high. If so, the speed with which vaccine-type carriage prevalence is 
reduced will determine how fast improved responses are realised in later 
years after vaccine introduction, when cohorts of children with reduced 
vaccine-type carriage rates replace the cohorts in high prevalence period. We 
did not identify clear correlates of protection against carriage acquisition 
among toddlers in this population. Given the limited information from the few 
studies that have reported on correlate of protection against carriage, 
assessing the potential of new vaccines through the use of correlate of 
protection against carriage remains difficult, as there are no clear-cut 
serotype-specific correlates. 
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Table 1: Newborn study. Geometric mean fold rise between 36 and 37 weeks (with 95% confidence limits) stratified by carrier 
status, as well as the difference in the response between carriers and non-carriers expressed as a ratio. These ratios, and 
associated p values were derived from log-linear regression models of the booster response taking account of the vaccine group 
(EPI vs. newborn), the type of booster given (Pneumococcal polysaccharide vaccine vs. Pneumococcal conjugate vaccine) and log 
IgG in week 36. 
Serotype Carriers at 36 weeks  Non-carriers at 36 weeks Ratio (95% CIs) 
for carrier/non-carrier 
P-value 
 n  GM fold-rise 37/36  
Weeks (95% CI) 
 n GM fold-rise 37/36 
Weeks (95% CI) 
  
        
4 0  -  235 4.92 (4.36 – 5.55) - - 
6B 6  2.85 (0.69 – 11.68)  229 13.52 (11.52 – 15.88) 0.18 (0.07 – 0.46) <0.001 
9V 4  1.62 (0.64 – 4.11)  231 5.32 (4.72 – 6.00) 0.31 (0.14 – 0.69) 0.005 
14 10 1.29 (0.86 – 1.92)  225 2.79 (2.47 – 3.15) 0.49 (0.30 – 0.80) 0.004 
18C 3  1.25 (0.87 – 1.79)  232 7.74 (6.87 – 8.73) 0.15 (0.05 – 0.40) <0.001 
19F 30  1.91 (1.34 – 2.73)  204 7.19 (6.11 – 8.45) 0.32 (0.21 – 0.48) <0.001 
23F 2  3.59 (0.02 – 663.49)  231 10.33 (8.80 – 12.14) 0.25 (0.06 – 1.09) 0.064 
n: number of individuals 
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Table 2: Toddler study. Geometric mean fold-rise between day 0 to 30 or day 30 to 90/210 stratified by carrier status at the time of 
vaccination (day 0, 60 or 180), as well as the difference in the response between carriers and non-carriers expressed as a ratio. 
The ratios and associated p-values were derived from log-linear serotype specific regression models, using GEE, of the individual 
level fold-rise on the carriage status, taking account of the vaccine group (Group A and B), age group (12-23, 24-35, 36-47 and 48-
59 months), season (month of swab) and pre-vaccine (day 0 or 30) log IgG. 
Serotype Carriers at point of vaccination  Non-carriers at point of 
vaccination 
Ratio (95% CIs)  
for carrier/non-carrier 
P-value 
 na  GM fold-rise (95% CI)  na GM fold-rise (95% CI)   
        
6B 23  1.65 (1.22 – 2.24)  457 2.35 (2.14 – 2.59) 0.70 (0.51 – 0.97) 0.034 
9V 10  1.88 (0.98 – 3.61)  466 3.06 (2.65 – 3.53) 1.53b (0.89 – 2.65) 0.119 
14 15  3.02 (1.99 – 4.58)  445 5.32 (4.65 – 6.10) 0.71 (0.50 – 1.02) 0.067 
19F 38  2.12 (1.57 – 2.87)  439 7.61 (6.50 – 8.90) 0.30 (0.19 – 0.46) <0.001 
23F 22  3.39 (1.35 – 8.47)  455 4.28 (3.66 – 5.00) 1.01 (0.63 – 1.63) 0.955 
aThere are two repeated measures for almost all participants. These numbers reflect the number of samples rather than individuals. 
bThe reason why the adjusted ratio is above 1 (instead of approx. 1.88/3.06=0.61, which is the unadjusted ratio) is because one of the factors adjusted for (pre-vaccine log IgG) was unevenly 
distributed among carriers vs. non-carriers; the GMC of pre-vaccine log IgG among carriers was significantly higher at 1.61 compared to 0.49 in non-carriers. Similar case for 23F.  
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Table 3: Toddler study. The serotype-specific serological thresholds for vaccine efficacy against acquisition for five most commonly 
carried serotypes at day 0. The thresholds are computed using a step-shaped function where the step corresponds to the threshold 
with different infection probabilities below and above the threshold. The threshold with the highest profile likelihood is chosen as the 
parameters estimate. Confidence intervals are constructed by bootstrapping.   
Serotype Threshold (95% CI) Carriage prevalence  
Ratioa (95% CI) 
 Test for presence  
of a thresholdb 
Goodness of fit  
p-valuec 
6B 0.48 (0.07 - 2.68) 0.21 (0.04-0.72) 0.079 0.048 
9Vd 1.86 (1.86 - 22.67) -- >0.999 0.219 
14 0.26 (0.16 - 14.34) 0.26 (0.04-0.87) 0.542 0.851 
19F 1.66 (0.85 - 6.60) 0.10 (0.00-0.60) 0.171 0.314 
23Fe 1.93 (0.09 - 1.94) 0.00 (0.00-0.00) 0.430 0.625 
 
a Carriage prevalence ratio is the carriage risk above the threshold divided by carriage risk below threshold, the confidence interval is obtained by bootstrapping 
b likelihood ratios test for the presence of a threshold. Achieved by comparing the a:b model to a model with constant probability of infection independent of assay value. Values above 0.05 indicate no sufficient evidence of a 
difference in the two models at % level of significance. 
cThis is the Hosmer and Lemeshow goodness of fit p-value testing the null hypothesis that there is no difference between observed and model predicted values. The test assesses whether the step function represented by the 
a:b model is an appropriate representation of infection or whether another relationship such as a gradual one between titre and infection might be more likely than a stepped relationship. All the p-values, except that for 
serotype 6B, which is borderline, are above 0.05 indicating insufficient evidence against the null hypothesis at the 5% level of significance. 
dThere were no carriers of serotype 9V below the threshold of 1.86 mcg/ml hence the risk ratio was undefined  
eThere were no carriers of serotype 23F above the threshold of 1.93 mcg/ml hence the risk ratio was zero 
	 108	
 
 
 
Figure 1: The incidence rate ratio (blue solid line) as a function of log IgG titre (x-
axis) for each serotype labelled above the graph. The ratios are between the values 
of log IgG on the x-axis relative to someone with the average log IgG. For instance, 
for serotype 6B, the rate ratio between individuals with log IgG of -3 relative to 
individuals with the mean log IgG is slightly below 1 (95% CI: ~ 0.5 to 2). The red 
dashed lines are the 95%CI bounds of the rate ratio. The three vertical (grey) lines 
mark the 2.5th, 50th and 97.5th percentiles of the distribution of log IgG whose density 
is shown in grey on the x-axis. The green line shows the CoP obtained by the a:b 
model while the light green shade around it shows the region covered by the 
bootstrapped 95%CI of that CoP. The likelihood ratio (LR) test p-value for the 
significance of log IgG in predicting carriage acquisition and the test for the presence 
of a threshold estimated by the a:b model is indicated in the plot.  	
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Appendix 
Table S1: Newborn study. Geometric mean post-vaccination (at 37 weeks) stratified by carrier status, as well as the difference in 
the response between carriers and non-carriers expressed as a ratio. These ratios, and associated p values were derived from log-
linear regression models of the booster response taking account of the vaccine group (EPI vs. newborn), the type of booster given 
(Pneumococcal polysaccharide vaccine vs. Pneumococcal conjugate vaccine) and log IgG in week 36. 
Serotype Carriers at 36 weeks  Non-carriers at 36 weeks Ratioa (95% CIs) 
for carrier/non-carrier 
P-value 
 n  GM at 37 weeks (95% CI)  n GM at 37 weeks (95% CI)   
        
4 0  -  236 3.69 (3.21 – 4.24) - - 
6B 6  0.71 (0.06 – 8.01)  230 10.13 (8.44 – 12.16) 0.18 (0.07 – 0.46) <0.001 
9V 4  1.28 (0.06 – 26.16)  232 4.04 (3.48 – 4.69) 0.31 (0.14 – 0.69) 0.005 
14 10 4.23 (1.18 – 15.17)  226 7.61 (6.45 – 8.98) 0.49 (0.30 – 0.80) 0.004 
18C 3  14.98 (2.52 – 89.07)  233 3.49 (2.98 – 4.09) 0.15 (0.05 – 0.40) <0.001 
19F 30  2.25 (1.47 – 3.43)  206 6.45 (5.50 – 7.57) 0.32 (0.21 – 0.48) <0.001 
23F 2  2.58 (0.61 – 10.95)  232 5.49 (4.61 – 6.52) 0.25 (0.06 – 1.09) 0.064 
n: number of individuals 
a The ratio comparing carriers vs. non-carriers obtained by regressing the log-concentration post-vaccination against carriage status at the point of vaccination (adjusting for pre-vaccination log-
concentration, among other variables) is similar to that obtained when the response variable is instead  the log of fold-rise (post-vaccination IgG divided by pre-vaccination IgG) and adjustment is 
also made for pre-vaccination log-IgG (Table 1). This is because only the coefficient of the pre-vaccination log-IgG will be altered across the two models; the coefficients of the rest of the predictors 
remain equal across the models. 
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Table S2: Toddler study. Geometric mean post-vaccination (day 30, 90/210) stratified by carrier status at the time of vaccination 
(day 0, 60 or 180), as well as the difference in the response between carriers and non-carriers expressed as a ratio. The ratios and 
associated p-values were derived from log-linear serotype specific regression models, using GEE, of the individual level post-
vaccination log-IgG level on the carriage status, taking account of the vaccine group (Group A and B), age group (12-23, 24-35, 36-
47 and 48-59 months), season (month of swab) and pre-vaccine (day 0 or 30) log IgG. 
Serotype Carriers at point of vaccination  Non-carriers at point of vaccination Ratiob (95% CIs)  
for carrier/non-carrier 
P-value 
 na  GM post-vaccination (95% CI)  na GM post-vaccination (95% CI)   
        
6B 23  1.03 (0.66 – 1.62)  457 1.23 (1.12 – 1.36) 0.70 (0.51 – 0.97) 0.034 
9V 10  3.04 (1.36 – 6.77)  468 1.51 (1.40 – 1.64) 1.53 (0.89 – 2.65) 0.119 
14 15  2.24 (1.14 – 4.42)  449 3.18 (2.79 – 3.63) 0.71 (0.50 – 1.02) 0.067 
19F 39  0.58 (0.32 – 1.06)  442 7.18 (6.21 – 8.30) 0.30 (0.19 – 0.46) <0.001 
23F 22  0.74 (0.38 – 1.41)  457 0.80 (0.72 – 0.89) 1.01 (0.63 – 1.63) 0.955 
aThere are two repeated measures for almost all participants. These numbers reflect the number of samples rather than individuals. 
b The ratio comparing carriers vs. non-carriers obtained by regressing the log-concentration post-vaccination against carriage status at the point of vaccination (adjusting for pre-vaccination log-
concentration, among other variables) is similar to that obtained when the response variable is instead  the log of fold-rise (post-vaccination IgG divided by pre-vaccination IgG) (Table 2). This is 
because only the coefficient of the pre-vaccination log-IgG will be altered across the two models; the coefficients of the rest of the predictors remain equal across the models. 
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Abstract 
Background 
In developing countries, introduction of pneumococcal conjugate vaccine has 
not eliminated circulation of vaccine serotypes. Vaccinating pregnant mothers 
to increase antibody concentrations in their newborn infants may reduce the 
acquisition of pneumococcal carriage and subsequent risk of disease. We 
explored the efficacy of passive immunity, attributable to anti-protein and anti-
capsular pneumococcal antibodies, against acquisition of carriage. 
 
Methods 
We examined the rate of nasopharyngeal acquisition of pneumococci in the 
first 90 days of life associated with varying anti-capsular and anti-protein 
antibody concentrations in infant cord/maternal venous blood in Kilifi, Kenya. 
We used multivariable Cox proportional hazard models to estimate continuous 
functions relating acquisition of nasopharyngeal carriage to the concentration 
of maternally-derived antibody. 
 
Results 
Cord blood or maternal venous samples were collected from 976 mother-
infant pairs. Pneumococci were acquired 561 times during 33,905 person-
days of follow up. Increasing concentrations of anti-protein antibodies were 
associated with either a reduction (PhtD1, PspAFam2, Spr0096, StkP) or, 
paradoxically, an increase (CbpA, LytC, PcpA, PiaA, PspAFam1, RrgBT4) in 
acquisition rate. We observed a non-significant reduction in the incidence of 
homologous carriage acquisition with high concentrations of maternally-
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derived anti-capsular antibodies to five serotypes (6A, 6B, 14, 19F and 23F). 
 
Conclusion 
The protective efficacy of several anti-protein antibodies supports the strategy 
of maternal vaccination to protect young infants from carriage and invasive 
disease. We were not able to demonstrate that passive anti-capsular 
antibodies were protective against carriage acquisition at naturally occurring 
concentrations though it remains possible they may do so at the higher 
concentrations elicited by vaccination. 
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Introduction 
Among infants in low-income countries, pneumococcal carriage is acquired 
rapidly. In Kenya, in the pre-vaccination era, more than 80% of newborns 
acquired nasopharyngeal carriage by the age of 90 days [1]. The median time 
to colonization was 45 days in Thailand [2] while in India 54% of infants aged 
2 months carried pneumococci [3]. Colonization is an essential step in the 
pathway to invasive pneumococcal disease (IPD) [4]. In a pre-vaccine 
surveillance exercise in Kilifi, Kenya, 15% of IPD episodes occurred in the first 
two months of life [5].   
 
Pneumococcal Conjugate Vaccine (PCV) has been introduced in many low 
income countries in schedules where infants are first vaccinated at either 6 
weeks or two months of age [6]. In addition to direct protection of the 
vaccinated infant, the vaccine provides herd protection to unvaccinated 
individuals by interrupting transmission [7]. However, in contrast to developed 
countries [8], herd protection has not eliminated the circulation of vaccine 
serotypes in low-income countries and evidence from Kenya [9] and The 
Gambia [10] suggests that the prevalence of vaccine serotypes remains 
relatively high several years after vaccine introduction.  
 
This justifies the evaluation of maternal or newborn vaccination as strategies 
to protect young infants. Newborn vaccination with the 7-valent PCV was safe 
and immunogenic in Kenya and Papua New Guinea [11,12]. In a review of 
studies of maternal vaccination, no safety concerns were reported with the 23-
valent pneumococcal polysaccharide vaccine (PPV-23) or in the only study of 
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maternal vaccination with a 9-valent PCV [13,14]. Vaccination increased the 
passive transfer of antibodies to newborns, more so with the PCV [13]. 
Protein and whole cell pneumococcal vaccines, currently in clinical 
development, are designed to protect recipients against all serotypes of 
pneumococcus [15] and could be used, potentially, to protect young infants 
through newborn or maternal vaccination.  
 
The correlates of protection (CoP) against invasive pneumococcal disease 
(IPD) have been established [16]. Attempts to derive CoP for vaccine-induced 
protection against carriage have not provided a clear-cut threshold [17,18]. In 
addition, previous studies of this relationship have been constrained by 
several methodological limitations.  
 
Most studies, for example, relating newborn colonization to maternally-derived 
antibodies, with [19,20] or without maternal vaccination [21–23], have failed to 
account for the colonization status of the mother at birth. Children born to 
carrier mothers have a higher risk of infection by the mother and are also 
likely to receive higher antibody concentrations by passive transfer, thus 
confounding the relationship between antibody concentration and carriage.  
 
Secondly, the ascertainment of carriage acquisition in infants has been 
relatively insensitive. The earliest swabs were obtained at no younger than 1 
month of age [20–25] and the period between subsequent swabs was also at 
least a month in all of the studies. Thirdly, previous studies have been 
undermined by the relatively small sample sizes, which limits the power to 
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detect modest protective efficacies. Clinical trials of maternal vaccination 
studied samples of both vaccinated and control children ranging in size from 
46 to 437 infants [14] and studies without maternal vaccination had sample 
sizes in the range 51-310 [21–23,25]. Finally, only one previous study has 
measured both anti-capsular and anti-protein antibodies in the mother-infant 
pairs and, even here, they were assessed independently [25].  
 
Understanding the association between maternally-derived antibodies and the 
rate of carriage acquisition for a panel of pneumococcal proteins and capsular 
polysaccharides is likely to guide antigen selection in future maternal/newborn 
immunization strategies. We aimed to characterize this association using a 
study where the carriage status of the mother at birth is already known; the 
ascertainment of carriage in the infant begins early and recurs frequently; the 
study population is of sufficient size to detect moderate associations; and the 
effects of anti-protein and anti-capsular antibodies are analyzed 
simultaneously to determine the independent protective efficacies of each. 
 
Methods  
Data 
The study population and design have been described in detail elsewhere [1]. 
The study was conducted before the introduction of PCV vaccination in 
Kenya. Briefly, we collected nasopharyngeal swab specimens from 
participating newborns, aged at most 7 days, twice weekly for 2 weeks and 
weekly thereafter until a pneumococcus was cultured from an infant's swab or 
until 13 weeks after study entry, whichever was the sooner. Mothers were 
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swabbed at the time of birth and monthly thereafter. Cord blood was collected 
at the time of birth if the delivery took place at the hospital. Venous blood was 
collected from the mother if the child was born at home and reported to 
hospital within 7 days.  
 
The environmental risk factors for carriage ascertained were: sex, mother’s 
HIV status, history of cough, history of coryza, observed cough, observed 
coryza, observed runny nose and breastfeeding status. At the household level 
we ascertained: type of fuel used for cooking, number of siblings aged <10 
years, number of other children aged <10 years, number of adults, number of 
smokers and number of carers.  
 
Laboratory methods 
A direct binding electrochemiluminescence-based multiplex assay [26] was 
used to measure serum IgG antibodies to 27 pneumococcal protein antigens. 
Pneumococcal reference serum 007sp was used as a standard and assigned 
a value of 1000 arbitrary units for each antigen [27]. Antibody levels in serum 
samples were expressed as concentrations with reference to the amount in 
007sp. 
 
We used ELISA to assay serum samples for antibodies to 6A, 6B, 14, 19F 
and 23F capsular polysaccharides as described previously [28]. The assays 
were done at the WHO reference laboratory for pneumococcal serology, 
University College London Institute of Child Health, UK. These five serotypes 
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were chosen because they were the serotypes most frequently acquired in the 
study. 
 
Statistical analysis 
Univariable Cox proportional hazard (Cox PH) models were fitted to assess 
the relationship between the hazard of acquisition of carriage and anti-protein 
antibody concentrations for each of the 27 proteins. Non-linear effects of 
antibodies were modeled using restricted cubic splines [29]. The univariable 
Cox PH models were also fitted for homologous carriage against serotype-
specific anti-capsular antibody concentrations. Subjects were censored upon 
acquiring any pneumococcal serotype. For serotype-specific analyses this 
introduces a competing-risk scenario. Therefore, instead of estimating the 
standard hazard rates, we estimated the cause-specific hazard rates [30].  
 
The principal problem with serotype-specific analyses is power, since only a 
subset of all pneumococcal acquisitions are used. We replicated timespan 
records for each individual four times resulting in five copies. We then 
associated each replicate record with a standardized log IgG concentration, 
as well as an indicator for acquisition, for each of the five serotypes. The log 
IgG concentrations were standardized using serotype-specific means and 
standard deviations. This restructured dataset allowed us to estimate the 
impact of anti-capsular antibodies on the acquisition of any of the five 
serotypes in a single model. We calculated cluster robust standard errors to 
account for the correlation introduced by replication. 
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We used the Least Absolute Shrinkage and Selection Operator (lasso) 
penalty to select anti-protein antibodies and environmental risk factors to 
retain in multivariable Cox PH models. We assumed that these factors were 
independent of serotype and therefore examined their effect by fitting a 
penalized Cox PH model with acquisition of any pneumococcus as outcome. 
The lasso procedure shrinks the coefficients of the less relevant variables to 
zero and results in a set of variables that have optimal predictive value. 
Simulations indicate that the lasso procedure can be more accurate than 
stepwise selection [31]. In the presence of strong correlations between 
candidate predictors, the lasso may not be consistent in variable selection 
[32]. Consistency here refers to a higher ability to recover the correct model 
with growing number of observations. To achieve consistency we used an 
ensemble voting approach [33]. This involved fitting the penalized model to 
the observed dataset and across 200 bootstrap-resampled datasets, and 
using this pool of estimated coefficients to vote on which variables to include 
in the model. A variable was selected if its coefficient was not reduced to zero 
in more than 50% of the resampled datasets, a threshold that is a balance 
between being too restrictive or too lenient.   
 
We estimated non-linear effects on acquisition of any serotype of each 
selected anti-protein antibody adjusting for selected environmental variables 
and remaining selected protein variables. All the Cox PH models of the effect 
of anti-capsular IgG on the hazard of serotype-specific acquisition were 
adjusted for the selected environmental and protein variables. In these 
models, we entered the anti-capsular or anti-protein IgG coefficient of interest 
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unpenalized unlike the rest of the predictors used in adjustment. We also 
estimated non-linear effects on acquisition of the five serotypes of each 
selected protein antibody adjusting for selected environmental variables, the 
remaining selected protein variables and the standardized anti-capsular 
antibodies. Anti-capsular concentrations below the minimum detectable limit 
of 0.15 mcg/ml were imputed as half the value i.e. 0.15/2=0.075. All anti-
protein and anti-capsular concentrations were log-transformed before 
analysis.  
 
Results 
Acquisition rates 
Cord or venous blood samples were collected from 976 newborns; 342 (35%) 
of these were venous blood. The newborns were followed for a total of 33,905 
days resulting in 561 acquisitions of pneumococcus; 218 (39%) of these were 
for serotypes 6A, 6B, 14, 19F and 23F. The rate of acquisition per infant per 
1000 days ranged from 0.77 for serotype 14 to 2.18 for serotype 19F (Table 
1).  
 
Univariable analyses  
Higher levels of anti-protein IgG were associated with reduction in acquisition 
of any serotype for a number of proteins; nearly monotonic relations between 
acquisition hazard and IgG level were estimated for PhtD1, PhtD2, PhtE and 
StkP (p>0.15 for each). Higher anti-protein antibodies to PiaA, RrgBT4, 
RrgB6B and RrgB23F were associated with increased acquisition of carriage 
(p<0.033 for each) (Figure S1). 
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The serotype-specific hazard of acquisition as a function of homologous log 
IgG concentration did not show a monotonically decreasing trend with higher 
concentrations (Figure 1). For serotypes 14 and 19F, there was favorable 
reduction in acquisition hazard at higher IgG levels. In the joint analysis 
combining all five serotypes, higher anti-capsular IgG concentrations, on the 
extreme right of the distribution of IgG concentrations, were associated with a 
reduction in acquisition (Figure 2) however we did not find evidence of an 
association across the whole range of values (p=0.797). The point-wise 
confidence intervals (CIs) in the figures, at the upper bound descends below 
the hazard ratio (HR) of 1; this can be used to mark log IgG levels which 
result in a significant reduction in carriage rates compared to typical (mean) 
log IgG values. In the univariable analysis, the upper limits of the CIs are all 
above a HR of 1. 
 
Multivariable analyses 
Table 2 shows the set of environmental and anti-protein antibody variables 
selected by the lasso procedure. In the set of candidate environmental 
predictors, sex, history of cough, observed cough, observed runny nose and 
breastfeeding status were voted out of the model. Among the 27 candidate 
anti-protein antibody predictors, 17 were voted out. Except for antibodies to 
PhtD1, PspAFam2, StkP and Spr0096, in which higher concentrations were 
associated with reduction in carriage acquisition, higher IgG levels for the 
remaining proteins were associated with increased acquisition (Table 2). The 
group of newborns who were born in hospital, had a lower rate of 
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pneumococcal acquisition (18% lower) compared to newborns who were born 
at home (Table 2). 
 
Among the ten proteins in which adjusted non-linear effects on carriage 
acquisition were analysed, higher concentrations of PhtD1 and StkP were 
associated (p=0.020 and 0.036, respectively) with reduced acquisition. Higher 
concentrations of RrgBT4 were associated (p=0.003) with an increase in 
acquisition rate for the greater part of the distribution of anti-RrgBT4 
antibodies (Figure 3). The function for anti-RrgBT4 concentration was non-
monotonic; we also observed higher carriage rates in the lower tail of the 
distribution. The effects of the anti-protein concentration on acquisition of any 
of the five serotypes without adjusting for the anti-capsular concentrations 
(Figure S2) were similar with adjustment (Figure S3). 
 
Adjusting for environmental and anti-protein antibody variables in the models 
of the effect of serotype-specific anti-capsular antibodies only marginally 
influenced the shape of the hazard functions compared to the unadjusted 
analyses. In serotype 19F there was lower risk in the upper tail of the 
distribution of IgG concentration, however, there was no evidence an overall 
effect of serotype-specific IgG (p=0.13-0.97) (Figure 4). In the joint 
multivariable analysis of all the five serotypes, individuals with standardized 
log IgG concentration of about 2 and above had significant reduction in the 
rate of acquisition, by 50% or more, compared to individuals with the average 
standardized log IgG (Figure 2, right panel). A standardized log IgG 
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concentration of 2 is equivalent to an absolute IgG concentration of 11.1, 9.8, 
3.1, 5.5 and 19.0 mcg/ml for serotypes 6A, 6B, 14, 19F and 23F, respectively. 
 
Discussion 
We assessed the association between maternally-derived anti-protein and 
anti-capsular antibodies and the rate of carriage-acquisition in the first 90 
days of life among mother-infant pairs in the pre-vaccination period in Kenya. 
Among anti-protein antibodies, we found that higher concentrations of 
antibody to some proteins (PhtD1, PspAFam2, Spr0096 and StkP) were 
associated with a reduction in the acquisition rate while some (CbpA, LytC, 
PcpA, PiaA, PspAFam1 and RrgBT4) were associated with an increase in 
acquisition rate (Figure 3).  
 
Some of the associations are consistent with our understanding of the protein 
functions. For instance, higher anti-protein antibodies to histidine triad protein 
(PhtD) were significantly associated with a reduction in acquisition. PhtD is a 
pneumococcal cell surface protein that contributes to the adherence of S. 
pneumoniae to epithelial cells [34]. This protein has been used as a vaccine 
candidate [35].  
 
Several associations are apparently inconsistent with known functions of the 
proteins. The presence of pilus has been implicated in adhesion to epithelial 
cells in humans and mice [36], suggesting a role in colonization. RrgB is a 
backbone subunit of pneumococcus pilus-1, anti-RrgBT4 antibody binding to 
pilus might reduce its capacity to bind epithelial cells and thereby abrogate its 
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role in adhesion. Therefore, higher anti-RrgBT4 concentrations would result in 
lower carriage acquisition. The pneumococcal serine threonine protein kinase 
(StkP) has recently been shown to repress the expression of pilus and 
modulate bacterial adherence to human epithelial cells [37]. Thus, higher anti-
StkP antibodies imply impaired repression of the pilus in the pneumococcus 
enhancing the attachment capacity of the bacterium, leading to increased 
carriage acquisition. 
 
However, we observed a non-monotonic relation between carriage acquisition 
anti-RrgBT4 concentrations; the hazard was higher at the lower and upper 
extremes of the concentration scale. We also observed a significant reduction 
in acquisition rate with increasing anti-StkP concentrations (Figure 3). The 
pilus is only expressed in 30-50% of pneumococci [38], therefore any effect 
mediated through pilus is likely to be diluted, thus the observed effect of anti-
RrgBT4 and anti-StkP antibodies might not be entirely explained through their 
effect on the pilus. We did not determine pilus phenotypes of pneumococci 
isolated in this study, so we were unable to include the phenotype in our 
analysis. Nonetheless, StkP is a global kinase involved in regulating a number 
of pneumococcal functions that are critical for the resistance of 
pneumococcus to various stress conditions, one such function is cell wall 
biosynthesis [39]. Antibodies to StkP may inhibit the role it plays in cell wall 
development and that would lead to a decrease in pneumococcal viability and 
therefore reduced carriage. Some of these paradoxical associations may be 
due to the observational nature of the study, where it is difficult to control 
completely for confounding; the findings could be tested in an experimental 
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design using nasopharyngeal challenge studies in animal models. 
Understanding both the positive and negative impacts of antibodies on 
adhesion may be useful for vaccine design. 
 
Several prior studies have documented the limited role of maternally-derived 
antibodies in protecting infants from pneumococcal colonization [21,22,40]. 
Maternal vaccination in the third trimester of pregnancy increases the amount 
of antibody passed on to the newborn [20,41]. However, there is insufficient 
evidence that maternal vaccination during pregnancy could reduce infant 
carriage or infections [42].  
 
We observed a reduction in the rate of acquisition associated with high levels 
of maternally-derived anti-capsular antibodies to five serotypes even though 
none of the associations was statistically significant across the whole range of 
concentrations (Figure 2&4). The limited effect of anti-capsular antibodies on 
carriage acquisition rates in our study could suggest that these antibodies are 
not effective against carriage acquisition, at least in an environment such as 
Kilifi with a high force of infection. However, we did observe a steep reduction 
in acquisition of carriage at very high concentration of antibodies in the range 
of 3.1-19.0 mcg/ml across different serotypes, though concentrations this high 
were attained by only about 3% of the newborn population (Figure 2). In other 
settings the proportion attaining these concentrations at birth might be higher; 
about 25% of newborns had these level of antibodies for serotypes 14 and 
19F in a study of American children [43]. This provides some rationale for 
maternal vaccination, if the vaccine can raise the level of transferred 
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antibodies to very high concentrations above those observed as a 
consequence of repeated natural exposure.  
 
One limitation of the analysis is that the HIV status of the mothers was not 
considered. Immunosuppressed mothers are more likely to be colonized by 
pneumococcus and have reduced immunological responses following 
colonization [44]. Therefore, HIV positive mothers are more likely to transmit 
pneumococcal carriage to their newborns and transfer lower antibody 
concentrations to their newborns compared to HIV negative mothers. 
Consequently, the association between maternal antibodies and the risk of 
acquisition of carriage among children born to HIV positive mothers is likely to 
be stronger (large effect size) compared to the same association among 
children born to HIV negative mothers. Not accounting for mother’s HIV status 
might therefore bias upwards the estimate of the hazard of acquisition per unit 
increase in maternal antibodies. The magnitude of this bias in a study 
population would depend on the prevalence of HIV among women in the 
childbearing age, where a small prevalence of HIV would reduce the bias. The 
prevalence of HIV in women in coastal Kenya reduced from 11% 2007 to 4% 
in 2012 [45], the period between which data analysed in this study was 
collected. 
 
There are few analyses of CoP against carriage acquisition for anti-capsular 
antibodies. A value of 5mcg/ml was associated with protection against 
carriage of serotype 14 [17]. Our analysis suggests that the CoP is likely to be 
very high, in the range 3.1-19.0 mcg/ml. In the only reported study of maternal 
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vaccination with a PCV, the geometric mean concentrations (GMC) of anti-
capsular antibodies in cord-blood of newborns to vaccinated mothers were 
between 3 and 19 times higher, depending on serotype, compared to 
newborns to mothers who received a placebo. The GMC in cord-blood among 
newborns from vaccinated mothers ranged between 2.4 to 14.3 mcg/ml [13]. 
This increases the potential of PCVs for use in maternal vaccination. 
  
The serotype-specific rates of acquisition observed among the subset of 
newborns whose cord or maternal venous blood were collected were very 
similar to the total sample of 1400 newborns that constituted the original study 
[1] suggesting that the subset analysed was representative (Table 1). The 
newborns born in hospital, had lower rates of pneumococcal acquisition 
compared to those born at home. The blood type (cord or venous) provided 
was therefore a potential confounder in the relationship between antibodies 
and carriage acquisition. However, we adjusted for blood type in all 
multivariable models.  
 
In conclusion, we observed a significant association between carriage 
acquisition and several anti-protein antibodies but only a limited role for 
maternally-derived anti-capsular antibodies, at high concentrations, on 
serotype-specific acquisition of pneumococci. This disparity between anti-
protein and anti-capsular effects may be attributable to differential study 
power, as the anti-capsular analyses was restricted to homologous 
acquisitions but the anti-protein analysis included all acquisitions. 
Nonetheless, a strategy of maternal vaccination to improve the level of 
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transferred antibodies and thus protect newborns against acquisition of 
carriage may be successful if vaccine formulation is focused on enhancing 
specific anti-protein antibodies that are associated with reduced carriage, or if 
the strategy induces very high concentrations of anti-capsular antibodies, 
above those normally observed in physiological trans-placental transfer.  
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Table 1: Acquisitions rates of serotypes 
 
Serotype Acquisitions Incidence  
(per 1000 days) 
95% CI Incidence in larger cohort*  
(per 1000 days) 
6A 45 1.33 0.97-1.77 1.49 
6B 38 1.12 0.79-1.54 1.26 
14 26 0.77 0.50-1.12 0.79 
19F 74 2.18 1.71-2.74 2.54 
23F 35 1.03 0.72-1.44 1.24 
The total time at risk was 33,905 person-days.  
*The incidence estimated from the cohort of 1400 that included all newborns; those 
who gave and those who did not give serum samples. 
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Table 2: Adjusted hazard ratios quantifying the association of acquisition of any 
pneumococcal serotypes with selected environmental and anti-protein antibody 
variables 
Variable Hazard Ratio* 95% CI 
Coryza observed at last visit 1.36 1.03-1.60 
History of coryza at last visit 1.20 0.87-1.63 
Runny nose at last visit 1.17 0.96-1.51  
Fuel used for cooking   
     Firewood Ref.  
     Charcoal 0.61 0.37-0.94 
     Paraffin 0.81 0.67-0.97 
     Gas 2.04 1.03-6.48 
No. of Siblings  1.06 1.01-1.13 
No. of carers in household 0.94 0.89-0.99 
No. of children aged <10 years in household 1.08 1.01-1.16 
No. of smokers in household 1.11 0.97-1.30 
Mother positive of carriage around time of birth 1.58 1.06-2.06 
Type of sample: Cord vs. Venous blood (Ref) 0.82 0.69-0.98 
Month of Swab   
     January Ref.  
     February 1.22 0.76-1.87 
     March 1.22 0.78-1.94 
     April 1.12 0.72-1.64 
     May 1.02 0.63-1.53 
     June 1.95 1.08-2.92 
     July 2.57 1.37-3.64 
     August 2.19 1.13-3.17 
     September 1.99 1.04-2.71 
     October 1.93 1.06-2.79 
     November 1.84 1.01-3.27 
     December 0.88 0.55-1.32 
CbpA 1.17 1.00-1.35 
LytC 1.17 1.01-1.32 
PcpA 1.13 1.00-1.24 
PhtD1 0.79 0.70-0.95 
PiaA 1.16 1.02-1.27 
PspAFam2 0.85 0.77-0.98 
PspAFam1 1.07 0.99-1.19 
RrgBT4 1.15 1.05-1.25 
Spr0096 0.92 0.85-1.00 
StkP 0.88 0.81-0.99 
 
*The hazard ratios for the anti-protein antibodies should be interpreted as the hazard 
ratio per unit increase in log IgG concentration. 
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Figure 1: Univariable analysis of the effect of anti-capsular IgG on serotype-
specific carriage acquisition rate. The figure shows the relative hazard of 
acquisition (blue solid line) as a function of log IgG concentration (x-axis) for each 
serotype labeled above the graph. The hazard at each level of log IgG is relative to 
the mean log IgG. The red dashed lines are the 95%CI bounds of the hazard ratio. 
The three vertical (grey) lines mark the 2.5th, 50th and 97.5th percentiles of the 
distribution of log IgG whose density is shown in grey on the x-axis. The likelihood 
ratio (LR) test p-value compares a model with and that without the log IgG 
concentration variable, thus indicating the overall significance of antibody 
concentration. The point-wise confidence intervals in the figures, at the point where 
the upper bound descends below the hazard ratio of 1, can be used to mark log IgG 
levels which results in significant reduction in carriage rates compared to typical 
(mean) log IgG values. 
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Figure 2: Univariable (left panel) and Multivariable (right panel) analysis of the 
effect of anti-capsular IgG concentration on carriage acquisition rates of any of 
the serotypes: 6A, 6B, 14, 19F and 23F. The figure follows the convention 
described in the legend for figure 1. The 95% CIs for the multivariable analysis are 
percentile-based and computed from 200 cluster bootstrap (clustered on 
subject/individual) resamples of the data. PLR stands for penalized likelihood ratio 
test, comparing a model with the log IgG concentration variable and one without. 
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Figure 3: Multivariable analysis of the effect of the selected anti-protein IgG on 
all pneumococcal carriage acquisition rates. The figure follows the convention 
described in the legend for figure 1. The 95% CIs are percentile-based and 
computed from 200 cluster bootstrap (clustered on subject/individual) resamples of 
the data. PLR stands for penalized likelihood ratio test, comparing a model with the 
log IgG concentration variable and one without. 
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Figure 4: Multivariable analysis of the effect of anti-capsular IgG on serotype-
specific carriage acquisition rate. The figure follows the convention described in 
the legend for figure 1. The 95% CIs are percentile-based and computed from 200 
cluster bootstrap (clustered on subject/individual) resamples of the data. PLR stands 
for penalized likelihood ratio test, comparing a model with the log IgG concentration 
variable and one without. 
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Supplementary Figure S1: Univariable analysis of the effect of anti-protein IgG 
concentration on all pneumococcal carriage acquisition rates. The figure follows 
the convention described in the legend for figure 1. 
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Supplementary Figure S2: Multivariable analysis of the effect of anti-protein 
IgG concentration on carriage acquisition rates of any of the serotypes: 6A, 6B, 
14, 19F and 23F not adjusting for anti-capsular antibodies. Adjustment variables 
for the functions presented in the plot include the environmental variables and rest of 
the selected anti-protein variables. The figure follows the convention described in the 
legend for figure 1.  
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Supplementary Figure S3: Multivariable analysis of the effect of anti-protein 
IgG concentration on carriage acquisition rates of any of the serotypes: 6A, 6B, 
14, 19F and 23F, adjusting for standardized anti-capsular antibodies. 
Adjustment variables included the environmental variables, the rest of the selected 
anti-protein variables and standardized log anti-capsular antibodies of the five 
serotypes. The figure follows the convention described in the legend for figure 1.  
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Abstract 
Introduction 
Most low-income counties have introduced pneumococcal conjugate vaccines 
(PCVs), all with substantial financial support from Gavi, the Vaccine Alliance. 
Within the next decade many of them will enter an accelerated transition 
phase and within the subsequent 5 years will need to either discontinue or 
gradually take over the full costs of their PCV programmes. Kenya introduced 
the ten valent PCV (PCV10) in 2011 and will enter Gavi transition in 2022. 
Using Kenya as a case study we assessed the cost-effectiveness of such 
strategies. 
 
Methods 
We fitted a dynamic compartmental model of pneumococcal carriage to 
annual carriage prevalence surveys and invasive pneumococcal disease 
(IPD) incidence in Kilifi obtained two years pre- and four years post- vaccine 
introduction and extrapolated this to the whole of Kenya. The incidence of 
pneumococcal sepsis, meningitis, bacteraemic pneumonia and non-
bacteraemic pneumonia was estimated as a proportion of IPD incidence. The 
treatment costs of predicted cases of these four syndromes and vaccination 
cost of birth cohorts over a decade were estimated and used to calculate the 
costs per disability-adjusted-life-year (DALY) averted and associated 
predictive intervals (PI). 
 
Results 
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We predict that overall IPD incidence will increase by 93% (PI: 72% - 114%) 
from 8.4 in 2022 to 16.3 per 100,000 per year in 2032, if vaccination is 
stopped. Continuing vaccination would prevent 15,355 (PI: 10,196–21,125) 
deaths and 112,050 (PI: 79,620–130,981) IPD and non-bacteraemic 
pneumonia cases during that time. The cost-effectiveness becomes more 
favourable as the effects of the current programme wane. The incremental 
cost per DALY averted of continuing PCV use versus discontinuing was 
predicted at $142 (PI: 85 - 252) in 2032. We estimate that continuing the PCV 
programme after 2022 will require an additional US$15.6 million annually 
compared to discontinuing vaccination. This is approximately triple Kenya’s 
current annual immunization expenditure of US$ 4.8 million. 
 
Conclusion 
Continuing PCV use is essential to sustain its health gains. Based on the 
Kenyan GDP per capita of $1445, and in comparison to other vaccines, 
continued PCV use at full costs is still cost-effective. This supports an 
expansion of the vaccine budget, however, affordability may be a concern.  
 
	 149	
Introduction 
The majority of African countries have introduced the pneumococcal 
conjugate vaccine (PCV) in their childhood immunization programmes which 
has led to a substantial reduction in pneumococcal disease [1,2]. In Kilifi, a 
coastal area in Kenya with enhanced surveillance for bacterial diseases, 
overall invasive pneumococcal disease (IPD) decreased by 68% in the post 
vaccination period (2012-2016) in children aged <5 years [3]. 
 
PCVs are among the most expensive vaccines available. However, most 
African countries did not undertake a cost-effectiveness analysis before 
deciding to introduce PCV as Gavi, the Vaccine Alliance, took over most 
vaccine costs. However, countries are expected to transition from Gavi 
support and subsequently take over the full cost once their average Gross 
National Income per capita over the past three years exceeds $1580. 
Currently four African countries (Angola, Congo Rep., Ghana and Nigeria) are 
in the accelerated transition phase [4] and five more (Ivory Coast, Lesotho, 
Sudan, Kenya and Zambia) are expected to join within the next five years. 
With the increase in PCV costs upon transition countries will need to 
independently assess the cost-effectiveness and the affordability of sustaining 
the PCV infant vaccination programme. 
 
Kenya introduced the 10 valent PCV (PCV10) in 2011 with Gavi’s support and 
has recently entered the preparatory transition phase, which will see their 
current contribution of $0.21 per dose increase by 15% every year. In 2022 
Kenya will enter the accelerated transition phase that gradually increases their 
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cost contribution to 100% by 2027 [5]. Before entering the accelerated 
transition-phase Kenya will need to decide whether to continue with PCV 
vaccination and or discontinue the programme. We here assess the impact 
and cost-effectiveness of those two policy options.   
Methods  
We used a dynamic pneumococcal transmission model in combination with a 
costing model to estimate the cost-effectiveness of the two major policy 
options for PCV use in Kenya from 2022; i.e. continuation of PCV use at 
Gavi’s scheduled prices or discontinuing the programme. The approach 
accounts for the uncertainty in both epidemiology and costing estimates and 
appropriately propagates it to the predicted outcomes. 
 
Disease model and incidence prediction 
The details of the transmission model are described elsewhere [6]. In brief, it 
is a compartmental, age-structured, dynamic model with 14 carriage states 
(Appendix, Supplementary Figure 3). The model has a Susceptible-Infected-
Susceptible (SIS) structure for three serotype groups: the vaccine serotypes 
(VT), strongly competitive non-vaccine serotypes (sNVT) and weakly 
competitive non-vaccine serotypes (wNVT). We fitted the model to age 
stratified pre-vaccination (2009-2010) and post-vaccination (2011-2016) 
pneumococcal carriage data. This also allowed estimation of the vaccine 
efficacy against carriage.  
 
In Kilifi, PCV vaccination was introduced together with a catch-up campaign in 
children <5 years old. To extrapolate findings to the rest of Kenya, where PCV 
	 151	
was introduced without a catch-up campaign, the fitted model was re-run 
under these conditions. We predicted carriage incidence for a 15-year period, 
from 2017 to 2032. We predicted IPD incidence by multiplying modelled 
carriage incidence with case-to-carrier ratios (CCR). For each model posterior 
the CCRs were calculated as the ratio of the observed pre-vaccination IPD 
incidence at Kilifi Country Hospital (KCH) [7] to modelled pre-vaccination 
carriage incidence. The CCR were assumed to remain unchanged post-
vaccination.  
 
IPD was defined as isolation of Streptococcus pneumoniae from a sterile site 
culture in an individual admitted to KCH. We split the predicted IPD incidence 
into the age dependent proportions that are pneumococcal meningitis, 
pneumococcal sepsis and bacteraemic pneumococcal pneumonia incidence 
based on the distribution observed in clinical data from KCH (Supplementary 
Table S1). We defined pneumococcal meningitis as isolation of Streptococcus 
pneumoniae from cerebrospinal fluid (CSF) or isolation of S. pneumoniae 
from blood, accompanied by a CSF white blood cell count of 50 x 106 cells/L 
or greater or a ratio of CSF glucose to plasma glucose less than 0.1. 
Bacteraemic pneumococcal pneumonia was defined as IPD with no 
pneumococcal meningitis but with WHO severe or very severe pneumonia. 
Pneumococcal sepsis was defined as IPD not meeting the definitions of 
pneumococcal meningitis or bacteraemic pneumococcal pneumonia. We 
further assume that for every prevented case of IPD one would prevent 5.3 
cases of clinically-defined pneumonia [3,8]. This ratio was estimated by 
dividing the vaccine preventable clinical pneumonia incidence (351 per 
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100,000 per year) [3] to vaccine preventable IPD incidence (66.3 per 100,000 
per year) [8] that were both estimated from surveillance at KCH. 
 
Vaccination program costs 
The program costs included vaccine costs, vaccine wastage, safety boxes, 
administering syringes for each dose, reconstitution syringes for each vial, 
syringe wastage and vaccine delivery cost (Table 1). The vaccine delivery 
cost included the vaccine supply chain cost and immunization service delivery 
cost. The initial investment in expanding the cold chain capacity in 2011 was 
not included.  A switch from 2-dose to 4-dose presentation is expected during 
2017. The 4-dose presentation has a preservative and once opened for the 
first time the vial can be kept for up to 28 days, therefore, Gavi expects no 
change in assumed vaccine wastage rates [9]. 
 
Treatment costs	
We adopted a societal perspective in our analyses, i.e. including direct 
medical costs, the opportunity cost of caretaker time and household out-of-
pocket costs. The hospital surveillance in KCH was found to underestimate 
the incidence of pneumonia and meningitis by 45% and 30% respectively [10]. 
We accounted for this age-independent under reporting in our analysis by 
inflating case numbers commensurately. 
 
To apply the appropriate treatment costs, we divided the cases into three 
groups depending on where they were treated: hospitalised cases, cases 
treated as outpatients and those that did not reach medical care (Table 1). All 
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costs not referring to 2016 were expressed in 2016 US dollars for our analysis 
by using the International Monetary Fund’s (IMF) GDP deflators for Kenya 
[11].   
 
Disability Adjusted Life Years (DALYs) 
The treatment costs for the predicted number of cases for the four syndromes 
considered and the vaccination cost of birth cohorts over a decade were 
estimated and used to calculate the costs per disability-adjusted-life-year 
(DALY) averted. Age weighting for the societal value of health loss was not 
considered in the analysis [12]. The years lost due to disability (YLD) were 
calculated as the product of disease incidence, duration of disease and 
disability weights. We used disability weights from the 2013 global burden of 
disease study [13] in calculating YLD component of DALYs. We used the 
disability weight of 0.133, assigned for infectious diseases with severe acute 
episodes, for both IPD and non-bacteraemic pneumonia episodes. For 
meningitis sequelae, we used a disability weight of 0.542 assigned for motor 
plus cognitive impairment. We assumed duration of 15 days for all IPD 
syndromes and 7 days for non-bacteraemic pneumonia. Meningitis sequelae 
were assumed to last a lifetime. We used the Kenyan age specific life 
expectancies [14] in calculating the Year of Life Lost (YLL) due to death. The 
discount rate on costs and DALYs was set at 3%.  
 
Sensitivity analysis of the cost inputs and disease model 
The full uncertainty of both epidemiological and costs parameters is 
propagated to the results as follows: for each posterior estimate of the 
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epidemiological model we sampled a set of cost parameters from the pre-set 
distributions, effectively combining probabilistic fitting of the epidemiological 
mode with a probabilistic sensitivity analysis of the costing model (Table 1).  
 
In Kenya, children who are carriers of VT pneumococci have been observed 
to respond less well to vaccine than non-carriers [15]. To assess structural 
uncertainty in our model we ran our analyses either with or without accounting 
for hyporesponsiveness. In the base case, we estimated a single vaccine 
efficacy independent of carrier status; in the sensitivity analysis, vaccine 
efficacy was estimated separately in vaccine-type carriers and in others. We 
also present two scenarios of discounting, i.e. discounting both costs and 
DALYs at 3% (base case) or discounting costs alone. 
 
Results 
Model fit and predicted IPD incidence 
There was good agreement between the observed and fitted age-group and 
serotype-group specific carriage prevalence (Supplementary Figure 1 & 
Appendix). If cohorts of children born after the start of year 2022 are no longer 
vaccinated with PCV, the model predicts that IPD incidence will bounce back 
from 8.4, in 2022 to 16.3 per 100,000 per year in 2032 equalling pre PCV 
levels (Figure 1). Continuing with the PCV programme is predicted to result in 
additional small reductions in IPD incidence to 7.8 per 100,000 per year in 
2032, and to avert 15,355 (PI: 10,196–21,125) deaths and 112,050 (PI: 
79,620–130,981) IPD and non-bacteraemic pneumonia cases during the 11 
years considered, if compared to discontinuing the PCV programme in 2022. 
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Estimated costs and cost effectiveness 
The average annual treatment and vaccination costs for continuing the PCV 
programme during 2022-2032 were estimated as $18,904,576. If vaccination 
was to be stopped in 2022 the estimated average annual treatment cost for 
pneumococcal disease in Kenya would be $3,275,143 (Table 2). 
Discontinuing the PCV programme was predicted to partially sustain direct 
and indirect protection from the vaccination of previous cohorts for much of 
the study period with only gradually declining impact on IPD incidence. As a 
result, we predict that continuation of the current PCV programme will not be 
cost effective initially. However, we show that within only one year after the 
decision to continue PCV vaccination the incremental cost-effectiveness ratio 
(ICER), in comparison to discontinuing the programme, rises substantially 
towards the threshold of the Kenyan GDP per capita ($1455 in 2016) and 
continues to improve throughout the study period (Figure 2). Compared to 
discontinuing PCV in 2022, we predicted that, in 2032, the cost per DALY 
averted is $142.7, the cost per case averted $878.4 and the cost per death 
averted $6386.8 (Table 2).  
 
Sensitivity analyses  
Using the Kenyan GDP per capita of $1455 in 2016 as a threshold to 
determine cost effectiveness, all posterior samples indicated that continuation 
of PCV vaccination is cost effective no more than six years after 2022. 
Compared to discounting both costs and DALYs, discounting costs alone 
resulted in an ICER that was twice as favourable (Table 2). 
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We estimate that the effect of hyporesponsiveness is relatively small. Vaccine 
serotype carriers had a vaccine efficacy estimate against carriage that was 4 
percentage points lower than that for other vaccinees (Appendix, table A1). 
Hence omitting this mechanism in the model structure led to similar results 
(Supplementary Figure 2). Therefore, we did not include hyporesponsiveness 
in our final model.  
 
Discussion 
In the near future Kenya, like many other low income countries, will be 
expected to take over the full cost of the national pneumococcal conjugate 
vaccination programme [16]. In this study, we have estimated the cost-
effectiveness of continuing with the vaccination programme using Gavi’s 
schedule of vaccine prices, which reach a peak at $3.05 per dose in 2027, at 
which point Kenya becomes fully self-financing. Our model projects that 
discontinuing the PCV vaccination programme would lead to an increase in 
IPD burden equivalent to pre-vaccination levels within ten years. Initially, 
however, continuing vaccination may not be cost-effective because of the 
benefits accrued through vaccination of previous cohorts. However, the cost-
effectiveness becomes more favourable within a few years and, by 2032, the 
cost (in 2016 US dollars) plateaus at $142.7 ($85.1-$252.4) per discounted 
DALY averted. 
 
The most commonly used threshold for judging the cost-effectiveness of an 
intervention is a country’s Gross Domestic Product (GDP) per capita. Using 
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this criterion, we find continuation of the PCV programme in Kenya after 
transition from Gavi support highly cost-effective. The GDP per capita 
threshold was initially supported by the Commission on Macroeconomics and 
Health [17]  and adopted by WHO’s Choosing Interventions that are Cost-
Effective project (WHO-CHOICE). The use of GDP-based thresholds has 
been criticized because it: (i) does not consider potential benefits of other 
competing interventions; (ii) does not adequately address the willingness to 
pay; (iii) does not address affordability and (iv) is easily attained [18]. 
Alternatives include benchmarking interventions and league tables. A 
benchmark approach is a way of assessing willingness to pay by comparing 
cost-effectiveness ratios of the intervention under consideration with those of 
other interventions that have already been introduced. In the league table 
approach interventions are lined up in order of increasing ICER, then 
implemented in that order until the available budget runs out. 
 
The cumulative costs per DALY averted of introducing the Rotarix or the 
RotaTeq rotavirus vaccines in Kenya have been estimated as $200.1 and 
$405.9 (2016 US Dollars) respectively, from a societal perspective [19]. The 
analysis was based on annual incidence of rotavirus associated diarrhoeal 
disease in children aged under 5 years estimated from national and sentinel 
surveillance data with 3% discounting on both cost and benefits, as in our 
current analysis. The Haemophilus influenzae type B (Hib) vaccine was 
introduced in 2001 Kenya as part of the pentavalent vaccine. In a static model 
developed to follow the Kenyan 2004 birth cohort until death, with and without 
Hib vaccine, it was estimated that the discounted (3% for both costs and 
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benefits) cost per DALY averted of introducing Hib vaccine was $85 (2016 US 
Dollars) from a health provider perspective [20]. These ICERs suggest that 
continuation of the PCV programme is higher in value to the Hib vaccine 
programme and superior to the rotavirus vaccine programme. However, these 
comparisons must be tempered by the fact that the rotavirus analysis ignored 
herd immunity, which increases the ICER, while the Hib analysis took a health 
provider perspective, which reduces ICER.   
 
Cost-effectiveness, however, does not necessarily imply affordability. The 
later depends on available resources in the health budget, or any other 
sources within the national accounts that can fill the gap in the health budget. 
Budgetary allocation to the health sector as a fraction of national government 
budget has slightly declined from 4% in financial year 2014/15 to 3.7% in 
financial year 2016/17 [21]. The Kenyan annual health budget for 2015 was 
$600 million [21]. Out of this $4.88 million (0.8%) [22] was spent on routine 
immunization. This has been possible because Kenya only needs to fund 10% 
of its routine immunization programme from its revenues, donors fund the rest 
of the budget [22]. We have estimated that continuing with the PCV 
vaccination after 2022 will require an additional $15.6 million annually 
compared to discontinuing vaccination; in other words, it will more than triple 
Kenya current expenditure on vaccines.   
 
Several initiatives indicate that the cost of the PCV programme may be 
reduced in future. For instance, the Serum Institute of India is developing of a 
10-valent PCV with a target per-dose price of $2.00 [23]. Also, in settings 
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where vaccine serotypes have been eliminated from circulation it may be 
possible to sustain control of transmission using a two-dose or even one-dose 
schedule[24]. If vaccine serotypes can be eliminated in Kenya, for example by 
additional efforts such as a catch-up campaign, then the shift to a reduced 
dose schedule may also be feasible. Most of these options will have a wider 
evidence base that may allow their formal consideration by 2022, however, 
currently there is insufficient support to include them in our analyses. 
 
There are some potential limitations in our study. The proportion of 
pneumococcal disease cases that are hospitalized, treated as outpatients or 
do not access care is a key determinant of both costs incurred as well as 
DALYs, by determining the case fatality rate. Overestimating the proportion of 
cases that get hospital treatment would mean that the overall costs of 
treatment were overestimated while the fatal cases, and therefore DALYs, 
were underestimated. The overall effect would be an overestimated ICER, 
which is conservative. In our analysis, we estimated the proportion of cases 
that were hospitalized using local surveillance data [10]. However, we did not 
have local information on what proportion among unhospitalised cases are 
treated as outpatients; this was obtained from a Ugandan verbal autopsy 
study among fatal pneumonia cases [25]. It is possible, therefore, that we 
have overestimated the number of patients among unhospitalised treated as 
outpatients, and, by extension, overestimated the ICER.  
 
Many low-income countries will soon be transitioning out of Gavi support and 
will need to decide whether to sustain their pneumococcal conjugate 
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vaccination programme. We demonstrate, using Kenya as an example, how 
ongoing detailed surveillance can be combined with mathematical modelling 
and health economics to inform an upcoming decision of a country’s National 
Immunization Technical Advisory Group (NITAG) on the cost-effectiveness of 
different policy options. We estimate that maintaining the PCV programme is 
essential to sustain the decreased burden of pneumococcal disease and that 
it is cost-effective against conventional criteria. However, to afford PCV 
vaccination in the post-Gavi era, Kenya will need to substantially increase the 
proportion of health spending on routine immunization. 
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Table 1: Economic and health parameters varied in sensitivity analysis  
Parameter  Point estimate Statistical  
distribution  
Source 
Access to care proportions for pneumococcal diseases    
    Hospitalised sepsis, bacteraemic and non-bacteraemic cases  55% Beta (55,45) [10] 
    Hospitalized meningitis cases  70% Beta (70,30) [10] 
    Unhospitalised IPD and non-bacteraemic cases treated as 
outpatient  
63% Beta (63,37) [25] 
Health outcomes     
    Proportion of meningitis cases developing sequelae 25% Beta (25,75) [26] 
    CFR with hospital care    
           Sepsis, bacteraemic and meningitis: Children (<15 years) 19% Beta (19,81) KCH  
           Sepsis, bacteraemic and meningitis: Adults (>=15 years) 46% Beta (46,54) KCH 
           Non-bacteraemic pneumonia 5.7% Beta (6,94) [27] 
    CFR without hospital care     
          Meningitis 97% Beta (97,3) [28] 
          Sepsis and bacteraemic pneumonia 50% Beta (4,4) [28] 
          Non-bacteraemic pneumonia 12% Beta (12,88) [28] 
Vaccination costs (US$)    
    Vaccine price per dose $0.21-$3.05 
(Table S2) 
Fixed [4,29,30] 
    Safety boxes $0.46 Fixed [31] 
    AD syringes $0.045 Fixed [31] 
    Reconstruction syringes $0.052 Fixed [31] 
    Vaccine delivery cost per dose $1.42 Gamma (4,0.4) [32] 
    Syringe wastage 5% Fixed   [28] 
    Vaccine wastage 15% Fixed [9,28,33] 
Treatment costs (US$)    
     With hospital care    
          Meningitis $357.74 Gamma (4,97) [34] 
          Sepsis, bacteraemic and non-bacteraemic pneumonia $74.64 Gamma (4,19) [34] 
     With outpatient care (All four syndromes) $2.74 Gamma(4,0.75) [35] 
     Without hospital care (All four syndromes)  $1.15 Gamma (4,0.3) [35] 
 
	 168	
 
Table 2: Estimated costs and cost-effectiveness ratios for different scenarios 
Scenario Average annual cost  
Over 2022-2032, millions of 
US$ 
 (95% PI) 
Cost per case  
averted in 2032, US$  
(95% PI)  
Cost per death  
averted in 2032, US$ 
(95% PI) 
Cost per DALY  
Averted in 2032, 
US$  
(95% PI) 
     
Stopping vaccination in year 2022  3.3 (1.3 – 7.1) Ref. Ref. Ref. 
Continuing vaccination 18.9 (13.2 – 29.4) 878.4 (566.9- 1446.3) 6386.8 (3819.0 – 11250.1) 142.7(85.1 – 252.4) 
Continuing vaccination (discounting costs only) 18.9 (13.2 – 29.4) 531.4 (343.0 – 875.0) 3864.1 (2310.6 – 6806.5) 67.5 (40.1 – 120.1) 
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Supplementary table S1: Invasive Pneumococcal disease (IPD) 
separation in to meningitis, pneumococcal bacteraemic pneumonia and 
sepsis. IPD cases are obtained from hospitalized cases at the Kilifi County 
hospital among residents of the Kilifi Health and Demographic Surveillance 
System for the period 1999-2016 (<15) for children and 2007-2016 for adults 
(>=15). 
 Pneumococcal 
Meningitisa 
Pneumococcal 
Bacteraemic  
Pneumoniab  
Pneumococcal 
Sepsisc   
Age category n % n  % n % 
       
<1 52 28.0 85 45.7 49 26.3 
1-5 32 11.3 126 44.4 126 44.4 
6-14 39 29.8 47 35.9 45 34.4 
15-20 1 33.3 0 0.0 2 66.7 
21-49 11 29.7 3 8.1 23 62.2 
50+ 3 11.5 2 7.7 21 80.8 
a Isolation of S. pneumoniae from cerebrospinal fluid (CSF) or isolation of S. pneumoniae from blood, accompanied 
by a CSF white blood cell count of 50 x 106 cells/L or greater or a ratio of CSF glucose to plasma glucose less than 
0.1 
bIPD with no pneumococcal meningitis but with WHO severe or very severe pneumonia.  
cIPD not meeting any of the above definitions of pneumococcal meningitis and bacteraemic pneumococcal 
pneumonia.  
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Supplementary table S2: Vaccine price per dose paid by Kenya in each year 
Gavi transition phase Year Vaccine 
price per 
dose (US$) 
Preparatory transition phase:  
Contribution to price per dose increases by 15% annually 
2017 0.21 
2018 0.24 
2019 0.28 
2020 0.31 
2021 0.37 
   
Accelerated transition phase:  
Contribution starts at an additional 20% of the difference between 
the projected price of the vaccine in the year a country enters fully 
self-financing phase and the co-financing amount per dose paid in 
the preceding year, and increases linearly over four years to 
reach the projected price. 
2022 0.91 
2023 1.34 
2024 1.77 
2025 2.20 
2026 2.63 
   
Fully self-financing: 
Country pays the full vaccine price 
2027 - 2032 3.05* 
*This is the price assumed when Kenya enters the fully self-financing phase. It is the current price of PCV10. The 
actual price then might be lower since prices are generally expected to go down, but there are currently no 
projections from Gavi.  
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Figure 1: Invasive pneumococcal disease (IPD) impact by age group  
Predicted incidence of IPD when vaccination is continued in 2022 (red line), 
its 95% prediction interval (light-red shade), and when vaccination is stopped 
(blue line, with 95% prediction interval shown in light-blue shade) over time 
since vaccine introduction in Kenya in 2010.  
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Figure 2: Costs, DALYs and incremental cost-effectiveness ratios 
(ICERs) by year 
The topmost panel shows the cost of treatment and vaccination in each year 
(blue line with light-blue shade for 95% PI) when vaccination is continued, and 
the cost of treatment in each year when vaccination (red line, with light-red 
shade for 95% PI) is discontinued in 2022. The middle panel shows the 
corresponding DALYs gained in each year. The bottom panel shows the ICER 
(y-axis), incremental (continuing vaccination over stopping vaccination) cost 
per DALY averted (green line) and its 95% prediction interval (light-green 
shade) in each year (x-axis). 
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Supplementary Figure 1: Model fit to carriage data  
Observed (circular dots with 95% credible intervals shown by spikes) and predicted (lines with 95% predictive intervals shown by 
shaded areas) carriage prevalence of vaccine-serotypes (VT), shown in red, strong non-vaccine serotypes (sNVT), shown in blue, 
and weak non-vaccine serotypes (wNVT), shown in lime green, over time. The age groups are labelled at the panel title.		
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Supplementary Figure 2: IPD projection with and without 
hyporesponsiveness by age group 
Predicted incidence of IPD when hyporesponsiveness is ignored in the 
carriage model (red line with 95% prediction interval shown in light-red shade, 
and when hyporesponsiveness is allowed for in the model structure (blue line, 
with 95% prediction interval shown in light-blue shade) over time since 
vaccine introduction in Kenya. Age groups are labelled on the panel titles. 
 
	 175	
 
Supplementary Figure 3:  Model structure flow diagram 
The epidemiological states include individuals that are susceptible (non-
carrying), !; carry a vaccine serotype, !; carry a weak non-vaccine serotype, !!; carry a strong non-vaccine serotype, !!; carry simultaneously a weak and 
a strong non-vaccine serotype, !!"; carry simultaneously a vaccine serotype 
and a weak non-vaccine serotype, !!; or carry simultaneously a vaccine 
serotype and a strong non-vaccine serotype, !! (see text). Once vaccinated, 
the individual moves to one of the corresponding 
states, !(!),  !(!),!!(!),!!(!),!!(!)!"# !!(!) . The acquisition rates from the 
single to multiple serotype carriage states are reduced by competition 
parameters denoted by ! with two subscripts; the first denoting the serotype 
group (!, ! !"# !, for VT, strong NVT and weak NVT respectively) of the 
resident serotypes and the second denoting the age-group. The competition 
parameters have two sets of values, one for age group <6 and another for 
age group ≥6 years (see Appendix). The age-group specific VT, weak NVT 
and strong NVT clearance rates are denoted by r!", r!"# and r!"#, 
respectively. In addition to the transitions between the 14 epidemiological 
states as shown in the Figure, individuals die from any states at age-specific 
death rates and new individuals are born into the completely susceptible 
state.  
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Supplementary Figure 4: Model structure flow diagram including 
hyporesponsiveness 
The epidemiological states include individuals that are susceptible (non-
carrying), !; carry a vaccine serotype, !; carry a weak non-vaccine serotype, !!; carry a strong non-vaccine serotype, !!; carry simultaneously a weak and 
a strong non-vaccine serotype, !!"; carry simultaneously a vaccine serotype 
and a weak non-vaccine serotype, !!; or carry simultaneously a vaccine 
serotype and a strong non-vaccine serotype, !! (see text). Once vaccinated, 
individuals not carrying vaccine serotypes move to the corresponding states 
(S(!),N!(!), N!(!), N!"(!)) while those carrying vaccine serotypes  (V,B!(!), B!(!)) 
move to the corresponding hyporesponse-associated states (ℎV, ℎB!(!), ℎB!(!)) 
The acquisition rates from the single to multiple serotype carriage states are 
reduced by competition parameters denoted by ! with two subscripts; the first 
denoting the serotype group (!, ! !"# !, for VT, strong NVT and weak NVT 
respectively) of the resident serotypes and the second denoting the age-
group. The competition parameters have two sets of values, one for age 
group <6 and another for age group ≥6 years (see Appendix). The age-group 
specific VT, weak NVT and strong NVT clearance rates are denoted by r!", r!"# and r!"#, respectively. In addition to the transitions between the 21 
epidemiological states as shown in the Figure, individuals die from any states 
at age-specific death rates and new individuals are born into the completely 
susceptible state.  
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Appendix: Model structure and parameters estimates 
Model structure  
A more detailed description of the model and the likelihood function is 
presented in1. The brief description provided in this appendix is to help in the 
understanding of the notation used, without necessarily referring to1. The 
model is compartmental, age-structured and dynamic. Compartments are 
defined according to pneumococcal carriage states (Supplementary Figure 3). 
It has a Susceptible-Infected-Susceptible (SIS) structure for three serotype 
groups: the PCV10 serotypes, strong NVT and weak NVT.  
At any point in time, an unvaccinated individual can be susceptible (non-
carrying) in state S; carry a VT, V; carry a weak NVT, N!; carry a strong NVT, N!; carry simultaneously a weak and strong NVT, N!"; carry simultaneously a 
VT and weak NVT, B!; or carry simultaneously a VT and a strong NVT, B!. 
Once vaccinated, the individual moves to one of the corresponding states 
(S(!), V(!),N!(!), N!(!), N!"(!), B!(!), B!(!)). We also fitted a model in which the 
efficacy of the vaccine on carriage acquisition is reduced due to prevailing 
carriage at the point of vaccination (hyporesponsiveness) is considered. 
Under this model, upon vaccination, individuals not carrying vaccine 
serotypes move to the corresponding states (S(!),N!(!), N!(!), N!"(!)) while those 
carrying vaccine serotypes  (V,B!(!), B!(!)) move to the corresponding 
hyporesponse-related states (ℎV, ℎB!(!), ℎB!(!)) (Supplementary Figure 4). 
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Parameterisation  
A susceptible unvaccinated individual in age group i becomes colonised with 
VTs, strong NVTs or weak NVTs at age-group-specific time-dependent rates 
(forces of infection) denoted by λ!"(t), λ!"#(t) and λ!"#(t), respectively. The 
forces of infection were expressed as functions of the social mixing matrix and 
age-group specific factors (q!) that scale the rate of social contacts into 
infectious contacts. Due to competition between serotypes in colonising the 
nasopharynx, the acquisition rate of a secondary serotype is lower than the 
acquisition rate of that serotype in a completely susceptible individual. Three 
competition parameters, c!", c!" and c!", represent the fraction by which 
acquisition rates of secondary serotypes are reduced in <6 year olds infected 
with VTs, weak NVTs and strong NVTs, respectively. Two competition 
parameters, c!" = c! = c! and c!, were used for individuals aged ≥ 6 years 
infected with VTs/weak NVTs and strong NVTs, respectively. In the 
vaccinated compartments the rate of acquisition of VTs are reduced by the 
vaccine efficacy against carriage acquisition denoted !, or !! according to 
whether the compartment is associated with hyporesponsiveness. 
The Metropolis-Hastings algorithm was used to draw samples from the 
posterior distributions of the parameters. Uniform priors in the range 0-1 were 
used for competition parameters and the social contact scaling parameters 
(q!). For the vaccine efficacy parameters we used a normal prior centered 
around 50% with 95% uncertainty interval of 40-60%. 50,000 adaptive MCMC 
iterations were used. After a burn-in of 25,000 was discarded the remaining 
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stationary samples were thinned to 5000 to estimate the posterior distribution. 
Convergence was assessed graphically, by observing was no negative or 
positive trend (zero gradient) in the chain, and by using Geweke diagnostic to 
check if a chain was stationary. The thinned posterior samples of the 
parameters were summarised to obtain point estimates (posterior mean) and 
probability (credibility) intervals. The parameter estimates are shown in Table 
A1. 
 
1 Ojal J, Flasche S, Hammitt LL, Akech D, Kiti MC, Kamau T, et al. Sustained reduction in vaccine-type invasive 
pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: a mathematical model based 
on pre-vaccination data. Vaccine. 2017;35:4561–8. 
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Table A1. Estimated parameters of the dynamic transmission models 
 
Parameter Estimate (95% Credible Interval)  Estimate accounting for  
hyporesponsiveness (95% Credible 
Interval) 
    
Competition parameters !!! = 0.42 (0.24, 0.62) 
 !!! = 0.73 (0.44, 0.97)  !!! = 0.44 (0.25, 0.70) !! = 0.11 (0.01, 0.40) !!" = !! = !! = 0.70 (0.30, 0.98) 
 
 !!! = 0.41 (0.25, 0.59) 
 !!! = 0.70 (0.43, 0.97)  !!! = 0.46 (0.27, 0.70) !! = 0.10 (0.01, 0.30) !!" = !! = !! = 0.66 (0.24, 0.98) 
 
Probability of infection per 100 contacts  !! = 0.14 (0.11, 0.19) !! = 0.45 (0.38, 0.55) !! = 0.30 (0.26, 0.35) !! = 0.08 (0.06, 0.11) !! = 0.16 (0.13, 0.19) !! = 0.06 (0.05, 0.07) 
 !! =0.14 (0.11, 0.19) !! =0.45 (0.39, 0.54) !! =0.30 (0.26, 0.35) !! =0.08 (0.06, 0.10) !! =0.16 (0.13, 0.19) !! =0.06 (0.05, 0.07) 
Vaccine efficacy against carriage ! = 0.59 (0.49, 0.68)   ! = 0.58 (0.47, 0.68) 
Vaccine efficacy against carriage for VT 
carriers (hyporesponsiveness) N/A 
 !! = 0.54 (0.40, 0.68) 
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Chapter 6: General discussion 
 
Kenya introduced PCV10 in 2011 in a 3+0 schedule in which infants are 
vaccinated at 6, 10 and 14 weeks of age. In Kilifi, a town in coastal Kenya, the 
introduction was accompanied by a catch-up campaign among children <5 
years, which achieved coverage of 65%. Data from KHDSS, the demographic 
surveillance site in Kilifi, has shown a significant drop in both vaccine-serotype 
carriage and vaccine-serotype IPD. Carriage of vaccine serotypes was 
reduced by two-thirds both in children younger than 5 years and in older 
individuals [1,2]. In children <5 years, the incidence of vaccine-serotype IPD 
fell by 92% while the overall IPD decreased by 68% in the post vaccination 
period (2012-2016) [3].  
 
1.1 Summary of findings 
On top of this epidemiological background, I developed a transmission model 
fitted to pre-vaccination (2009-2010) carriage data. I validated the model 
predictions against post-vaccination carriage data (2011-2015) and showed 
that the model closely predicted the observed magnitude and timing of 
serotype replacement carriage. This illustrates the utility of transmission 
dynamic modelling in predicting disease changes from carriage data in the 
absence of disease data, as has been observed with several other models of 
pneumococcal transmission. However, most of the previous pneumococcal 
carriage models in literature have consolidated non-vaccine serotypes (NVT) 
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in to a single group. In the model I have developed, some of the heterogeneity 
in bacterial fitness parameters, such as susceptibility to the competition that 
exist across individual serotypes, has been accounted for by splitting NVT into 
weak and strong groups. Differentiating the non-vaccine serotypes into two 
groups led to different predictions for weak and strong NVT and these 
predictions matched well with the observed data. 
 
A concern of the rapid and substantial impact of PCV10 in Kilifi was its 
sustainability once the effects of the catch-up campaign have waned. In the 
model presented, the current schedule was predicted to be sufficient to limit 
vaccine-type pneumococcal carriage to current levels even after incorporating 
demographic change; however, it is unlikely to lead to the elimination of 
vaccine serotypes [4]. 
 
If newborn infants are protected naturally in the first few months of life by 
maternally-derived serotype-specific antibodies and if the levels of these 
antibodies in mothers are maintained by repeated re-infection, then one of the 
consequences of introducing PCV10 into a population will be a reduction in 
the protection afforded to young infants through passive maternal protection; 
this comes about simply because the PCV10 programme will reduce 
transmission in the population, and reduce re-stimulation of mothers.  
However, in most settings this effect is likely to be amply compensated for by 
the reduced exposure of young infants to the vaccine serotypes.  In Kilifi, 
unlike most developed country settings, transmission of vaccine types was not 
completely eliminated and so young infants remain at risk of infection and 
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disease. Also, a transmission model ignoring the effect serotype-specific 
maternal antibody protection would overestimate the impact of vaccination 
since that effect would be wholly, and wrongly, attributed to the herd 
protection from vaccination.  
 
In the analysis of the protective effect of maternally-derived antibodies against 
carriage acquisition I found a significant association between carriage 
acquisition and several anti-protein antibodies but only a limited protective 
effect of maternally-derived anti-capsular antibodies and only at high 
concentrations [5]. The effect of anti-protein antibodies to a particular 
pneumococcal protein, whether in decreasing or increasing the risk of 
carriage acquisition, is not serotype-specific. I observed a limited protective 
effect of maternally-derived anti-capsular antibodies to five common serotypes 
(6A, 6B, 14, 19F and 23F) in the pre-vaccination period in Kenya at high 
concentrations, but those concentrations were achieved by only 3% of the 
newborn population [5]. The limited applicability of these findings in the 
natural setting justifies our decision to omit protection from maternally-derived 
anti-capsular antibodies in transmission models. In addition, I predict that a 
resurgence of VT disease in young infants as a result of reduced capsular 
protection from maternally-derived antibodies is unlikely.   
  
Despite a significant reduction in VT carriage following PCV10 introduction we 
observed sustained transmission of VT serotypes within the surveillance 
population at KHDSS. If children are vaccinated while carrying a VT serotype 
the vaccine will have a reduced efficacy, designated as ‘hyporesponsiveness’. 
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One would predict that, as VT carriage prevalence is reduced by the 
maturation of the PCV10 programme there would be a positive feedback loop, 
with increasing vaccine efficacy caused by a declining probability that the 
vaccine is given to a VT serotype carrier. If the impact of this 
hyporesponsiveness turned out to be immunologically significant, then, with 
time there should be improved protection from VT carriage that cannot be 
attributed to direct and herd protection alone and hence the issue of residual 
VT carriage may resolve itself more quickly than expected.  
 
My analyses of the link between carriage and vaccine responses confirmed 
hyporesponsiveness in both infants and toddlers [6]. Hyporesponsiveness 
was quantified as the difference in geometric mean antibody concentrations, 
observed at a specific point after vaccination, between carriers and non-
carriers at the time of vaccination. As we found no valid estimate of the 
correlates of protection against carriage acquisition, the clinical implication of 
the observed hyporesponsiveness, i.e. the percentage reduction of vaccine 
efficacy against carriage acquisition, could not be quantified. Therefore, it was 
not possible to account for hyporesponsiveness by reducing vaccine efficacy 
among VT carriers in the transmission model. Instead, the reduction in 
efficacy was estimated by fitting a model that incorporated 
hyporesponsiveness in its structure to age and serotype group dependent 
carriage data (research paper 4). From the fit of this model, VT carriers were 
estimated to have a vaccine efficacy against carriage that was 4% lower than 
that among non-VT carriers. This very small reduction in efficacy may be a 
function of the relatively short period of observation post-vaccination, during 
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which the effect of hyporesponsiveness on carriage may not yet have had 
sufficient opportunity to accelerate carriage clearance in the population. 
Nonetheless, in comparison with a model structure that ignored 
hyporesponsiveness, the model that included hyporesponsiveness did not 
significantly improve on the predictions for carriage or disease (research 
paper 4). It is therefore unlikely that the effect of hyporesponsiveness is of 
epidemiological relevance for the vaccination programme in Kenya.  
 
Most countries have now introduced PCV in to their childhood immunisation 
programmes. Because PCVs are expensive, the majority of developing 
countries were only able to introduce these vaccines with substantial financial 
support from Gavi, the Vaccine Alliance. However, these countries will be 
expected to transition out of Gavi support and begin to pay the full cost of their 
PCV vaccination programmes as their economies grow. Countries 
approaching the ‘transition threshold’ in economic development will need to 
assess the cost-effectiveness and affordability of sustaining their PCV 
programmes to guide policy decisions concerning these programmes. 
Kenya’s contribution to the vaccine price will increase rapidly from US$0.91 to 
US$3.05 per dose over the five years from 2022-2027. I show that sustaining 
PCV10 vaccination is cost-effective by conventional criteria in Kenya but it will 
present major challenges to affordability for the Kenya Government. 
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1.2 Limitations 
Natural immunity can be acquired after exposure to pneumococcal carriage 
and can reduce the duration of carriage in subsequent episodes [7,8]. This 
means that those who are have more prior experience (and are therefore 
generally older) will be less susceptible to carriage acquisition. However, 
natural immunity was not explicitly incorporated in the structure of the 
transmission model. Some of the protection derived from natural exposure 
would be captured in the age-group dependent risk of pneumococcal 
acquisition estimated in the model. Nonetheless, not explicitly incorporating 
natural immunity in the model might lead to an overestimate of the impact of 
vaccination, especially in the early years of vaccine introduction.  
 
The model did not fully account for the heterogeneity in fitness characteristics 
across individual serotypes because it relied on broad serotypes groups. 
There was no formal validation of the optimal number of NVT groups. The 
decision to use two NVT groups was conservative in order to avoid potential 
difficulties in model fitting in a highly-compartmentalised model. A model 
comparison process with varying number of groups of VT and NVT could help 
in choosing the optimal number of serotype groupings. The grouping of 
serotypes may also artificially promote their co-existence in the model 
because it artificially reduces serotype-specific fitness differences.  
 
It is an assumption of the model process that the case-to-carrier ratios remain 
constant across the whole period of observation. These, were estimated using 
pre-vaccination data and used to translate changes in carriage into changes 
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in disease incidence. However, there is some evidence to suggest that 
vaccine driven selection pressure can result in genetic shifts in the 
pneumococcal population and this may bring about serotype switching [9–11]. 
In fact, serotype switching has been documented even in the absence of 
vaccination [12]. Because the capsule is a determinant of virulence including 
the invasive capacity, serotype switching may lead to a change in the case-to-
carrier ratio. For instance, it has been shown in the USA introduction of PCV7 
led to genetic shifts such that strains carrying vaccine serotype 4 adopted the 
capsular genes of a 19A strain – which was non-PCV7 serotype [10]. The 
original serotype 4 strain carried virulence proteins that were likely to give rise 
to invations, therefore, the case-to-carrier ratio for 19A probably increased 
across the vaccine eras as it incorporated strains of serotype 4 origin. If case-
to-carrier ratios of non-vaccine serotypes generally become higher due to 
vaccine escape recombinants, then the future incidence of non-vaccine 
serotype IPD would be under predicted by the model. In Kenya, pneumococci 
collected pre-PCV10 have been genotyped [13], genotyping post-vaccination 
isolates will determine whether there is capsular switching linked to 
vaccination.  
 
The model was fitted to data where only a single serotype was recorded per 
nasopharyngeal sample. Since the model had states in which individuals are 
carrying two serotypes simultaneously, fitting the model to the data was made 
possible through an assumption that in a doubly-colonised individual either of 
the two colonising serotypes was detected with equal probability. This implies 
that the relative abundance of the two serotypes were equal, which might not 
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be true. Genotypic laboratory methods that can measure the relative 
abundance of pneumococcal serotypes in a nasopharyngeal sample are now 
developed [14], and will be input in future transmission models. The 
mathematical model I developed can be fitted to multiple serotypes carriage 
data without structural modification, assuming that carriage of more than two 
serotypes is negligible. However, it is not yet clear if the density of carriage of 
serotypes is correlated with its ability to transmit, a dynamic that future 
pneumococcal transmission models might have to consider.      
 
The principal limitation of the study of the effect of maternally-derived 
antibodies on the rate of acquisition of carriage in newborns was its 
observational design; the absence of a randomised intervention means it is 
difficult to control completely for confounding. Environmental factors can 
predispose mothers to increased carriage and this can lead to higher antibody 
concentrations which will be passively transferred to their newborns. Since the 
newborn is also brought up in the same high transmission environment, it 
might be estimated that higher antibody concentrations are associated with 
carriage if confounding by environmental factors cannot be adequately 
controlled for in the analysis. My analysis adjusted for household level risk 
factors for carriage such as: type of fuel used for cooking, number of siblings 
aged <10 years, number of other children aged <10 years, number of adults, 
number of smokers and number of carers. However, there could be residual 
confounding attributable to additional environmental factors beyond those 
already adjusted for. For instance, a poor social-economic status has been 
associated with increased carriage [15]. Incomplete adjustment for 
	 189	
confounding in the analysis could be overcome by testing the phenomenon in 
an experimental design using nasopharyngeal challenge studies in animal or 
human models [16–18]. Our lack of understanding of the primary biological 
role of different proteins limited the interpretation of some associations 
between high levels of anti-protein antibody and high levels of acquisition.  
 
In the cost-effectiveness analysis, I focused on a single dichotomous decision 
- continuing with PCV10 vaccination versus discontinuing PCV in 2022. These 
are not the only options available for Kenya. For example, Kenya may choose 
to introduce a novel 10-valent PCV which is currently in clinical development 
by the Serum Institute of India and is aimed at a price of $2.00 per dose [19]. 
Alternative vaccination schedules, for example using a booster dose in the 
second year of life with a reduced number of doses in infancy, may enhance 
the cost-effectiveness of PCV10 by further reducing VT carriage and disease 
and/or vaccination costs. However, this was not assessed within the current 
scope of the PhD. Furthermore, future cost-effectiveness models that 
incorporate the impact of vaccines on economic development [20], and not 
just the health loss in form of DALYs, may be more persuasive to 
governments and societies. This approach has not been taken in the current 
work though it may lead to a revision of the affordability of vaccines by 
government – the principal challenge identified in the CEA study. 
 
Lastly, the predictions of the impact of PCV10 vaccination in this study can 
only be generalised to countries with similar pre-vaccination epidemiology as 
Kenya. This means that they should have similar carriage and IPD patterns, 
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similar transmission dynamics, similar vaccine serotype coverage and similar 
vaccination uptake. Nonetheless, the model can be re-parameterised with 
data from other settings and used to predict carriage and disease impact in 
those settings. 
 
1.3 Future work 
In African countries that have been using PCV for at least 5 years, vaccine 
serotypes continue to circulate at relatively higher levels [1,21] than in 
developed countries where carriage prevalence is now usually <2% [22]. 
Among infants and children aged <5 years in Kilifi, Kenya, the prevalence of 
PCV10 serotypes in carriage in 2016 is estimated from a cross-sectional 
carriage study at about 8% and 6%, respectively [3]. It is therefore necessary 
to maximise herd protection by eliminating VT circulation.  
 
There are a number of factors that could explain the high residual VT carriage 
in children in these African countries. The first factor is a higher force of 
infection in African children. The population density, the effective contact 
patterns and environmental factors such as poor hygienic conditions can 
influence the force of infection. A high population density increases the 
frequency of contacts between individuals and consequently intensifies the 
force of infection. The population density in Africa (40 persons/km2) countries 
is higher than in developed countries (25 persons/km2) [23]. In addition, 
families in rural and semi-urban areas are organised into households with 
sizes that are much larger on average than those in developed countries [24]; 
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this increases the frequency of close interactions. Poor hygienic conditions 
increase the transmission probability and therefore the force of infection. 
 
Given this higher force of infection, the coverage of routine vaccination may 
not be sufficient to eliminate VT transmission; one solution therefore, might be 
to raise vaccine coverage to almost 100%. In The Gambia, the coverage of at 
least two doses of PCV13 in children aged 2-23 months plateaued at 73% in 
2013 following replacement of PCV7 with PCV13 in 2011 [25]. Carriage 
prevalence of PCV13 serotypes in infants was 18.3% in 2013 [21], data on 
carriage in more recent years has not been published yet. In Kenya, the 
coverage of at least two doses of PCV10 in children aged 2-23 months was 
about 80% in 2011 and 85% in 2016 [3]. A modelling study in The Gambia 
projected that with 100% coverage the low to middle prevalence VT (i.e. 
vaccine serotypes with pre-vaccination prevalence <2%) would be eliminated, 
as a result the prevalence of all VT in the population would decline 
significantly from 20.1% before vaccination to 3.0% 10 years after [26]. Such 
an assessment of the impact of complete vaccine coverage has not yet been 
done for Kenya, which uses a difference formulation of PCV and the model 
results from The Gambia cannot be assumed to apply directly.  
 
The absence of a booster dose in the childhood immunisation schedule can 
be a factor too; most developed countries, which have achieved elimination of 
PCV7 serotypes, have incorporated a booster does following either a 2-dose 
or 3-dose primary series in infancy [27]. In a systematic review of dosing 
schedules, a booster dose in the second year of life following a 2-dose 
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primary series induces substantially higher concentrations of anti-capsular 
antibodies compared to a schedule with 3-dose primary series without a 
booster [28]. Theoretically, the higher antibody concentrations imply longer 
duration of protection as well as reduction in carriage the second year of life, 
when carriage transmission is still high. The impact of the booster dose on 
carriage in the second year of life might also lead to more rapid induction of  
herd immunity, which accelerates VT elimination. This herd immunity could 
compensate for the potential increased risk of acquisition, between the 
second and the booster doses, associated with not giving the third primary 
dose. 
 
Each of the above mechanisms through which VT circulation is hypothesised 
to be sustained in African populations could be incorporated in the baseline 
model to help inform related policy questions such as: (i) is there room for 
increasing vaccine coverage within current regime in the effort of eliminating 
of VT carriage in Kenya?; (ii) will a switch to a vaccination schedule that 
includes a booster dose bring about elimination?; (iii) will a mass campaign in 
age groups with high carriage prevalence bring about elimination?; (iv) what 
are the considerations of the optimal extent of campaigns to eliminate VT? 
 
Finally, there are also protein and whole cell vaccines in different stages of 
development and clinical trials [29]; it would be useful to project their impact 
on carriage and disease and whether they are cost-effective once information 
concerning their efficacy becomes available and mechanism of protection 
against carriage and disease is more clearly understood in humans.  
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1.4 Conclusion 
PCVs, introduced into the childhood immunisation programme, are highly 
effective in reducing the burden of disease caused by pneumococcus. 
Compared to older vaccines, PCVs are very expensive but there are ongoing 
efforts to lower the prices, and the development of lower cost PCV by the 
Serum Institute of India is one such example. Meanwhile, as other cost-
reducing options are developed and assessed, sustaining the PCV10 
programme beyond 2022 will depend upon Kenya’s financial resources.  
 
Kenya has not previously been in a position where it is required to pick up the 
full cost of a vaccine introduced in a subsidized way. The first vaccines 
introduced through Gavi subsidies in 2001 are the Pentavalent and Yellow 
fever vaccines, which continue to be almost fully funded by Gavi since Kenya 
currently pays 6.87% of the price per dose of US$1.24 and US$1.19 
respectively [30]. There is some impetuous from Angola, which has been fully 
self-financing Pentavalent Vaccine since 2016, and will support PCV in full 
from 2018 [31]. However, Angola’s GDP per capita of US$3110 is double that 
of Kenya. The Kenya National Immunization Technical Advisory Group 
(KENITAG) is mandated to issue recommendations to the Kenyan Ministry of 
Heath (MoH) on national vaccine policy. KENITAG is supposed to issue these 
recommendations based on the best available, ideally local, supporting 
evidence. This work provides KENITAG with the much-needed evidence 
base. The PCV10 vaccine programme is cost-effective based on acceptable 
thresholds. However, to afford PCV vaccination Kenya will need to 
substantially increase the budget for routine immunization. 
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Background: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a
catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study
based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given
the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may
re-emerge once the effects of the catch-up campaign wear off.
Methods: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and
invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-
vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to
age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage
prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the
observed carriage prevalence after vaccine introduction.
Results: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence
from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine
introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall
reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type
IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to
increase by 52%. The model’s predictions of carriage prevalence agrees well with the observed data in
the first five years post-vaccination.
Conclusion: We predict a sustained and substantial decline in IPD through PCV vaccination and that the
current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that
the observed impact is likely to be sustained despite waning effects of the catch-up campaign.
! 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Reduction in nasopharyngeal carriage of vaccine-type pneumo-
cocci has been documented after vaccination with pneumococcal
conjugate vaccines (PCVs) [1–3]. Moreover, by reducing pneumo-
coccal acquisition, PCVs reduce pneumococcal transmission in
the community offering indirect protection to the unvaccinated
[4]. However, non-vaccine-type pneumococci rapidly colonise this
vacated ecological niche, which can result in serotype replacement
carriage [5] and replacement disease reducing the overall impact of
PCVs [6]. With support from Gavi, The Vaccine Alliance, African
countries have been introducing PCVs since 2009. Kenya intro-
duced a 10-valent PCV (PCV10) targeting serotypes 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F and 23F in 2011. In Kilifi, a coastal area with
enhanced surveillance for invasive pneumococcal disease (IPD)
and carriage prevalence, the introduction was supplemented by a
catch-up campaign in children <5 years old. At the same time
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annual carriage prevalence surveys have been conducted in the Kil-
ifi Health and Demographic Surveillance System (KHDSS) popula-
tion since 2009 [5].
Within a few months post-vaccination vaccine-type pneumo-
coccal carriage and disease had dropped substantially in all age
groups. However, vaccine serotypes (VTs) continue to circulate in
the community [7,5]. This raises the concern that, after the popu-
lation effects of the catch-up campaign have worn off, vaccine-
type pneumococcal disease will re-emerge.
We developed a dynamic compartmental model parameterized
with detailed data from the KHDSS population [8] to describe the
pre-vaccination pneumococcal epidemiology and predict the
long-term impact of PCV10 in Kilifi. We use post-vaccination data
on carriage and disease over the past five years for validation of the
model predictions.
2. Methods
2.1. Data
Kilifi County Hospital (KCH) is the main referral hospital in
KHDSS. At KCH, morbidity events linked with the population regis-
ter have been used to define the incidence of hospital presentation
with infectious diseases, including IPD [8,9]. Datasets on pneumo-
coccal carriage, IPD and contact patterns in KHDSS are described in
detail elsewhere [5,10,11]. Here we briefly describe them as used
in the current analysis.
2.1.1. Nasopharyngeal pneumococcal carriage surveys
Two cross-sectional surveys of pneumococcal carriage were
done pre-vaccination. Nasopharyngeal swabs were collected and
pneumococcal serotype-specific carriage ascertained [5] to obtain
the pre-vaccination age-specific prevalence and serotype distribu-
tion of carriage. The two datasets were combined since there were
no significant differences between them in the carriage prevalence
or serotype distribution (Appendix chapter 1).
The non-vaccine serotypes (NVTs) were classified as weak or
strong based on their susceptibility to competition and carriage
incidence, as estimated in a prior field study within KHDSS [12].
Strong NVTs (23B, 11A, 15A, 6A, 16F, 35B, 10A, 13, 23A 19A, 21;
ordered by increasing susceptibility to competition) were less sus-
ceptible to competition. Two NVTs (34, 15B/C) were classified as
strong for their higher carriage incidences compared to many of
the ones chosen on the basis of susceptibility. The remaining NVTs
were classified as weak (Appendix chapter 2).
2.1.2. Prospective diary survey
Selected residents from KHDSS filled in a diary on the ages of all
persons they physically contacted on one randomly assigned
weekday [10]. For children, the diary was completed by their guar-
dians. This information defined a social mixing matrix of contact
frequencies between age groups.
2.2. Carriage model structure
We developed a compartmental, age-structured dynamic model
with 14 pneumococcal carriage states (Fig. 1). The model has a Sus
ceptible-Infected-Susceptible (SIS) structure for three serotype
groups: the PCV10 serotypes, strong NVT and weak NVT.
At any point in time, an unvaccinated individual can be suscep-
tible (non-carrying) in state S; carry a VT, V; carry a weak NVT, Nw;
carry a strong NVT, Ns; carry simultaneously a weak and strong
NVT, Nsw; carry simultaneously a VT and weak NVT, Bw; or carry
simultaneously a VT and a strong NVT, Bs. Once vaccinated, the
individual moves to one of the corresponding states (SðvÞ, V ðvÞ,
NðvÞw , N
ðvÞ
s , N
ðvÞ
sw , B
ðvÞ
w , B
ðvÞ
s ). The equations of inter-state transitions
are presented in Appendix chapter 3.
Fig. 1. Model structure flow diagram. The epidemiological states include individuals that are susceptible (non-carrying), S; carry a vaccine serotype, V; carry a weak non-
vaccine serotype, Nw; carry a strong non-vaccine serotype, Ns; carry simultaneously a weak and a strong non-vaccine serotype, Nsw; carry simultaneously a vaccine serotype
and a weak non-vaccine serotype, Bw; or carry simultaneously a vaccine serotype and a strong non-vaccine serotype, Bs (see text). Once vaccinated, the individual moves to
one of the corresponding states, ðSðvÞ;V ðvÞ;NðvÞw ;NðvÞs ;BðvÞw andBðvÞs Þ. The acquisition rates from the single to multiple serotype carriage states are reduced by competition
parameters denoted by c with two subscripts; the first denoting the serotype group (v ; sandw, for VT, strong NVT and weak NVT respectively) of the resident serotypes and
the second denoting the age-group. The competition parameters have two sets of values, one for age group <6 and another for age group #6 years (see text). The age-group
specific VT, weak NVT and strong NVT clearance rates are denoted by rVi; rNwi and rNsi , respectively. In addition to the transitions between the 14 epidemiological states as
shown in the figure, individuals die from any states at age-specific death rates and new individuals are born into the completely susceptible state.
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2.3. Parameterisation
2.3.1. Population structure
The model population is stratified into six age groups (<1, 1–5,
6–14, 15–20, 21–49 andP50 years) corresponding to those in the
diary survey and reflecting the age structure in KHDSS as of 1st
January 2010. Individuals in the model are born completely sus-
ceptible to carriage according to prevailing birth rates and die
according to age-specific mortality rates from KHDSS (Table 1).
2.3.2. Acquisition of carriage
A susceptible unvaccinated individual in age group i becomes
colonised with VTs, strong NVTs or weak NVTs at age-group-
specific time-dependent rates (forces of infection) denoted by
kViðtÞ, kNsiðtÞ and kNwiðtÞ, respectively. The forces of infection were
expressed as functions of the social mixing matrix and age-group
specific factors (qi) that scale the rate of social contacts into infec-
tious contacts (Appendix chapter 3). Due to competition between
serotypes in colonising the nasopharynx, the acquisition rate of a
secondary serotype is lower than the acquisition rate of that sero-
type in a completely susceptible individual. Three competition
parameters, cv0, cw0 and cs0, represent the fraction by which acqui-
sition rates of secondary serotypes are reduced in <6 year olds
infected with VTs, weak NVTs and strong NVTs, respectively. Two
competition parameters, cvw ¼ cv ¼ cw and cs, were used for indi-
viduals aged P6 years infected with VTs/weak NVTs and strong
NVTs, respectively.
2.3.3. Clearance of carriage
The immune clearance rates of carriage (Appendix chapter 4)
depend on the serotype group and age (<1, 1–5 and >5 years)
and were obtained from a prior study in Kenyan children [12].
2.3.4. Disease
For each serotype group and age group, case-to-carrier ratios
were calculated as ratios of the observed IPD incidence at KCH
[11] to the respective model-predicted pre-vaccination carriage
incidence. The case-to-carrier ratios were assumed to remain
unchanged post-vaccination and were multiplied with the pre-
dicted carriage incidence to predict post-vaccination IPD incidence.
2.3.5. Vaccination
In Kenya, children receive PCV10 at age 6, 10 and 14 weeks. In
the model, g=80% of all newborns are considered vaccinated at
age 18 weeks, one month after the third dose of the 3-dose series
(Table 1). A catch-up programme is simulated by vaccinating 65%
of children younger than 5 years at the onset of the vaccination
programme. Upon vaccination, an individual moves to the corre-
sponding state in the vaccine-protected compartment based on
his/her prevailing carriage status.
The vaccine efficacy against carriage is modelled as a 50% reduc-
tion (e ¼ 0:50) in the acquisition rate of VTs in a vaccinated indi-
vidual relative to an unvaccinated individual (Table 1). The
vaccine efficacy against carriage progression to disease (VEprog)
was calculated as a function of e and the vaccine efficacy against
IPD (VEIPD = 85%) as:
VEprog ¼ 1$ 1$ VEIPD1$ e ¼ 70%:
We assumed that a proportion u = 0.12 of the vaccinated popu-
lation loses their protection every year. This corresponds to an
average duration of protection for an individual of just over 8 years
(Table 1).
2.3.6. Implementation and model calibration
In the first stage, the stationary solution of the transmission
model was fitted to the age-stratified pre-vaccination carriage
prevalence and serotype distribution (Appendix chapter 1). Using
a multinomial likelihood function and uninformative priors in a
Bayesian framework, the five competition parameters (cvw, cv0, cs,
cs0 and cw0) and six scaling/infectivity parameters
ðq1; q2; q3; q4; q5; q6Þ were estimated (Appendix chapter 5). In each
iteration, bootstrapping the social contact data and reconstructing
the mixing matrix incorporated uncertainty in the social contact
rates. A stationary population with equal birth and mortality rates
was assumed.
In the second stage, the posterior samples of model parameters
obtained in the first stage were applied in a prediction model. Pro-
jections were made assuming a constant population. To measure
how fast the effect of the catch-up campaign wanes, we calculated
the additional cases of IPD the campaign prevents in the first
10 years and estimated the time required to achieve 90% of that
effect. Simulations were performed in R [13].
2.4. Sensitivity analysis
The sensitivity of the predicted IPD incidence averted, i.e., the
difference in the overall incidence of IPD before and at 10 years
post-vaccination, was assessed with respect to uncertainties in
the assumed levels of: (i) vaccine efficacy against carriage acquisi-
tion; (ii) vaccine efficacy against IPD; (iii) the waning rate of
vaccine-induced protection against carriage; (iv) vaccine coverage.
We performed additional simulations under a growing popula-
tion using birth and death rates corresponding to the local demo-
Table 1
Parameters of the dynamic transmission model and the sources of information. The
parameters are classified as those estimated (calibrated) in the context of the model
and those derived from external sources.
Parameter/input Estimate/value
(intervala)
Source
Calibrated
Competition parameters cs0 = 0.44 (0.13, 0.82)
cw0 = 0.59 (0.19, 0.96)
cv0 = 0.39 (0.15, 0.71)
cs = 0.11 (0.004, 0.49)
cvw ¼ cv ¼ cw = 0.77
(0.30, 0.99)
Estimated
Probability of infection per 100
contacts
q1 = 0.13 (0.07, 0.25)
q2 = 0.40 (0.30, 0.55)
q3 = 0.32 (0.24, 0.43)
q4 = 0.07 (0.04, 0.13)
q5 = 0.16 (0.11, 0.23)
q6 = 0.06 (0.04, 0.09)
Estimated
Case-to-carrier ratiosb Appendix chapter 7 [11]
From external sources
Clearance rates Appendix chapter 3 [12]
Birth rate 32.0 per 1000/year [8]
Age-specific mortality Appendix chapter 5 [8]
Contact rates [10]
Vaccine efficacy against carriage
acquisition (e)
50% (40–60) [3,25–27]
Vaccine efficacy against IPD 85% (80–90) [34]
Waning rate of protection against
carriage (u)
0.12 per year (0.09–0.20) [35]
Routine vaccination coverage (g) 80% (70–90) [9,11]
Catch-up coverage 65% (60–70) [9,11]
a The intervals indicated for the estimated parameters are 95% credible intervals.
The intervals indicated for the rest of the parameters are the ranges within which
they were sampled in the model to account for their uncertainty and assess the
model’s sensitivity.
b IPD incidence from Kilifi district hospital in KHDSS is divided by the carriage
incidence from the model to obtain case-to-carrier ratios (Appendix chapter 7).
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graphics [8]. The probabilities of contact per person per day were
recalculated for each time step according to the current population
(Appendix chapter 6).
2.5. Model validation
We visually assessed proximity of the base-case predictions of
the age-group specific carriage of VTs and NVTs to the correspond-
ing observed values over a five-year period post-vaccination
(2011–2015).
3. Results
3.1. Model fit to pre-vaccination epidemiology
There was a good agreement between the observed age-group
and serotype-group specific pre-vaccination carriage prevalence
and their posterior estimates (Fig. 2). Within each age group, the
95% credible intervals agreed with the data. Nonetheless, the dif-
ferences in the posterior mean estimates of the proportions of car-
riers of VTs and NVTs among pneumococcal carriers were in most
instances larger than observed in individuals !6 years old, com-
pared to the differences in individuals <6 years old.
3.2. Competition parameters
The probability of infection per contact was higher among 1–5
and 6–14 year olds as compared to other age groups (Table 1).
An individual <6 years carrying a vaccine-serotype had a 61%
(95% credible interval, CrI, 29–85%) protection against acquiring
NVTs, relative to an uninfected individual of the same age group.
In older age groups, the corresponding level of protection was
23% (95% CrI 1–70%).
3.3. Model projections on pneumococcal carriage
Under the base-case model, the overall prevalence of pneumo-
coccal carriage was estimated to remain essentially at its pre-
vaccination level, with only a slight reduction from 44% to 41%
within 10 years post-vaccination. The prevalence of VTs in the
overall population was estimated to reduce from 16% to 4%, with
a simultaneous increase in the prevalence of NVTs from 28% to
36%.
The prevalence of VTs was predicted to reduce in all age groups.
In the older, mostly unvaccinated population, the reduction was
estimated to be about two thirds of the pre-vaccination level
(Table 2), suggesting a benefit of herd immunity. Changes in the
prevalence of VTs and NVTs occur within the first 4–5 years post-
vaccination and little change was predicted thereafter (Fig. 3).
3.4. Model projections on IPD
The incidence of IPD from VTs was projected to decline in all age
groups. The changes in IPD and carriage were linked and over 50%
reduction in IPD occurs within the first 4–5 years after PCV intro-
duction. The overall reduction in the incidence of IPD ten years
post-vaccination is predicted to be 56% (Table 3). The overall
reduction in the incidence of IPD from year 5 to 10 was 7% (95%
predictive interval: "0.4% to 14%). As a result of waning direct
Fig. 2. Model fit. Observed prevalence (red points) of pneumococcal carriage across age groups (top-left panel) and the proportion of carriers of VT (top-right panel), strong
NVT (bottom-left panel) and weak NVT (bottom-right panel) among pneumococcal carriers prior to vaccine introduction. The black points show the corresponding estimated
values of the prevalence/proportion, based on data given in Appendix chapter 1. The capped bars represent the 95% credible intervals. The dotted lines in the top-left panel
(and the points they pass through) are the observed (red) and the predicted (black) proportions of double carriers among <1 and 1–5 year olds. For these two age groups, the
top-right, bottom-left and bottom-right panels present the proportions of single carriers of the respective types (VT, strong NVT, weak NVT) among all carriers in the age
group. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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effects of the catch-up campaign and increasing herd-effects of
routine immunisation with time, we estimated that the incremen-
tal benefit of a catch-up over routine vaccination alone would be
negligible from year 7 after introduction of PCV10.
3.5. Sensitivity analyses
Among the variables included in the sensitivity analysis, the
duration of protection had the largest effect on the predicted IPD
incidence averted in year 10, followed by the vaccine efficacy
against carriage. The vaccine efficacy against IPD had the least
influence (Fig. S1).
Assuming a growing population, the overall prevalence of car-
riage was projected to decline to a somewhat lower level of 35%
(95% prediction interval 30–40%) ten years post-vaccination
(Appendix chapter 7).
3.6. Model validation
The point predictions and corresponding 95% prediction inter-
vals (PI) of carriage prevalence cover most of the observed values,
showing good predictive ability (Fig. S2). Among <1 and 1–5 year
olds the model predicted much lower carriage prevalence of NVTs
in year 2015 (49% vs. 70% observed and 38% vs. 52% observed,
respectively).
4. Discussion
We used a model calibrated with local data to predict the
incidence of pneumococcal carriage and IPD in Kilifi, Kenya, over
a 10-year period post-vaccination to assess whether additional
measures have to be considered to prevent a resurgence of
vaccine-type pneumococci once the impact of the catch-up
campaign wanes. We validated the model against immediate
post-vaccination epidemiological data, a unique exercise in
pneumococcal carriage models, and found that such resurgence
is unlikely if the routine immunisation programme continues.
Most PCV introductions in African countries have occurred since
year 2011. Therefore, only a few years of observation are available
to assess impact. A meta-analysis of four randomized trials in
African children aged 9–24 months showed that carriage of VTs
decreased with vaccination but the overall carriage remained the
same [14]. In the United Kingdom, the overall prevalence of pneu-
mococcal carriage was stable four years post-vaccination [15]. In
our model predictions, the overall carriage prevalence remains
essentially unchanged due to serotype replacement in carriage.
Replacement carriage was most prominent in <6 year olds because
the pre-vaccination proportion of VTs among pneumococcal
carriers was highest in young children (Appendix chapter 1). We
predict that elimination of VTs in this community is unlikely. In
high-income countries that have almost eliminated circulation of
VTs, a reduced-dose schedule has been considered to improve
the cost-effectiveness of the programme [16]. The World Health
Organization (WHO) also recently convened a working group to
review the policy recommendations for the optimal use of PCVs
in low- and middle-income countries, which includes discussion
of reduced dose schedules [17]. Theoretically, where herd protec-
tion has been established, it may be possible to sustain it using,
for example, a single dose in infancy and a booster dose in the sec-
ond year of life. In the Kenyan setting, however, where vaccine-
type pneumococci continue to circulate several years post intro-
duction of PCV with a catch-up campaign, it would be difficult to
argue that disease prevention among infants is currently guaran-
teed by herd protection.
In the model presented, the incidence of IPD is predicted to
decline across all age groups. The non-vaccine-type IPD incidence
is expected to increase by 52%, which translates to an increase in
the annual incidence of 1.9 per 100,000, suggesting little replace-
ment disease relative to the reduction in the annual overall
vaccine-type IPD incidence of 12.3 per 100,000. This is explained
by the lower average case-to-carrier ratios (i.e., lower invasive-
ness) of the replacing non-vaccine serotypes (Appendix chapter 8).
South Africa and The Gambia introduced PCV7 in 2009 and
replaced it with PCV13 in 2011 [18,19]. The reduction in vaccine-
type and overall IPD reported in these countries are similar to
the predictions our model produces for Kilifi, Kenya, over the first
few years post-vaccination. This, however, does not validate the
model because of differences across the settings. The vaccination
coverage in Kenya is likely to differ from coverage in The Gambia
and South Africa, and Kenya introduced PCV10. We thus validated
our model predictions against observed carriage prevalence and
IPD incidence in Kilifi. The model predictions were generally con-
sistent with the observed data (Fig. S2). The model, however,
underestimated prevalence of carriage of NVTs in <6 year olds in
2014–15. Relaxing the assumption of a constant population size
only made minimal difference to the goodness of fit (Fig. S3).
Pneumococcal serotypes are heterogeneous in transmissibility
and mutual competition [12,20]. By splitting the NVTs into two
groups and allowing unequal mutual competition between these
groups, our model accounts for some of this heterogeneity. We
did not split VTs because we aimed to reproduce serotype replace-
ment with as small a number of parameters as possible, by limiting
the number of compartments. Splitting NVTs was preferred
because the group has a larger number of serotypes and hence
more heterogeneity. The model projected differing magnitudes of
change in the prevalence of the strong and weak NVTs. Given the
different case-to-carrier ratios of the two groups of NVTs
Table 2
The prevalence of nasopharyngeal carriage of pneumococci pre- and 10 years post-vaccination. The table presents the posterior predictive mean values with the 95% posterior
predictive intervals.
Age group
(years)
Pre-vaccination 10 years post-vaccination
Carriage prevalence VTa Strong NVTb Weak NVT Carriage prevalence VT Strong NVT Weak NVT
<1 80.8 (67.8–90.1) 32.6 (25.1–40.5) 37.5 (30.6–45.8) 9.9 (7.1–13.2) 75.7 (61.4–87.2) 8.3 (1.6–18.2) 50.9 (40.9–62.6) 15.2 (10.5–22.2)
1–5 72.5 (65.2–78.5) 29.5 (23.9–35.2) 29.7 (24.6–35.2) 13.1 (9.6–17.0) 67.2 (58.9–74.6) 8.0 (1.5–16.9) 39.2 (32.2–48.5) 19.3 (14.1–25.5)
6–14 54.0 (43.1–64.8) 17.0 (13.9–21.2) 26.8 (18.9–35.0) 9.9 (7.4–13.5) 49.7 (38.6–61.0) 4.4 (0.9–9.6) 32.0 (23.6–41.2) 12.8 (9.5–17.1)
15–20 27.9 (17.0–41.7) 9.1 (5.7–13.9) 13.4 (7.6–20.7) 5.3 (3.1–8.6) 25.3 (15.6–38.0) 2.5 (0.5–6.0) 15.8 (9.5–24.3) 6.8 (4.1–10.8)
21–49 25.5 (17.0–35.5) 8.6 (5.8–12.1) 12.0 (7.6–17.5) 4.8 (3.0–7.2) 23.2 (15.2–33.0) 2.5 (0.5–5.6) 14.2 (9.2–20.9) 6.2 (3.9–9.3)
50+ 21.0 (14.0–30.0) 7.1 (4.7–10.1) 9.8 (6.2–14.6) 4.0 (2.6–6.0) 19.1 (12.7–27.3) 2.0 (0.4–4.5) 11.7 (7.6–17.2) 5.2 (3.3–7.9)
Overall 44.4 (40.2–48.9) 15.9 (13.3–18.7) 20.4 (16.8–24.2) 8.0 (6.1–10.2) 40.8 (36.0–46.0) 4.3 (0.8–9.1) 25.4 (21.2–30.0) 10.9 (8.4–13.8)
a Vaccine serotypes.
b Non-vaccine serotypes.
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(Appendix chapter 8), the projected non-vaccine-type IPD inci-
dence is different from what would have been predicted using a
single group of NVTs. Nonetheless, grouping serotypes can create
some ‘super types’ that might have different characteristics, e.g.
higher acquisition rate of the VTs group compared to the individual
serotypes in the group. This might lead to conservative vaccine
effectiveness estimates. Grouping of serotypes may also result in
the estimated acquisition rate of NVTs being lower than that of
individual serotypes in the group. This would lead to an underesti-
mation of the indirect impact of vaccination on NVTs - lower than
the observed predicted prevalence of NVTs.
To limit the number of estimated parameters, age dependency
in competition was considered using two age classes (<6 and
P6 years). Some discrepancies between the fitted and observed
age-specific serotype distributions were present. The proportion
of carriers of VTs was overestimated among carriers aged
!15 years (Fig. 2); the susceptibility to competition of VTs against
NVTs is likely biased downwards in adults, thus underestimating
the reduction in prevalence of VTs. With our current specification,
the estimates of competition parameters in age group !6 years lar-
gely depends on data from the age groups 6–14 years. A model
including more groups of VTs and NVTs or individual serotypes
Fig. 3. Model projections on carriage prevalence over 10 years by age group. Projected cumulative prevalence of pneumococcal carriage of VT (red), strong NVT (blue) and
weak NVT (lime green) by age group over time since vaccine introduction. For each age group, the dotted lines show the 95% predictive intervals for the overall prevalence of
pneumococcal carriage. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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[21–23] would allow for even more heterogeneity. However, the
estimation of competition parameters from available carriage data
would become increasingly difficult in a highly compartmentalized
model.
We estimated case-to-carrier ratios using hospital-based data
on IPD incidence in KHDSS [8]. The access to care for IPD is
unknown in KHDSS, but meningitis incidence is underestimated
by over 30% by hospital-based surveillance [24]. Since IPD and
meningitis are severe syndromes, the underestimation of IPD inci-
dence could be similar implying case-to-carrier ratios are likely
underestimated. Nonetheless, since the ratios estimated pre-
vaccination are applied post-vaccination, the predicted reduction
in IPD is not affected.
We excluded partial protection from first and second doses. Our
estimates of the vaccine impact may thus be conservative if the
vaccines’ efficacy is substantial after fewer than three doses. We
treated vaccine efficacy against carriage and its waning as equal
for routine and catch-up vaccination. A Kenyan trial estimated vac-
cine efficacy against carriage of 40% among children aged 1–
4 years [3], lower than the 50% for infant vaccination [25–27].
The duration of protection of catch-up vaccination is not docu-
mented yet. One dose of PCV administered outside of infancy
may have a more enduring effect than 3 routine infant doses. If
so, our similar treatment of the duration of immunity means there
is no inflection on the carriage prevalence of VTs as the cohort of
highly immune <5 year olds who received a catch-up dose is
replaced by a new birth cohort of less immune children over time.
We assumed children are born completely susceptible to acqui-
sition of pneumococcus ignoring the influence of maternal anti-
bodies. Newborns in a Kenyan study had a very high rate of first
acquisition [20]. Early acquisition has also been reported in other
African settings [28–30]. In Netherlands and Papua New Guinea a
protective effect of maternal IgG antibodies against colonisation
in infancy was not observed [31,32]. Based on high early acquisi-
tion rates and insufficient evidence of protection from maternal
antibodies in some studies, this assumption is plausible.
A significant reduction in IPD caused by vaccine-related sero-
types 6A and 19A IPD has been observed in some PCV10-using set-
tings [33]. However, surveillance in Kilifi recorded no change in
carriage of serotype 6A and increased carriage of serotype 19A
after vaccine introduction [7]. We have not observed a change in
IPD caused by these serotypes. We therefore did not account for
6A and 19A as vaccine serotypes.
In conclusion, we predict a substantial and sustainable decline
in the carriage prevalence of VTs among vaccinated and unvacci-
nated individuals and consequently a reduction of about 56% in
overall IPD incidence ten years post-vaccination. While we show
that the current schedule is sufficient to limit vaccine-type pneu-
mococcal carriage to current levels, it is unlikely to achieve elimi-
nation of VTs. Strategies that heavily rely on protection from the
herd, including a reduced dose schedule, will need additional
efforts to stop circulation of VTs before their implementation.
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Background: Prior studies have demonstrated hyporesponsiveness to pneumococcal conjugate vaccines
(PCVs) when administered in the presence of homologous carriage. This may be substantially more
important in Africa where carriage prevalence is high. Deriving a correlate of protection (CoP) for carriage
is important in guiding the future use of extended PCVs as population control of pneumococcal disease by
vaccination is now focused principally on its indirect effect. We therefore explored the complex relation-
ship between existing carriage and vaccine responsiveness, and between serum IgG levels and risk of
acquisition.
Methods: We undertook secondary analyses of data from two previously published clinical trials of the
safety and immunogenicity of PCV in Kenya. We compared responses to vaccination between
serotype-specific carriers and non-carriers at vaccination. We assessed the risk of carriage acquisition
in relation to PCV-induced serum IgG levels using either a step- or continuous-risk function.
Results: For newborns, the immune response among carriers was 51–82% lower than that among non-
carriers, depending on serotype. Among toddlers, for serotypes 6B, 14 and 19F the post-vaccination
response among carriers was lower by between 29 and 70%. The estimated CoP against acquisition ranged
from 0.26 to 1.93 lg/mL across serotypes, however, these thresholds could not be distinguished statisti-
cally from a model with constant probability of carriage independent of assay value.
Conclusion: We have confirmed hyporesponsiveness in an equatorial African setting in both infants and
toddlers. Population responses to vaccination are likely to improve with time as carriage prevalence of
vaccine serotypes is reduced. We have not found clear correlates of protection against carriage acquisi-
tion among toddlers in this population. Assessing the potential of new vaccines through the use of CoP
against carriage is still difficult as there are no clear-cut serotype specific correlates.
! 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The first pneumococcal conjugate vaccine (PCV), which con-
tained seven serotypes, reduced the incidence of pneumococcal
disease and the prevalence of nasopharyngeal carriage in both vac-
cinated and unvaccinated children as well as adults when intro-
duced into routine infant immunisation programme in the USA
in 2000 [1]. The indirect protective effect of PCV is caused by a
vaccine-induced reduction in the risk of acquiring colonisation by
vaccine serotypes (VTs), which leads to a reduction in onward
transmission from young children.
Recently, data have emerged that highlight the complexity of
interactions between pneumococci, the human immune system
and the nasopharynx. Infants carrying serotypes 6B, 19F or 23F
at the time of PCV immunisation have reduced primary IgG
responses to those serotypes [2,3] and this effect persists through
to post-booster responses [4]. Rodenburg and colleagues showed
that, at 24 months of age, children’s responses to PCV against these
three serotypes were reduced if they had carried them at any point
in the 2 years prior to vaccination [5].
PCV responses in African children are generally thought to be
higher than those seen in developed country settings [6–9]. For
instance, the serotype-specific geometric mean fold-rise between
http://dx.doi.org/10.1016/j.vaccine.2017.05.088
0264-410X/! 2017 The Author(s). Published by Elsevier Ltd.
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the time of the first dose and one month after the third dose of PCV
were lower in USA [7] and Finland [9] compared to South Africa [6]
and The Gambia [8]. Nonetheless, in parts of Africa like The Gambia
[10] and Kenya [11,12], carriage rates from very early in life are
extremely high. Given high responses to PCV it is possible that
hyporesponsiveness does not occur, or is immunologically irrele-
vant, in equatorial Africa.
The immunological mechanism that mediates vaccine-induced
protection against colonisation at the mucosal level, or against dis-
ease, is not known. While circulating IgG may have a role in pre-
venting colonisation, as demonstrated in a mouse model in
which antibody blocked colonisation through agglutination [13],
local B cells producing IgG and/or IgA in the nasopharynx may also
be relevant and a role for T cells has also been suggested [14,15].
Nonetheless, to facilitate the licencing of new formulations of
PCV, a single aggregate serological correlate of protection against
invasive pneumococcal disease (IPD), has been derived based on
circulating IgG [16,17]. However, a recent analysis that suggested
correlates of protection (CoP) for IPD vary widely by serotype
[18] has questioned the biological relevance of a single aggregate
CoP common to all serotypes. It is likely that, as with IPD, the
CoP against carriage also vary by serotype.
Numerous assumptions were made during the development
of the common serological CoP and there is equipoise in the sci-
entific community about the relevance of the CoP to carriage and
mucosal disease [19]. For some serotypes, greater concentrations
of serum IgG were likely to be required to protect at mucosal
surfaces (e.g. in the nasopharynx) than in blood [20]. Subsequent
analysis of vaccine-induced antibody and the prevention of car-
riage reinforced the notion that if circulating IgG is indeed a rel-
evant correlate for carriage, remarkably high concentrations are
required to reduce carriage acquisition [21]. Deriving CoP for
carriage would guide the future use of extended PCVs, as popu-
lation control of pneumococcal disease by vaccination is now
focused principally on its indirect effect mediated through car-
riage [22].
We therefore set out to explore both the relationship between
existing carriage and vaccine responsiveness and between serum
IgG levels and risk of acquisition by undertaking new analyses of
two existing field studies of PCV in Kenya, with the following ques-
tions: (i) Does hyporesponsiveness occur in high carriage settings
like Kenya? (ii) If so, can we detect this for serotypes other than
the most common (e.g. 6B, 19F and 23F)? (iii) Is it possible to
derive a serological correlate of protection against carriage acquisi-
tion using vaccine-induced IgG responses detected within random-
ized controlled trials of PCV in Kenya?
2. Methods
2.1. Data
Data from two previously published clinical trials of the safety
and immunogenicity of PCV conducted in Kenya [14,15] were fur-
ther analysed in the current study. The first study (‘‘Newborn
study”) recruited 300 newborns that were randomized to receive
7-valent PCV (PCV7) in one of two vaccine schedules; at 0–10–
14 weeks or at 6–10–14 weeks. The subjects received a PCV7 or
23-valent Pneumococcal Polysaccharide Vaccine (PPV23) booster
dose of at 36 weeks. Serological measurements were made at 0,
6, 10, 14, 18, 36 and 37 weeks and nasopharyngeal carriage ascer-
tained at 18 and 36 weeks. The objectives of this study were to
examine the effect of a newborn vaccination schedule with PCV7
on the development of antibody and carriage prevalence. In the
current analysis we used the carriage data at the time of the boos-
ter (week 36) and the serological measurements at week 36 and
week 37.
The second study (‘‘Toddler study”) recruited 600 children aged
1–4 years to examine the effect of 0, 1 or 2 doses of a 10-valent PCV
(PCV10), on capsular antibody concentrations and nasopharyngeal
carriage. Children were given PCV10 in three different schedules:
Group A received PCV10 at day 0 and day 60; Group B received
PCV10 at day 0 and day 180. Diphtheria-tetanus-pertussis (DTaP)
was given as a control vaccine to group A at day 180 and to Group
B at day 60. A third group, which is not considered in this analysis,
received Hepatitis A virus (HAV) at day 0 and day 180 and DTaP at
day 60. Antibody measurements were made at days 0, 30, 90 and
210 and nasopharyngeal carriage assessed at days 0, 30, 60, 90
and 180. Details of the study have been published elsewhere
[23]. In the current analysis we used carriage data from vaccinees
in Groups A and B at day 0, 60 and 180 (vaccination time points),
and serological measurements 30 days post vaccination i.e. at 30,
90 and 210 days, respectively.
2.2. Analysis
For the newborn study, we calculated the fold-rise in serotype-
specific geometric mean concentrations (GMC) between weeks 36
and 37, separately, for carriers and non-carriers for each of the
seven serotypes in PCV7. The differences between the two groups
(homologous carriers vs. non-carriers) were quantified as ratios
of the GMC fold-rises. These ratios were derived from log-linear
regression models of the booster response taking account the vac-
cine schedule group (6–10–14 vs 0–10–14), type of booster given
(PCV7 vs PPV23) and the baseline log-concentration of IgG, at
36 weeks. Baseline IgG concentrations is adjusted for since individ-
uals with lower concentrations have more room for greater fold-
rise than individuals who already have high concentration at
baseline.
For the toddler study, we pooled paired carriage data and 30-
day serological responses for each of the time points of PCV10 vac-
cination (0, 60 and 180 days). We calculated serotype-specific fold-
rises in IgG concentration 30 days later (at 30, 90 and 210 days).
There were no blood samples at time 60 and 180 by design there-
fore we used the IgG at time 30 to adjust for responses to vaccines
given at 60 and 180 days. We would expect antibody concentra-
tions to decay from day 30 to day 60 (and from day 30 to day
180) at the same rate for subjects in both Group A and Group B;
therefore, the ranks in IgG baseline between time 30 days and
the time of vaccination are likely to be highly correlated, provided
that natural boosting is also distributed equally in both groups. To
assess the impact of carriage at the time of vaccination, GMC fold-
rise ratios between homologous carriers vs. non-carriers were esti-
mated from log-linear serotype-specific regression models of the
individual level fold-rise on the carriage status, taking account of
the vaccine group (Group A and B), age group (12–23, 24–35,
36–47 and 48–59 months), season (month of sample collection)
and pre-vaccine (day 0 or 30) log IgG. We used Generalized Esti-
mating Equations (GEE) to account for the correlations between
the repeated measures within an individual. Data for serotypes
6B, 9V, 14, 19F and 23F were selected for the analysis since they
were the most frequently carried of the 10 vaccine-type serotypes.
As a supplementary analysis, we also calculated the post-
vaccination GMC by pre-vaccination carriage status for both the
newborn and toddler studies.
In order to derive the serotype-specific antibody threshold for
vaccine efficacy against acquisition, we restricted our analysis to
data from the toddler study and, in particular, to toddlers who
were non-carriers at day zero. We compared carriage status at
day-30 against vaccine-induced IgG concentration measured at
day 30. We fitted to these two variables a model that incorporates
a threshold parameter that is estimated through a profile likeli-
hood [24], the a:b model. The model is a step-shaped function
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where the step corresponds to the antibody threshold. Thus, in
addition to the threshold parameter, the model also contains two
parameters for constant but different acquisition probabilities
below and above the threshold. A test for the presence of a thresh-
old was achieved by comparing the a:b model to a model with con-
stant probability of acquisition independent of assay value, using a
likelihood ratio test. Confidence intervals around the threshold
estimates were constructed through bootstrapping.
The a:b model does not allow for adjustment of covariates,
therefore, we also modelled the risk of serotype-specific acquisi-
tion as a continuous function of log-IgG concentration in a Cox pro-
portional hazards model that accounted for age group, carriage of a
heterologous serotype at the point of vaccination, log IgG on the
day of vaccination and season. Non-linear relationship between
the acquisition incidence and log-IgG concentration was allowed
through restricted cubic splines. Having no colonisation by any ser-
otype at day 0 predisposes one to considerably higher risk of
colonisation by an index serotype relative to someone colonised
by a different serotype to the index at day 0, due to serotype com-
petition [25,26]. This was the rationale for including carriage of a
heterologous serotype at the point of vaccination in the model.
3. Results
In the newborn study, 235 pairs of 36- and 37-week samples
were analysed. In these subjects the prevalence of carriage of
PCV7 serotypes at 36 weeks ranged from 0.9% for serotype 23F to
12.8% for serotype 19F. Compared to non-carriers, the GMC fold-
rise between week 36 and week 37 among carriers was substan-
tially lower by a factor of 51–82% (Table 1). The point estimates
of the GMC at post-booster (37 weeks) were higher among non-
carriers at the point of vaccination, except of serotype 18C (Supple-
mentary Table S1).
In the toddler study, between 460 and 480 samples were anal-
ysed depending on serotype. The carriage prevalence at the time of
vaccination ranged from 2.1% for serotype 9V to 8.0% for serotype
19F (Table 2). For serotypes 6B, 14 and 19F the GMC fold-rise post
vaccination among carriers was lower by between 29 and 70%. For
serotype 9V and 23F the GMC fold-rise were 53% and 1% higher
among carriers (Table 2). Except for serotype 9V the point esti-
mates of the GMC post-vaccination were higher among non-
carriers at the time of vaccination (Supplementary Table S2).
We computed the serological threshold for vaccine efficacy
against acquisition among serotype-specific non-carriers at the
first vaccination time-point (day 0) by using their titers and car-
riage status 30 days later in the toddler study. The estimated
thresholds ranged from 0.26 to 1.93 lg/mL across serotypes, how-
ever, a test for the presence of a threshold at these points sug-
gested no significant difference from a model with constant
probability of acquisition independent of assay value (Table 3).
We analysed carriage acquisition as a continuous function of log
IgG. There was no convincing monotonically decreasing rate of car-
riage with increasing log IgG for each of the five serotypes (Fig. 1).
In a situation where a higher level IgG had strong negative impact
on carriage, the prevalence ratios below the average (mean/me-
dian) log IgG would be above 1 and the prevalence ratios above
the average log IgG would be below 1, in the plots.
4. Discussion
While inferior quantitative antibody responses to the colonising
serotypes have been reported amongst children vaccinated with
PCV in Philipines [2], Israel [3] and South Africa [27], none have
studied this phenomenon in high carriage settings such as Equato-
rial Africa. Using data from two clinical trials in Kenya, we have
Table 1
Newborn study. Geometric mean fold rise between 36 and 37 weeks (with 95% confidence limits) stratified by carrier status, as well as the difference in the response between
carriers and non-carriers expressed as a ratio. These ratios, and associated p values were derived from log-linear regression models of the booster response taking account of the
vaccine group (EPI vs newborn), the type of booster given (Pneumococcal polysaccharide vaccine vs Pneumococcal conjugate vaccine) and log IgG in week 36.
Serotype Carriers at 36 weeks Non-carriers at 36 weeks Ratio (95% CIs) for carrier/non-carrier P-value
n GM fold-rise 37/36 Weeks (95% CI) n GM fold-rise 37/36 Weeks (95% CI)
4 0 – 235 4.92 (4.36–5.55) – –
6B 6 2.85 (0.69–11.68) 229 13.52 (11.52–15.88) 0.18 (0.07–0.46) <0.001
9V 4 1.62 (0.64–4.11) 231 5.32 (4.72–6.00) 0.31 (0.14–0.69) 0.005
14 10 1.29 (0.86–1.92) 225 2.79 (2.47–3.15) 0.49 (0.30–0.80) 0.004
18C 3 1.25 (0.87–1.79) 232 7.74 (6.87–8.73) 0.15 (0.05–0.40) <0.001
19F 30 1.91 (1.34–2.73) 204 7.19 (6.11–8.45) 0.32 (0.21–0.48) <0.001
23F 2 3.59 (0.02–663.49) 231 10.33 (8.80–12.14) 0.25 (0.06–1.09) 0.064
n: number of individuals.
Table 2
Toddler study. Geometric mean fold-rise between day 0 to 30 or day 30 to 90/210 stratified by carrier status at the time of vaccination (day 0, 60 or 180), as well as the difference
in the response between carriers and non-carriers expressed as a ratio. The ratios and associated p-values were derived from log-linear serotype specific regression models, using
GEE, of the individual level fold-rise on the carriage status, taking account of the vaccine group (Group A and B), age group (12–23, 24–35, 36–47 and 48–59 months), season
(month of swab) and pre-vaccine (day 0 or 30) log IgG.
Serotype Carriers at point of vaccination Non-carriers at point of vaccination Ratio (95% CIs) for carrier/non-carrier P-value
na GM fold-rise (95% CI) na GM fold-rise (95% CI)
6B 23 1.65 (1.22–2.24) 457 2.35 (2.14–2.59) 0.70 (0.51–0.97) 0.034
9V 10 1.88 (0.98–3.61) 466 3.06 (2.65–3.53) 1.53b (0.89–2.65) 0.119
14 15 3.02 (1.99–4.58) 445 5.32 (4.65–6.10) 0.71 (0.50–1.02) 0.067
19F 38 2.12 (1.57–2.87) 439 7.61 (6.50–8.90) 0.30 (0.19–0.46) <0.001
23F 22 3.39 (1.35–8.47) 455 4.28 (3.66–5.00) 1.01 (0.63–1.63) 0.955
a There are two repeated measures for almost all participants. These numbers reflect the number of samples rather than individuals.
b The reason why the adjusted ratio is above 1 (instead of approx. 1.88/3.06 = 0.61, which is the unadjusted ratio) is because one of the factors adjusted for (pre-vaccine log
IgG) was unevenly distributed among carriers vs. non-carriers; the GMC of pre-vaccine log IgG among carriers was significantly higher at 1.61 compared to 0.49 in non-
carriers. Similar case for 23F.
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confirmed hyporesponsiveness in equatorial Africa in both infants
and toddlers, and for the first time described it in serotype 14.
The reduced immune responses to PCV administered to an indi-
vidual with prevailing carriage may reduce the vaccine’s efficacy.
The clinical implication of this is an increased susceptibility to
acquisition of homologous pneumococcal serotypes, particularly
when the reduction in immune response results in lower than suf-
ficient protection against carriage. Several strategies can be useful
in high carriage settings to counter the effect of hyporesponsive-
ness. The use of a catch-up campaign at the time of PCV introduc-
tion can speed-up the reduction in vaccine-type carriage thus
improving the immune responses in cohorts vaccinated in the sub-
sequent period of reduced carriage. Using a booster dose in the sec-
ond year of life can also be used to overcome hyporesponsiveness
[3]. However, the cost-effectiveness of such strategies needs to be
evaluated to provide further evidence for or against their use.
We assessed the association between IgG concentration and the
incidence of carriage in two ways; using a step function, the a:b
model, which explicitly models a threshold and using a model with
carriage incidence as a continuous function of IgG concentration,
which does not explicitly model a threshold. The second approach
allowed us to study the relation while accounting for potential
confounding factors. The result from each of the approaches is
mutually important and complementary in interpreting results
from the alternative approach.
The CoP for carriage were generally higher than the recently
derived serotype-specific CoP for IPD with the exception of sero-
type 14 (0.26 lg/ml for carriage acquisition vs. 0.46 lg/ml for
IPD) [18]. It is expected that the CoP for carriage should be substan-
tially higher than that for IPD; therefore, the result for serotype 14
is surprising. The evidence for the CoP for carriage being lower is,
however, limited given the wide 95% confidence intervals of the
CoP estimate of this serotype (Table 3) and the function of IgG that
does not show drastic change around the estimated CoP (Fig. 1).
For serotype 9V, all the carriers were above the estimated CoP
against acquisition. This scenario reflects one of the potential prob-
lems with the a:b model, that in the estimation process the inci-
dence below a candidate threshold is not restricted to be higher
than that above it. This requirement is, however, imposed post-
estimation in the test for the existence of a threshold at the esti-
mated value [24], such that the test statistic always yields a non-
significant result in such cases. Whether circulating IgG is the cor-
rect correlate of protection also needs to be considered. The exact
mechanism by which pneumococci are prevented from colonising
the nasopharynx is still unclear.
The licensing of future PCVs will likely take into account the
potential impact on carriage [28]. Therefore, defining the CoP for
carriage would provide a way of assessing the non-inferiority of
new vaccines as has been the case for CoP for IPD [16,17]. However,
until a better understanding of existing CoP for IPD exists this may
be complex. For example, there is limited information to sufficiently
explain why IPD correlates for some serotypes are high and others
low. Consequently, predicting whether the CoP for a novel serotype
will be higher or lower, and by what factor, than available CoP for
other serotypes is difficult. New PCVs might incorporate serotypes
that are carried relatively infrequently further complicating the
use of CoP for carriage. Only one previous study that was conducted
in the United Kingdomhas reported on PCV CoP for carriagewhere a
clear threshold against carriage for a single serotype, serotype 14,
was identified [20]. A second study in the Navajo Nation andWhite
Mountain Apache tribal lands, in USA, did not find identifiable IgG
threshold level that was associated with prevention of carriage
acquisition for all the eight serotypes studied [29].
A limitation of the newborn study is that the period between
booster dose and the assessment of its effect was one week. It gen-
erally takes about 4 weeks for a full immune response following
vaccination. Therefore, what we show is that the impact of pre-
existing carriage on immune response is notable as early as one
week. It is possible that after 4 weeks the final concentrations
between carriers and non-carriers are similar. If that is the case
then the effect of pre-existing carriage is in delaying immune
response. From the toddler study, in which there was sufficient
time-lapse between vaccination and assessment of response, the
final concentrations were still different between carriers and
non-carriers. It is unlikely that the case is different for newborns,
because the mechanism causing hypo-responsiveness should be
similar between the two age groups.
In conclusion, we have confirmed hyporesponsiveness in an
equatorial African setting in both infants and toddlers. Pneumococ-
cal conjugate vaccines have been introduced in many African coun-
tries where carriage is generally high. Hyporesponsiveness might
reduce the vaccine’s effectiveness in the early years of introduction
when the prevalence of vaccine serotypes is still high. If so, the
speed with which vaccine-type carriage prevalence is reduced will
determine how fast improved responses are realised in later years
after vaccine introduction, when cohorts of children with reduced
vaccine-type carriage rates replace the cohorts in high prevalence
period. We did not identify clear correlates of protection against
carriage acquisition among toddlers in this population. Given the
limited information from the few studies that have reported on
correlate of protection against carriage, assessing the potential of
new vaccines through the use of correlate of protection against car-
riage remains difficult, as there are no clear-cut serotype-specific
correlates.
Table 3
Toddler study. The serotype-specific serological thresholds for vaccine efficacy against acquisition for five most commonly carried serotypes at day 0. The thresholds are
computed using a step-shaped function where the step corresponds to the threshold with different infection probabilities below and above the threshold. The threshold with the
highest profile likelihood is chosen as the parameters estimate. Confidence intervals are constructed by bootstrapping.
Serotype Threshold (95% CI) Carriage prevalence Ratioa (95% CI) Test for presence of a thresholdb Goodness of fit p-valuec
6B 0.48 (0.07–2.68) 0.21 (0.04–0.72) 0.079 0.048
9Vd 1.86 (1.86–22.67) – >0.999 0.219
14 0.26 (0.16–14.34) 0.26 (0.04–0.87) 0.542 0.851
19F 1.66 (0.85–6.60) 0.10 (0.00–0.60) 0.171 0.314
23Fe 1.93 (0.09–1.94) 0.00 (0.00–0.00) 0.430 0.625
a Carriage prevalence ratio is the carriage risk above the threshold divided by carriage risk below threshold, the confidence interval is obtained by bootstrapping
b A likelihood ratio test for the presence of a threshold. Achieved by comparing the a:b model to a model with constant probability of infection independent of assay value.
Values above 0.05 indicate no sufficient evidence of a difference in the two models at % level of significance.
c This is the Hosmer and Lemeshow goodness of fit p-value testing the null hypothesis that there is no difference between observed and model predicted values. The test
assesses whether the step function represented by the a:b model is an appropriate representation of infection or whether another relationship such as a gradual one between
titer and infection might be more likely than a stepped relationship. All the p-values, except that for serotype 6B, which is borderline, are above 0.05 indicating insufficient
evidence against the null hypothesis at the 5% level of significance.
d There were no carriers of serotype 9V below the threshold of 1.86 mcg/ml hence the risk ratio was undefined.
e There were no carriers of serotype 23F above the threshold of 1.93 mcg/ml hence the risk ratio was zero.
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Fig. 1. The incidence rate ratio (blue solid line) as a function of log IgG titre (x-axis) for each serotype labeled above the graph. The ratios are between the values of log IgG on
the x-axis relative to someone with the average log IgG. For instance, for serotype 6B, the rate ratio between individuals with log IgG of !3 relative to individuals with the
mean log IgG is slightly below 1 (95% CI: "0.5 to 2). The red dashed lines are the 95%CI bounds of the rate ratio. The three vertical (grey) lines mark the 2.5th, 50th and 97.5th
percentiles of the distribution of log IgG whose density is shown in grey on the x-axis. The green line shows the CoP obtained by the a:b model while the light green shade
around it shows the region covered by the bootstrapped 95%CI of that CoP. The likelihood ratio (LR) test p-value for the significance of log IgG in predicting carriage
acquisition and the test for the presence of a threshold estimated by the a:b model is indicated in the plot. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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